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ABSTRACT
Pancreatic and breast cancer are both architecturally heterogeneous and insidious diseases of which 90% of
patients succumb due to metastasis, the spread of tumour cells throughout the body. Tumour associated
fibroblasts and other stromal cells have been implicated as major facilitators of tumour invasion and metastasis.
Thus, there is a strong imperative to better elucidate tumour-stromal interactions in cancer as a means to develop
more effective therapies. In that regard, this thesis focused on the urokinase plasminogen activation system (PAS)
in stromal remodelling and invasion using two aggressive cancer types, pancreatic ductal adenocarcinoma (PDAC)
and triple negative breast cancer (TNBC), as both are well known to utilise the PAS system during their invasion
processes. The main activator of PAS is the serine protease, urokinase (uPA), and its overexpression is recognised
as an important biomarker of metastatic disease and a therapeutic cancer target. Receptor bound uPA activates colocalised plasminogen into the broad-spectrum protease, plasmin. The combined proteolytic and signalling events
initiated by this pathway drive extracellular matrix (ECM) degradation, cell proliferation, adhesion and migration.
Negative regulation of this pathway is provided at several levels, including inhibition and clearance of protease
activity by naturally occurring inhibitors, such as SerpinB2 (Plasminogen Activator Inhibitor Type-2). Elevated
tumour SerpinB2 expression is associated with prolonged survival, decreased metastasis, or decreased tumour
growth in a number of cancer types, with loss of stromal SerpinB2 expression associated with progression.
However, specific mechanisms have not been addressed. To directly interrogate the role of SerpinB2 in pancreatic
and breast cancer, ex vivo and in vivo models were developed using wild-type and SerpinB2-/- murine embryonic
fibroblasts (MEFs). The potential role of SerpinB2 in tumour cell invasion ex vivo was also investigated in breast
tumour epithelial cells with modulated SerpinB2 expression.

The effect of SerpinB2 deletion on the rate of collagen I matrix contraction and collagen density were measured
utilising wild-type or SerpinB2-/- MEFs (Chapter 3). Significant decreases were observed using SerpinB2-/- MEFs in
iv

matrix contraction rates, overall diameter, matrix integrity, collagen coverage and fibril network formation
compared to wild-type MEFs (P < 0.0001). Second harmonic generation (SHG) and scanning electron
microscopy (SEM) analyses of matrices formed by SerpinB2-/- MEFs revealed dysregulated, anisotropic dispersal of
collagen I, compared with the ordered, isotropic distribution observed in matrices formed with wild-type MEFs (P
< 0.0001). Further, stark differences in cellular adhesion, protrusion dynamics and migration between wild-type
and SerpinB2-/- MEFs were observed, suggesting that SerpinB2 is important in regulating fibroblast migration,
necessary for ECM remodelling.
Chapter 4 involved the implementation of 3D organotypic culture systems and in vivo models of PDAC to
interrogate the role of PAS pathway in PDAC invasion. PDAC cell invasion through 3D organotypic matrices
formed by SerpinB2-/- MEFs doubled compared to wild-type MEFs (27.2 % ± 1.9 versus 55.2 % ± 1.8; P <
0.001). Furthermore, a significant difference in invading PDAC cell morphology and migration mode was
observed in matrices formed by SerpinB2-/- MEFs. PDAC cells invading through wild-type matrices also exhibited
a predominantly mesenchymal migratory mode (>70% of cells), while PDAC cells in SerpinB2-/- matrices
displayed a predominantly amoeboidal phenotype (>80% of cells). PDAC organotypic results were reproduced in
vivo, as SerpinB2-/- MEFs in the PDAC mixed allograft model formed larger and more invasive tumours
(P = 0.0322), with altered collagen deposition (P = 0.0021). Significant differences in uPA/uPAR expression on
PDACs in allograft tumours formed with SerpinB2-/- MEFs was concomitantly reflected in an increased uPA
activity by SerpinB2-/- tumours (P < 0.05), which lead to an increase in tumour cell local invasion through both
muscle (P = 0.0314) and subcutaneous fat (P = 0.0024). These results thus indicate that SerpinB2 regulates
stromal remodelling of collagen and in turn, influences tumour growth and local invasion.
The 3D organotypic culture system was also used to interrogate the role of SerpinB2 in TNBC cell invasion using
the high uPA/uPAR expressing and invasive breast adenocarcinoma cell line, MDA-MB-231 (Chapter 5). In these
models, SerpinB2 shRNA lentiviral vectors (Chapter 2) were also utilised to knock-down expression in these
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cells. Down-regulation of SerpinB2 expression did not modify the invasion of MDA-MB-231 cells in vitro or ex vivo
(P > 0.05), highlighting the important influence of stromal SerpinB2 on tumour cell invasion, similar to that
reported in the PDAC cell invasion experiments. Further, a significant increase in breast tumour volume
(1.88-fold) was observed in mice with allograft tumours formed with SerpinB2-/- MEFs versus with wild-type
MEFs.
The in vivo models reported within this thesis show that co-injection of PDAC or TNBC cells and SerpinB2-/MEFs resulted in increased tumour growth, aberrant remodeling of collagen ECM and increased local invasion
from the primary tumour. Altogether, this confirms the significant role of SerpinB2 in the progression of cancer
invasion and metastasis, providing valuable information on the role of PAS in tumour biology.
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INTRODUCTION TO SERPINB2
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CHAPTER 1
INTRODUCTION TO SERPINB2
1.1 INTRODUCTION TO CANCER
Cancer is known medically as a malignant neoplasm or tumour, comprising a broad group of diseases that
involve unregulated cell proliferation, invasion and spread, known as metastasis, throughout the body. In 2014
in Australia, cancer was the fourth leading cause of all registered deaths (Australian Bureau of Statistics, 20141).
There are several hundred types of cancer reported (1), each initiated after one or more cells in a tissue
undergoes progressive genetic mutations and chromosomal disruptions to produce a self perpetuating cell that
possesses a malignant phenotype (2). The ability of a particular cancer cell type to invade and metastasise
throughout the vasculature is the primary determinant of cancer prognosis (3), with metastasis responsible for
90% of all cancer deaths and the underlying cause of treatment failure (1,4,5). Tumours are architecturally
heterogeneous (refer to section 1.3), which aids in remodeling the tumour microenvironment (TME) (1,6,7).
These tumour systems differ in vasculature, host invasiveness, and connective tissue components (7-10), in
which coagulation, cellular adhesion and angiogenesis, the growth of new capillary blood vessels from preexisting vessels, each contribute critically to the metastatic capacity of a tumour (1,4). Furthermore, it is
becoming increasingly clear that deregulated processes of stromal remodelling and collagen cross-linking
within the TME perpetuates both an inflammatory and early-developmental phenotype, where the continuous
cellular and molecular narrative aids malignant progression through local and distant tissues of the body (1114).

1 Australian Bureau of Statistics

http://www.abs.gov.au/ausstats
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Tumour-associated urokinase plasminogen activator (uPA) has long been recognised as a major cell surface
marker of invasion and metastasis and proven for its prognostic relevance, and now as major player in ECM
remodeling (15-23). The naturally occurring inhibitor of uPA, SerpinB2 (plasminogen activator inhibitor type2), specifically and irreversibly binds to cell surface receptor bound uPA, forming a covalent inhibitor-protease
complex, which is then internalised into the cell via receptor mediated endocytosis (RME) (24,25). Moreover,
the establishment of an activated stroma within the TME enhances a tumours metastatic potential and it has
been reported by many research groups that stromal fibroblasts and endothelial cells (ECs) overexpress uPA
and uPAR while downregulating SerpinB2 in order to facilitate this process (26-31) (refer to section 1.9 and
1.10).
This Chapter will first briefly describe the process of invasion and metastasis and the nature of tumour
heterogeneity before describing the different plasminogen activation system (PAS) members, with a particular
focus on SerpinB2, and their modulated expression in cancer with reference to clinical relevance. Following
this, an in depth assessment of the TME, with direct association to the biological functional importance of
SerpinB2 in ECM remodeling and cancer progression will be described.

1.2 Tumour invasion & metastasis
Cancer metastasis involves a multifaceted process between the interaction of stroma and tumour cells (32,33).
Initially a malignant cell must attain the ability to disengage from the biologically heterogeneous primary mass
(32,33) and network of structural proteins that holds it in place to the basement membrane (BM) and traverse
the protein rich, often dense extracellular matrix (ECM) (34,35). To accomplish this, the cell acquires an
inappropriate constitutive expression of several enzyme systems, including the matrix metalloproteinases
(MMPs) and the plasminogen activation system (PAS) (36). This affords the cell an ability to invade

3

surrounding host stroma, penetrate into the circulatory or lymphatic system, adhere to capillary beds of distant
organs, invade the host tissue there and proliferate (Fig. 1.1) (5,18,35,37). Tumour invasion is also facilitated
by the diminished expression of cellular adhesion molecules (CAMs) and epithelial–mesenchymal transition
(EMT), by which tumour cells weaken E-cadherin-dependent cellular adhesion and enhance motility, making it
possible for increased penetration into surrounding tissues (3,38). Through EMT, the tumour cell ultimately
acquires a migratory phenotype, binding growth factor proteins and ECM molecules to its own membrane
receptors, which generate a cascade of intracellular signals that promote invasion and metastases (3,38).
Furthermore, tumour invasion is greatly enhanced by the process of angiogenesis, as a tumour can only grow
to 2 mm3, before passive diffusion is inadequate to provide oxygenated blood, nutrients and removal of wastes
(39). To overcome this, growth factor proteins are increasingly released by the tumour into the local
environment, leading to the establishment of angiogenesis (5), and the conscription of host stromal cells into
the TME (1,40) (41).
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Fig. 1.1. Metastatic progression. Mutagenesis causes aberrant cell proliferation resulting in the formation of a primary tumour.
(A) Invasive cells adapt a migratory phenotype, known as EMT, and produce proteases that degrade the ECM and BM, allowing
them to break free of the primary tumour and enter the blood or lymphatic system through a process termed intravasation. (B)-(D)
Tumour cells are transported to a distant site in the circulation where they adhere to and breakdown the ECM and BM to allow
penetration to distant host tissue, known as extravasation. (E) Now at a secondary site in the body, the formation of a secondary
tumour can occur. Adapted from (5).

1.3 Tumour heterogeneity and stromal conscription
Tumours can be considered disorganised organs that contain heterogeneous cell types. It is known that
tumours contain evolving tumour cells, cancer stem cells (CSCs), conscripted ‘stromal’ cells such as fibroblasts
and myofibroblasts (carcinoma-associated fibroblasts - CAFs), infiltrated leukocyte sub-types (immune and
inflammatory cells), ECs, mesenchymal cells, such as pericytes and mural cells, as well as other vascular
smooth muscle cells (40,42,43). In addition, the tumour infiltrate is composed of bone marrow–derived
mesenchymal stem cells (MSCs), which along with CAFs, contribute both quantitative and qualitative changes
5

within the ECM (40). These tumour societies are highly adapted for survival against therapeutic intervention
by producing new variants and utilising subpopulation interactions to counteract damaging stimulus. Thus,
understanding tumour heterogeneity is one of the primary steps toward improving clinical efficacy and
managing ongoing treatment in cancer therapy. In regards to specific tumour cell heterogeneity, one
hypothesis proposed is the clonal evolution model. This model specifies that cancers evolve through random
mutations, clonal expansion and clonal selection within 3D adaptive landscapes of tissue beds (44). There are
highly variable and complex dynamics of gene expression that result in a multifarious clonal architecture.
Through utilising sophisticated mutational analysis, Kandoth et al. (2013) has shown the presence of many subclones of tumour populations within solid breast tumours (45). It is proposed that these different sub-clone
populations interact through paracrine signaling and even though therapeutic intervention can decimate certain
cancer clones and destroy much of their habitat, there are inadvertent selective pressures for resistant subclone expansion (46-48). Many studies have demonstrated the presence of both genetically alike and
genetically different sub-clones in primary tumours and metastatic lesions in the same patients, which is
consistent with clonal evolution models (48,49). This Darwinian character of cancer is the crux of therapeutic
failure, however this characteristic could eventually hold the key to more effectual control of cancer systems.
The second model proposed to account for tumour heterogeneity is the cancer stem cell (CSC) model. This
ideal postulates that tumours are organised in a hierarchy, where cells with stem cell properties (CSCs) are at
the zenith. There are two properties that are attributed to a CSC, the first is the ability for self-renewal, since
differentiated cells cannot divide indefinitely (constrained by the Hayflick limit) (50). The second property of a
CSC is the ability to generate differentiated tumour cells, which form the bulk of a tumour. These cells have
been termed CSCs to reflect such stem cell-like properties and was first demonstrated by Dominique Bonnet
and John Dick in human acute myeloid leukaemia in 1997 (51). Since that time CSCs have been demonstrated
in many solid malignancies, including those of the brain (52), ovaries (53), lungs (54), breast (55), colon (56),
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prostate (57), and pancreas (58), all of which exhibit a comparable hierarchical organisation. There is debate
regarding the origin of CSCs, whether from dysregulation of normal stem cells or from a specialised population
of tumour cells that acquired self-renewal ability (59). This cell plasticity is a significant feature of cancer due
to lowering the activation barrier for increased cellular plasticity (60). This ability, coupled with the processes
of EMT and mesenchymal-epithelial transition (MET), has profound implications for the plasticity between
CSC types and their TME interactions. The Weinberg laboratory at the Massachusetts Institute of Technology
have reported that EMT can result in increased numbers of CSCs (61), which causes significant challenges to
therapy through several avenues including increased invasion and dissemination of cells, decreased proliferation
of certain CSC populations avoiding chemo-cytotoxicity (62). Additionally, post-treatment, MET cells return
to a highly proliferative state and can mediate tumour relapse at distant metastatic sites (63). Thus,
compositional tumour heterogeneity and TME-induced selection pressures appear to guide a tumours
evolution, which significantly underwrites both tumour development and clinical efficacy of treatment. This
TME-imposed heterogeneity is produced by CSC self-renewal and differentiation (64). While normal stem cell
niches are predominantly located in hypoxic tissue areas (mammary gland ducts, GI tract pits etc.), which
promote this mesenchymal phenotype, poorly vascularised tumours also contain hypoxic regions that CSCs
thrive within (65). Yeung et al. (2011) have demonstrated that hypoxia attenuates colon cancer cell
differentiation maintaining a stem-like phenotype (66). In addition, it has also been recently shown that
activated myofibroblasts within the TME can secrete factors (especially HGF) which impose the CSC
phenotype (67). This interplay between stromal and CSCs is now beginning to emerge as a significant
underlying factor causing intratumour heterogeneity (68), however the in-depth molecular mechanisms of this
dynamic interplay are yet to be revealed. Advances in next-generation sequencing technology and the
establishment of cBio Portal for Cancer Genomics (cBio) and The Cancer Genome Atlas (TCGA) have both
significantly helped elucidate how heterogeneous cancer can be and the extent of the genetic mutational
landscape of cancer. The molecular level interactions that these aberrations precede have profound mechanistic
7

and clinical implications. Thus, while the task remains unprecedentedly large, it is imperative to completely
understand not only the pathophysiological context of disease but also the molecular and cellular events
occurring within the entire TME. Deciphering the evolutionary code of tumour heterogeneity will both allow
for better biomarkers and therapeutic strategies to restrain intratumoural heterogeneity and reduce selection
pressures as well as making the dream of personalised medicine a reality (69).

1.4

The plasminogen activation system (PAS)

Dissemination of human cancers are characterised by the acquisition of novel functional competences in order
to degrade the basement membrane, remodel the ECM, invoke angiogenesis and forming a TME, leading to
tissue invasion and metastasis. Specifically, in the context of tissue remodelling, PAS is the human body’s
extracellular proteolytic enzyme system. The aberrant expression of PAS genes and/or upregulation of
protease activity in tumourigenic tissue contributes to the attainment of important new cell capabilities that
potentiate malignancy. PAS is comprised of extremely powerful serine proteases, protease inhibitors of the
serpin family and various binding proteins (70). PAS is active under both physiological and pathophysiological
conditions and responsible for a large range of biological processes from fibrinolysis (primarily), angiogenesis,
tissue remodelling (17,71) and cell migration (17,72) to complement system activation (73), ovulation (74),
and embryonic development (70,75-77).
There are two types of plasminogen activators, tissue-type plasminogen activator (tPA), and urokinase-type
plasminogen activator (uPA). In contrast to tPA, which is fundamental in fibrinolysis (78), uPA plays an
essential role in tissue degradation as part of physiological and pathological processes. As tPA is not inherently
responsible for pericellular proteolysis or of emphasis in this research project, it will not be explored further in
this thesis (refer to (79) for further information).
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1.4.1 The urokinase plasminogen activation system
The urokinase plasminogen activation system (uPAS) directly consists of the serine protease uPA, its specific
GPI (glycosylphosphatidylinositol)-anchored protein receptor uPAR, their two natural serpin inhibitors, PAI-1
(SerpinE1) and SerpinB2, as well as the plasmin inhibitor, α2-antiplasmin (Fig. 1.3). uPA binds to uPAR,
where it efficiently cleaves co-localised plasminogen at its Arg580-Val581 bond, generating cell surface associated
plasmin (16) (Fig. 1.3). The main physiological inhibitor of plasmin, α2-antiplasmin, is an important regulator
of PAS, controlling the fibrinolysis process and facilitating degradation of many proteins within the ECM
(80,81). Overexpression of the serine protease urokinase (uPA) is recognised as an important biomarker of
metastatic disease and a therapeutic cancer target (19,82). uPA is responsible for plasminogen activation, the
proteolytic conversion of the inactive zymogen, plasminogen, into the active serine protease, plasmin (72)
(Fig. 1.2). Homeostatically, plasmin directly degrades fibrin and components of the ECM through conversion
of procollagenases (pro-MMP) to active collagenase (MMP) enzymes. Plasmin also activates other pro-MMPs
bound to the ECM, thus allowing basement membrane (BM) destruction, complete ECM deconstruction and
latent/active growth factor stimuli, each contributing to tissue remodeling processes (20,71,78,83,84).
Reich et al. (1978) were the first to recognise the integral role of plasminogen activation and localised ECM
proteolysis in cancer progression (75). Since then, numerous research groups have shown that malignant cells
and/or associated stromal cells over-express various components of PAS constitutively, particularly uPA and
its receptor uPAR, leading to unregulated proteolytic activity and a myriad of other non-proteolytic cell
processes allowing tumour cell invasion and metastasis (15-17,19,21,71,76,77,84,85). For example, PAS is
involved in multiple aspects of neoplastic evolution, including activation of pro-oncogenic cell signalling
leading to enhanced tumour cell proliferation and altered cellular adhesion and migration, intravasation and
extravasation

of

vasculature,

growth

at

the

metastatic

sites

and

tumour

neoangiogenesis

(17,36,70,76,77,84,86-88).
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Upon binding to its cellular receptor, uPAR, the pro-uPA zymogen is catalytically converted into its active
form, which in turn activates co-localised plasminogen into the broad-spectrum protease, plasmin. The
combined signalling and proteolytic outputs of this pathway activate a plethora of downstream events driving
ECM degradation, cell proliferation, adhesion and migration (89). Negative regulation of this pathway is
provided at several levels, including inhibition and clearance of protease activity by naturally occurring
inhibitors, such as SerpinB2 (19,25).

SerpinE1
SerpinB2

SerpinE1
SerpinB2

Fig. 1.2. PAS and the role of the serpins – SerpinE1 and SerpinB2. Plasminogen (PLG) binds to cell surface receptors via its
lysine-binding sites. Plasmin (PLN), cathepsin B and matriptase reside in the pericellular space and cleave either sc-uPA (single-chain
or pro-uPA) or plasminogen. The cleavage of sc-uPA initiates the plasminogen activation cascade by forming tc-uPA (two chain
uPA), which cleaves nearby cell-bound plasminogen, forming cell surface-bound plasmin. This feed-forward loop facilitates matrix
metalloprotease (MMP) activation, degradation of fibrin, fibronectin, laminin, and inhibition/activation of the complement system.
α2-antiplasmin inhibits tc-uPA formation by inhibiting any soluble plasmin available. SerpinE1 and SerpinB2 prevent plasmin
formation by inhibiting tc-uPA. Each serpin forms a complex with tc-uPA, which then binds to a member of the low density
lipoprotein receptor (LDLR) family, promoting endocytosis and degradation of the Serpin:uPA inhibition complex, followed by
recycling of the uPAR receptor. Modified from (19).
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1.4.2 uPA and the uPA receptor, uPAR
uPA is synthesised as a single chain 53 kDa proenzyme - pro-uPA (17). Proteolytic activation of pro-uPA to the
active two-chain serine protease uPA (tc-uPA) molecule occurs via plasmin-mediated (or cathepsin or
matriptase) cleavage of the Lys158– Ile159 bond of pro-uPA (20,90). The two chains are covalently linked by a
disulfide bridge, Cys148– Cys279 (Fig. 1.3) (17). Both pro-uPA and tc-uPA bind with high affinity (KD, < 1 nM)
to uPAR, however only tc-uPA is efficiently inhibited by SerpinE1 or SerpinB2 (37,84). Receptor uPAR
binding potentiates the initiation of a pro-enzyme activation positive-feedback loop, resulting in increased
plasmin production (refer to Fig. 1.2) (84,91). In addition to proteolytic functions, uPA binding to uPAR
initiates a range of biological processes including initiation of intracellular signalling, leading to cell adhesion,
proliferation and migration (84,92-95).

Duffy et al. (1988) were the first to demonstrate the prognostic value of uPA in cancer. Their research group
later reported that patients with primary breast carcinomas and high levels of uPA activity had a significantly
shorter disease-free interval and increased metastatic progression, in contrast to patients with low levels of
activity (96). As plasmin is an efficient activator of pro-uPA, there is a strong positive feedback mechanism
available, which can be exploited by a variety of malignancies, including breast (6), lung (97), endometrial
(98), gastrointestinal (99), pancreatic (100) and colorectal cancers (101).
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Fig. 1.3. Two-chain urokinase plasminogen activator. Synthesised as a 53 kDa serine protease, a single disulfide bond
(Cys148– Cys279) holds the two chains together. Antiparallel, up-and-down β-sheet barrels shown in purple, and α-helices shown in
yellow. Image constructed using PDB coordinates 1W0Z and the PyMOL molecular graphics system (102).

The uPA receptor, uPAR, is a 50-60 kDa (35 kDa deglycosylated) glycosylated phosphatidylinositol (GPI)anchored single chain protein with three similar-sized domains (103). The binding of uPA to uPAR requires all
three uPAR domains (103). As previously mentioned, uPAS also modulates cell responses such as migration,
cellular adhesion, differentiation, proliferation and apoptosis (37,104). These are not necessarily related to
proteolytic activity and require trans-membrane signalling, which is mediated by interactions between uPAR
and a variety of extracellular proteins and membrane receptors, such as integrins, EGF, FGF-2 and HGF
receptors, high molecular weight kininogen, caveolin, and the G-protein-coupled receptor (GPCR), FPRL1
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(91,104). Further, stromal cells within the primary tumour’s microenvironment may be activated to express
proteins such as uPA and/or uPAR and are capable of modifying the behaviour of a cancer cell to promote
angiogenesis, intravasation and metastasis (7,105). In a study by Hadler-Olden et al. (2011) the TME was
found to have a greater impact on tumour invasiveness than individual cancer cells in their tumour xenograft
mouse model (106). Moreover, increased levels of uPA and uPAR have been associated with a poor prognosis
in patients with breast (6) ovarian (107), endometrial (108), kidney (109), prostate (110), head and neck
(111), esophageal (112), colorectal (113), liver (114), lung (115,116), pancreatic (117,118) and leukaemicassociated cancers (119) (refer to Table 1.1 for further references).
It has been proposed that this transmembrane uPA/uPAR "signalosome" can activate intracellular signaling
molecules such as tyrosine- and serine-protein kinases, Src, focal adhesion kinase (FAK), Rac, extracellular-signalregulated kinase (ERK)/mitogen-activated protein kinase (MAPK) and the JAK/STAT pathways (104).
Overall, these activities confirm the inappropriate up-regulation of uPA and uPAR during pathophysiological states
such as tumour invasion and metastasis (16). Conversely, within a homeostatic system, this unchecked activity is
finely regulated by the protease inhibitors of uPAS, a superfamily of proteins known as the serpins.
1.4.3 Plasminogen activator inhibitors
Plasminogen activator inhibitors belong to the serpin (serine protease inhibitor) family. There are over 1000
known serpins, including 36 human proteins, making this the largest and most diverse family of protease
inhibitors (120). The majority of serpins are involved in serine (as well as cysteine) protease regulation in a
plethora of roles from coagulation, fibrinolysis, inflammation and complement activation to carcinogenesis,
angiogenesis and apoptosis (121). All inhibitory serpins undergo structural changes in order to inhibit their
target protease (122). Due to the far-reaching and potentially damaging effects of plasmin, regulation of uPAS
activity is crucial for normal, non-invasive cell function. Both PAI-1 (SerpinE1) and SerpinB2 efficiently inhibit
uPA in solution and at the cell surface (123), through the formation of covalent, irreversible enzyme:substrate
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complexes (124). A diagrammatic representation of the inhibitory mechanism of serpins is shown in Fig. 1.4.
SerpinE1 has been shown to be relatively unstable and rapidly convert to a latent form, which renders it
incapable of interacting with uPA (125). Additionally, SerpinE1 may bind to either vitronectin, uPA or tPA,
which causes exposure of integrins such as αvβ3, αvβ5 or αIIbβ3 binding sites on vitronectin, and activates the
Jak/Stat pathway that facilitates angiogenesis, vital for metastatic spread (25,126-128). This paradox is
observed in many tumour types where high levels of SerpinE1 are associated with a poor prognosis (refer to
Table 1.1). In contrast, SerpinB2 does not display these properties and has been successfully exploited in many
uPA-targeted therapies (129-131).

Fig. 1.4. Serpin inhibitory mechanism. Serpins exist in three main states. The secreted native (‘stressed’) serpin (A) is required for
inhibitory activity. The first step in the inhibitory mechanism is the interaction of the serpin with an active protease to form the reversible,
non-covalent Michaelis-like complex (B). The serpin forms an oxy ester linkage and an acyl-enzyme intermediate by covalently bonding
with the protease via the residues of the cleaved Reactive centre loop (RCL). The reaction can either proceed on an inhibitory or noninhibitory pathway. The inhibitory pathway results in the formation of a covalent complex; the cleaved RCL of the serpin inserts into its
own β-sheet and translocates the protease with it, distorting the active site resulting in an inactive protease and an inactive, relaxed serpin
(C). The non-inhibitory pathway results in the serpin not forming an acyl-intermediate, releasing the active protease and inactivating itself
via insertion of the cleaved RCL into the β-sheet (D). Adapted from (132,133).
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1.5 SerpinB2
1.5.1 Expression and structure
SerpinB2 is a clade-B ov-serpin (ovalbumin family) comprised of 415 amino acid residues, encoded by a single gene
– SERPINB2 (120). Akin to all clade-B serpins, SerpinB2 is synthesised without a cleavable N-terminal signal peptide.
However, unlike the traditional clade-B serpin, SerpinB2 is distributed bi-topologically, existing in two forms, as a
47 kDa non-glycosylated form mainly found intracellularly (134) and as a secreted, 60 kDa glycosylated form
(135,136). The gene encoding SerpinB2 possesses an exon encoding a polypeptide loop between the α-helices, C
and D (the CD-loop), which is the most extensive of all clade B serpins and the main site of protein binding (19).
The CD loop has been reported to confer SerpinB2 the ability to interact with a plethora of largely intraceullar
proteins (137-142), the exact functions of which are yet to be resolved (addressed in section 1.6). Uniquely to any
other serpin, SerpinB2 can spontaneously polymerise under physiological conditions in vitro, dependent mainly on
the CD loop and cellular redox status (143), without any known SerpinB2 serpinopathies unlike other serpins (19).
In addition, it has been previously been shown that removal of the CD-loop does not affect the ability of SerpinB2 to
fulfill it’s protease inhibitory mechanism (19), explained in section 1.6.
The small percentage of glycosylated SerpinB2 is secreted via the golgi secretory pathway (144,145) making it one
of only two clade B serpins (the other is Maspin) that are found both intra- and extracellularly. Of note, mouse
SerpinB2 protein is 80% conserved to that of human SerpinB2 (146) meaning mouse studies have and continue to
offer great insight into the pathophysiological modulated expression and function of human SerpinB2 (147).
Recently, Udofa et al. (2013) reported five homologous regions between the human and murine promoters of
SerpinB2, indicating that induction of SerpinB2 expression under certain physiological environments will be similar
across both species (148).
The crystal structure of human SerpinB2 revealed the tertiary formation of SerpinB2 is that of a typical serpin,
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with 9 α-helices (A-I) and 3 β-sheets (A-C) (Fig. 1.5) (149). SerpinB2 also possesses a reactive centre loop
(RCL) for uPA inhibition (refer to section 1.5.3), which is yet to be resolved by X-ray crystallography (19).

Fig. 1.5. Structure of SerpinB2. This serpin is comprised of 9 α-helices, 3 β-sheets and an RCL. SerpinB2 also possesses a CDloop – a polypeptide chain between α-helices C and D (indicated by a dotted line). The conformation of the CD-loop has yet to be
resolved and the structure shown is a CD-loop and RCL deleted mutant. Structure is coloured from N-terminus (blue) to C-terminus
(red). Image was constructed using PDB coordinates 2ARQ (149) and the PyMOL molecular graphics system (102).
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SerpinB2 is expressed by a number of cell types, including keratinocytes, trophoblasts, macrophages,
monocytes, ECs, smooth muscle cells, dendritic cells, fibroblasts and cancer cells smooth mm cells
(19,145,146,150,151). Expression of SerpinB2 is under strict regulation in homeostatic tissues (123), however
during inflammatory conditions, cell differentiation, and wound healing it is heavily induced (145,146,151).
Such inflammatory conditions can be invoked through viral (152-154), bacterial (142,155-157) and parasitic
(158) conditions, as well as growth factors and cytokines in pathophysiological conditions such as asthma (159),
lupus (160), adaptive immune system regulation (161)and cancer (24).
SerpinB2 expression is regulated through three genetic regions. Firstly, an inducible proximal promoter with
two activator protein (AP-1)-like sites propagates both constitutive and PMA-activated transcription of
SerpinB2 (162). This proximal promoter is conditionally dependent upon a CCAAT enhancer binding protein
(C/EBP) element, which has been shown by Udofa et al. (2013) to bind the transcription factor C/EBP-P in
order for both constitutive and LPS-inducible transcription of SerpinB2 (148). Secondly, SerpinB2 silencing is
conducted by an upstream silencer [PAI-2 upstream silencer element 1 (PAUSE-1)], responsible for regulating
both positive and negative control mechanisms of SerpinB2 (163). Thirdly, a distal AP-1 transactivator region
reportedly controls transcriptional derepression of SerpinB2, important for fine-tuning SerpinB2 expression in
both SerpinB2-expressing and -non-expressing cells (164). AP-1 has been described as a “nuclear decisionmaker”, critical for determining life or death cell fate decisions involved in apoptosis, cellular differentiation
and proliferation (165,166). Through this ménage of transcriptional and post-transcriptional mechanisms,
SerpinB2 is modulated homeostatically and pathophysiologically during stress, inflammation, cancer and when
proteolytic and/or fibrinolytic operations have fulfilled their duties (Fig. 1.6). Recently, Schroder et al. (2014)
reported that SerpinB2 expressed by B16 melanoma cells accesses the extracellular milieu upon the surface of
0.5–1 µm microparticles, through annexin-mediated binding to phosphatidylserine, where it still retained uPA
inhibitory function (167). SerpinB2’s binding modality is comparable to that reported for tissue
transglutaminase-2 (TG2) (168). Interestingly, both SerpinB2 and TG2 lack the signal sequence for a classical
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secretory mechanism (discussed further in Section 1.9.5). In addition, it was recently discovered that nonglycosylated (47kDa) SerpinB2 is secreted from ECs via trans-Golgi-network derived vesicles, upon
stimulation with LPS (169). These two secretory mechanisms could have direct consequences for SerpinB2
release into the extracellular milieu during times of inflammation, ECM remodelling and stress (refer to Fig.
1.6). Further, it has been reported that the ecotropic virus integration site 1 (EVI1) transcription factor
[associated with poor prognosis in human myeloid malignancy (170)] can bind and down-regulate SerpinB2
greater than 10-fold within leukemic cell lines, believed to inhibit myeloid differentiation (171). Glass et al.
(2013) suggest that decreased SerpinB2 could play an important role in enhancing cellular proliferation by
abrogating SerpinB2’s protective function to Rb (171). Further, Glass et al. (2013) identified that the EVI1
binding site lies directly within the SerpinB2 silencer element, and propose that EVI1 potentially inhibits or
alters normal binding and function of PAUSE-1. Bard et al. (2012) also showed that AP-1 physically interacts
with EVI1 and that they both share promoter binding to an extensive range of target genes involved in
malignant transformation, including SerpinB2 (170). Taken together, these two studies suggest that EVI/AP-1
could both collectively reduce expression of SerpinB2, increasing cellular proliferation in leukemic cells (171).
Additionally, SerpinB2 has been reported to be expressed over 105-fold by macrophages exposed to LPS (172),
and has been shown to be up-regulated 2.9-fold by hepatic stellate cells under hypoxic versus normoxic
conditions (173). Further, Copple et al. (2011) showed that HIF-1α activation not only up-regulated SerpinB2,
but other important genes (including Ccr1, Ccr5, IL-13rα1, VEGF and PGF) involved in angiogenesis and
collagen synthesis (173).
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Fig. 1.6. SerpinB2 expression and activity. SerpinB2 (SB2) expression is induced by inflammatory and cell stress pathways and
has a number of pleiotropic activities including uPA inhibition, cell survival, differentiation, immunity and extracellular matrix
remodeling. The main extracellular role of SerpinB2 (after secretion on microparticles) is the inhibition of uPA, a powerful protease
involved in proteolytic and fibrinolytic roles in vascular patency, ECM remodeling, cell migration and cancer. Rb – Retinoblastoma
protein, TGN – Trans-golgi network, C/EPB - CCAAT enhancer binding protein element.

1.5.2 SerpinB2 function
SerpinB2 has been reported to bestow a plethora of biological functions of both an inhibitory and noninhibitory nature (Fig. 1.6) [refer to (19) for an extensive review of SerpinB2 function].
1.5.2.1 uPA inhibition
SerpinB2 is an efficient inhibitor of tc-uPA (second order rate constant = 2.1 × 106 M-1s-1) and cannot stably
inhibit pro-tPA or fibrin bound tPA (174), potentially allowing pro-uPA to initiate the plasmin generation
cascade (refer to Fig. 1.3) (175). Unlike other serpins, SerpinB2 does not convert to a latent serpin
conformation, remaining active until interaction with uPA or through renal clearance (176). It has been
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previously been shown that removal of the CD-loop does not affect the ability of SerpinB2 to fulfill it’s
protease inhibitory mechanism of uPA or for the uPA:SerpinB2 complex to be internalised via RME (176).
Furthermore, removal of the CD-loop allows for simpler and more efficient recombinant expression and
purification of the protein (176).

SerpinB2 specifically inhibits uPA by the classical serpin inhibitory mechanism (refer to Fig. 1.4, B-C) forming
a non-covalent Michaelis-like complex (when the interaction proceeds down the inhibitory pathway through
interactions with the serpin’s RCL residues (Arg380–Thr381), flanking the scissile bond (P1–P1) (120). Yu et al.
(2002) have shown that a point mutation of the codon corresponding to the P1 (RCL) arginine residue at
position 380 with an alanine residue abolishes the uPA inhibitory activity of SerpinB2 (172). Following attack
of uPA at the active site on the scissile bond, a covalent ester linkage between Ser195 of the proteinase and the
backbone carbonyl of the P1 residue is formed, which cleaves the peptide bond (120). Here, the RCL inserts
into its own β-sheet (A) and transports the covalently bound uPA with it, distorting its active site. Upon
inhibiting uPA, a covalent uPA:SerpinB2 complex is formed, which increases the binding affinity of uPA with
endocytotic receptors of the LDLR family (i.e. VLDLR, LRP etc.), believed to be caused by conformational
changes in uPA(177). The interaction of uPA:SerpinB2 and an LDLR receptor initiates rapid internalisation of
the uPA:SerpinB2 complex from the cell surface into lysosomal compartments (124). This mediation results in
the degradation of SerpinB2 and its attached protease along with the removal of any uPA-associated proteolytic
activity from the cell surface (19,24).

Lastly, the strong inhibitory relationship between uPA and SerpinB2 within the TME appears to play a key role
in tumour invasion and metastases (19,71,178-180). There are other contexts where SerpinB2 appears to take
part in activities separate to uPA inhibition. In this perspective, a deeper elucidation of SerpinB2 roles within
the TME could represent a vital component within the ongoing quest for metastatic cancer treatments.
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1.5.2.2 Non-uPA inhibitory functions
Initially, extracellular SerpinB2 was identified as an inhibitor of uPA (refer to section 1.5.2.1), however it has
been shown to bind tPA as well as tissue transglutaminase (TG2) of both trophoblasts during endometrial
implantation, and keratinocytes of the cornified envelope (181) within both homeostatic and disease states
(refer to Section 1.5.1). Intracellularly, there have been a multitude of functions assigned to SerpinB2,
independent of uPA inhibition. These include cytoprotection [mainly in macrophages (152,182), dependent on
the RCL in one study (183)], gene expression modification (184), immunomodulation of both innate and
adaptive immunity (158), differentiation (135,185) inflammation and autophagy stabilisation (186),
neuroprotection (187), protection from proteotoxic stress and cancer [reviewed in (19)]. Boncela et al. (2011)
reported that SerpinB2 in ECs degraded the tumour suppressor gene, p53 (141). Moreover, it has also been
reported in mouse models that SerpinB2 binds TG2 mediating an anti-apoptotic response through TANKbinding kinase 1 (TBK1), inactivating procaspase-3 (182). This is interesting as TG2 will be recurring within
this project (refer to Sections 1.9.5, 3.4, 4.4) and has previously been shown to act on the Rb protein, playing
an important role in the cell progression through apoptotic pathways (188). Several studies implicate SerpinB2
in cytoprotective activities and warrant further research into SerpinB2’s interplay with TG2, defining exact
mechanisms within these post-translational modification processes. SerpinB2 has also been shown to alter the
secretory profile of cytokines in macrophages, specifically by blocking IL-1β secretion (189), indirectly
inhibiting caspase-1 activation acting downstream of NF-κB (190), and regulating CCL2 production (involved
in infiltration of monocytes, macrophages and T cells) in the development of Th2-mediated protective
immunity following viral (161) and nematode infection (191,192), as well as in asthmatics (193,194).
Additionally, SerpinB2 was recently shown to be up-regulated in middle cerebral arteries of hypertensive
rabbits (195), while Palacios et al. (2015) have shown that rheumatoid arthritic (RA) macrophages subjected to
ex-vivo isolated RA synovial fluid decrease expression of SerpinB2, reportedly in order to activate a pro-
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inflammatory environment (196).
Interestingly, studies report SerpinB2 to be involved with neuroprotection. For a long time it has been known
that neuronal cells express SerpinB2, especially proceeding kainite (an analogue of glutamate) dosing (187). It
has previously been reported that SerpinB2 is an important "activity-regulated inhibitor of death (AID)" gene,
produced in large concentrations by hippocampal neurons (197). Zhang et al. (2009) demonstrated that
SerpinB2 promoted cell survival in both their cell culture and mouse models of neurodegeneration (197).
Additionally, Lee et al. (2015) reported that SerpinB2-/- murine embryonic fibroblasts (MEFs) were much
more sensitive to huntingtin protein aggregation versus wild-type MEFs, concluding that SerpinB2 is involved
in the intracellular compartmentalization of aggregated proteins (198). Many studies report SerpinB2 to be
involved with neuroprotection. Further, it has recently been shown that SerpinB2 assists in neuronal cell
migration (199). Katie et al. (2014) demonstrated that SerpinB2 binds cell adhesion molecule close homologue
of L1 (CHL1), which functions in neural cell proliferation, migration, differentiation, and survival. SerpinB2CHL1 binding was shown to promote cerebellar granule cell migration and neurite outgrowth, involving
interactions with integrins and vitronectin (199).

Further, SerpinB2 also appears to be involved in processes other than uPA inhibitory function, associated with
cell adhesion and migration, through altering gene expression in many different cell types. These affects can
occur either through direct or indirect cell-cell or cell-ECM association. It has been reported that SerpinB2transfected HeLa cells expressed lower levels of intercellular adhesion molecule 1 (ICAM-1), which conferred
protection from picornavirus-induced lysis (184). Ksiazek et al. (2010) showed that ICAM-l (a transmembrane
glycoprotein) is expressed constitutively on many cell types and can promote tumour cell bindings to
mesothelial tissue (200). Moreover, it was recently shown that SerpinB2 transcription is necessary for
mammary cell migration induced through EGF, which activates a cascade linking the ERK-to-ERF axis
migration-promoting pathway (201).
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1.5.3 SerpinB2-/- mouse models
Apart from reduced adipose tissue development (202), SerpinB2-/- mice have been shown to progress normally
through development, survival, maturity and fertility (203), until directly exposed to pathogenic stimuli,
where they experience an impaired response to infection (19,151). It has been reported that SerpinB2-/- mice
exhibit an increased susceptibility to Legionella pneumophila (157), HIV-1 (138) and schistosoma infection
(158).

Recently, SerpinB2-/- mice were shown to have significantly increased venous thrombus resolution compared
to wild-type mice, with a 12-fold elevation in active uPA levels within SerpinB2-/- thrombi reported (204).
Siefert et al. (2014) found that SerpinE1 levels were concomitantly decreased (in SerpinB2-/- mice) potentially
also responsible for the elevated uPA levels, however this did not affect both MMP-2 and MMP-9 activation,
suggesting that enhanced thrombus resolution was via uPA-mediated mechanism (204). Moreover, SerpinE1-/mice also exhibited increased thrombus resolution comparable to SerpinB2-/- mice, yet there was also reduced
thrombus formation and altered MMP activity recorded (204). These data identify SerpinB2 as a novel
regulator of venous thrombus resolution, modulating both inflammatory and uPA activity mechanisms, distinct
from SerpinE1.
1.5.4

SerpinB2 in cancer

SERPINB2 is a multifaceted gene, constantly reappearing amongst experimental data across the wide realm of
biomedical research. Given the multifarious nature of SerpinB2, it is not surprising that the roles ascribed to
SerpinB2 within tumour systems are multifaceted and complex. There are many reports within the cancer field
associating SerpinB2 expression with both tumour suppression and tumour advancement, dependent upon the
specific tumour type, tissue context, ECM componency and TME regulation. This paradoxical nature of
SerpinB2 effects on tumourigenesis, invasion and metastasis is quite complex, however many tumours express
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SerpinB2 at tumourigenesis and at the initiation of metastasis, which could potentially be the body’s
homeostatic response, as a stress response modulator (198).
1.5.4.1 Tumour progression and inhbition
Recently, Kovacheva et al. (2014) have shown that sustained conditional knockdown of intracellular bone
sialoprotein was essential for breast cancer skeletal metastasis, and that this was associated with up-regulated
SerpinB2 expression (205), which otherwise is an indicator of good prognosis in breast cancer patients (19,82).
Chambers et al. (1995) previously reported that increased intracellular SerpinB2 expression within metastatic
ovarian tumour cells increased overall patient survival, while increased SerpinB2 levels detected in ascites
correlated with a poor prognosis (206,207). Research by Ashton et al. (2012) demonstrated that SerpinB2−/−
hematopoietic cells decrease leukemia stem cell (LSC) growth and survival leading to a significant reduction of
leukemia cells in bone marrow versus wild-type hematopoietic cells (208). SerpinB2 shRNA LSCs revealed the
same reduced phenotype of leukemia development demonstrating a new role for SerpinB2 specifically
regulating leukemic populations in vivo (208). Additionally, Subimerb et al. (2014) reported that
cholangiocarcinoma (a slow growing, highly metastatic bile duct tumour) patients with higher expression of
both uPA and SerpinB2 in peripheral blood leukocytes had lower survival than patients with lower expression
(209). Using a skin carcinogenesis model, Tonnetti et al. (2008) showed that SerpinB2-/- mice developed fewer
tumours compared to wild-type mice (139). More recently, studies by Rushworth et al. (2014) showed that
loss of dual-specificity phosphatase 5 (DUSP5) resulted in an increase in activated H-Ras/ERK-mediated by
SerpinB2 gene transcription, leading to increased skin cancer progression (210). Both of these papers suggest
that SerpinB2 expression is able to regulate the ERK pathway, necessary for cell migratory mechanisms. The
association of SerpinB2 with poor patient prognosis has also been reported in endometrial, bladder, and
colorectal cancers (211). SerpinB2 expression has also been reported to promote the development and
progression of epidermal papillomas, induced by 12-O-tetradecanoylphorbol-13-acetate (TPA), in a manner
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independent of uPA inhibition, proposed rather to be related to an apoptotic inhibition (212).

Furthermore, in regards to carcinomas of the brain, SerpinB2 has been shown to be prometastatic. In a recent
study by Valiente et al. (2014), uPA and tPA produced by astrocytes from lung and breast cancer metastatic
lesions were shown to be neuroprotective against metastatic advancement through activation of plasminogen to
plasmin (213). Converted plasmin was reported to inhibit metastatic tumour cells through FasL activation,
inactivating L1CAM, required for tumour cell spreading along capillaries, leading to cell apoptosis (213). The
expression levels of both SerpinB2 and Neuroserpin (SerpinI1) in human metastatic tumours were associated
with brain relapse, both individually and combined (213). SerpinB2 and SerpinI1 were suggested to be
produced by these metastatic tumour cells to protect them from FasL action, allowing them to proliferate and
migrate through the brain (213).

Contrary to the study by Valiente et al. (2014) and others described above, many in vitro and in vivo
experimental models implicate SerpinB2 expression to have anti-invasive and anti-metastatic cancer
consequences (24,167,214,215). There is also extensive clinical association between SerpinB2 expression and
metastasis suppression clinically (216). High SerpinB2 expression in breast (6,85,96,217-219), lung (220),
ovarian (221-223), prostate (224-227), head and neck (228-230), oesophageal (231,232) and pancreatic
(118,233-238) cancers has been significantly associated with good prognosis, including increased relapse-free
survival, disease-free survival, and mean overall survival time (Table 1.1). Further, in node negative breast
cancer high tumour SerpinB2 is only statistically relevant if uPA levels are concurrently high (6,19).
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Table 1.1. Individual PAS components involved in the prognosis of various human cancer types

(–) Poor Prognosis; (+) Good Prognosis; (NA) Not Associated; (ND) Not Determined.
Cancer type

uPA

uPAR

SerpinE1 SerpinB2

References

Breast

–

–

–

+

Ovarian

–

NA

–

+

Prostate

–

–

ND

+

Head & Neck

–

–

–

+

Oesophageal

–

–

–

+

(231,232)

Pancreatic

–

–

–

+

(118,233-238)

(6,85,96,217-219)
(221-223)
(224-227)
(228-230)

Recently, Huang et al. (2015) reported that low expression of SerpinB2 in head and neck squamous cell
carcinoma (HSCC) tissue was associated with a higher chance of recurrence in HSCC patients (239). Further,
Taoka et al. (2014) reported that SerpinB2 was up-regulated 1.5 fold in cisplatin resistant bladder cancer cells
versus cisplatin naïve cells (240). Whether this relates to the anti-apoptotic ability conferred by SerpinB2 was
not addressed. Importantly however, this is the first clinical finding where SerpinB2 has been shown to prevent
chemo-acquired resistance in patients with HSCC (216). Most recently, a new player, ΔNp63α (a pleiotropic
oncogene and member of the p53 transcription regulatory family), has been reported to negatively impact on
the survival outcome of patients with squamous cell carcinomas (241). Moreover, King et al. (2014) showed
that aberrant expression of ΔNp63α in keratinocytes, believed to precede squamous cancer development and
progression, down-regulated SerpinB2 (241). This finding links p53 homologs and SerpinB2 together in the
context of tissue homeostasis.
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Furthermore, research by Li et al. (2014) demonstrated that down-regulation of SerpinB2 was essential to
GPCR kinase-3 stimulated angiogenesis in a human prostate cancer in vivo model (242). This study and
personal observations by our laboratory and collaborators indicate that SerpinB2 might suppress tumour
angiogenesis. Several other animal models support these clinical findings. For example, Suwa et al. (2008)
found that nude mice bearing a human colon cancer xenograft overexpressing SerpinB2 helped to inhibit
primary tumour growth, decrease metastases and increase tumour apoptosis (243). Additionaly, treatment of
uPA over-expressing tumour xenografts in animal models with SerpinB2 has been demonstrated to inhibit or
complete prevent metastases (215,244). In a recent prostate cancer in vivo model, Zou et al. (2012) reported
that SerpinB2 expression was suppressed by the tumour promoting molecules protein kinase D2 and D3,
which increased the activity of uPA, uPAR and MMP9, suggesting that SerpinB2 loss contributes to prostate
cancer progression (245).
Thus, these studies highlight the complex interplay of SerpinB2 activity between invading tumour cells and
host tissue, revealing the enigmatic role this protein portrays. Interestingly, there are many studies that
implicate SerpinB2 in cell migratory processes, within both developmental, homeostatic and
pathophysiological systems and needs to be addressed. Studies over the last decade have shown that in cancer,
tumour associated cells, such as fibroblasts and immune cells, are facilitating a strategic role in invasion and
metastasis, helping attainment of cellular migratory pathways through engaging in cellular cross talk via
exchange of proteases and cytokines with tumour cells (43,246-248). It is this diverse cellular presence within
the TME that allows a tumour to facilitate a plethora of processes required through all stages of growth,
migration, invasion and malignant progression throughout the ECM to access distant sites of the body.
1.6 The extracellular matrix (ECM)
The ECM is directly responsible for the homeostatic functioning of cellular and tissue functions within the
human body. Strict control in regulating ECM turnover and remodelling is essential for proper embryonic
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development, angiogenesis, wound healing, pregnancy and normative organ functioning. During pathological
conditions, such as cancer, the dysregulated biochemical and biophysical functioning of the ECM perpetuates
processes that aid in tumour invasion, metastatic niche formation and metastases (249). Exactly how ECM
composition and remodelling is disrupted is of major concern to the field and is now widely accepted to be the
crux for success or failure of many clinical therapies.
1.6.1

The dynamic reciprocity of the ECM

In 1982, Dr Mina Bissell proposed the model of ‘dynamic reciprocity’, where tissue-specific function is
retained by information exchange between cells and their local ECM (250). This ongoing bidirectional
interaction controls homeostatic functions performing pivotal roles in regulating tissue regenerative responses,
from regulating cellular morphology, ECM contraction and remodelling, cellular differentiation, migration,
proliferation, and survival during tissue development (251,252). These cell–ECM interactions are also
impacted during pathologic processes including inflammation, haemostasis, cancer, diabetes, hypertension, and
chronic wound healing (251). Each cell has access to the ECM through transmembrane cell surface receptors
such as integrins, cadherins, selectins and syndecans (251). These receptor interactions occur with, and are not
limited to, the ECM componenets laminin, fibronectin, collagen, vitronectin, proteoglycans and other cell
surface anchored proteins eg. MT-MMPs, uPAR, and the Serpins, to name a few. Signal feedback moves from
the cytoskeleton to the nuclear matrix and chromatin in a cyclical fashion and demonstrates that the ECM and
cellular microenvironment are integral in determination of tissue specificity (250). This microenvironment
additionally comprises cytokines, chemokines and growth factors, providing soluble paracrine signals from
local cells, distant tissue beds, and CNS activity (253). Thus, this complex system of multifarious componency,
in constant cell-ECM communications, determines both an organ’s structure and function, and must act in
cooperation to maintain homeostasis within tissues. These processes are best modeled using ex vivo 3D systems.
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Prior to discussing these model systems an overview of collagen I, the major ECM component used in 3D
models, is described.
1.6.2 Collagen I
In homeostatic tissues a precise balance is maintained between the processes of biosynthesis and degradation in
order to preserve the physiological nativity of tissue collagens. Collagen makes up ~30% of all protein of the
human body and 90% of collagen is type-1 collagen (254). Thus, collagen I is not only the most abundant
protein the body, but also the most prevalent ECM component of breast and pancreatic tissue (the two cancer
types under investigation in this project). Collagen I is a long, fibrous structural protein and the main
constituent of skin, bones, tendons, cartilage, ligaments and fascia (255). It provides the framework and
support for nearly all of the human body’s tissues, though it can also be found intracellularly, particularly
within fibroblasts and macrophages. All collagens have immense tensile strength, and when bundled, form
large, eosinophilic fibers, known as collagen fibres (255). Collagens have more than fifty binding partners in
vivo, believed to be due to the requirement of such diversity of fibril patterns, ranging from parallel bundles in
tendon and ligament, to orthogonal lattices in cornea, and interlocking weaves in blood vessels, skin, and bone
(256). In healthy tissue this is beneficial, however, having such a large number of binding partners can have
detrimental impacts in diseased tissue states. Type-I collagen is first produced as the precursor molecule,
Procollagen I, characterised by a triple-helical rod-like core domain with N- and C-terminal globular
propeptides and linear telopeptides, respectively (255) (Fig 1.7 A). Procollagen chains are assembled into
triple helices within the rough endoplasmic reticulum and contain a three-residue repeat of glycine-proline-X
(where X can be any amino acid type) or glycine-X-hydroxyproline (257) and comprise three amino acids for
every left-handed helix turn, stabilised by hydrogen bonds (257). Formation of collagen fibrils is first instigated
by the enzymatic cleavage of Procollagen’s N- and C-terminal pro-peptides performed by disintegrin and
several metalloproteinases (BMP-1 and ADAMTS-2, -3, and -14), respectively (Fig 1.7 A) (255,258,259).
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This causes the exposure of telopeptides, which engage in site-specific intermolecular interactions driving
collagen self-assembly (Fig 1.7 B) (258). Procollagen I chains consist of two α1 (I)-chains and one α2 (I)-chain.
These associate into (15 Å wide) trimers, with a molecular mass of ~270 kDa, nucleate and assemble into a
triple-helix zipper formation and are translocated to the Golgi apparatus, where they are packaged into vesicles
that eventually fuse with the cell membrane and extrude into the extracellular space (260). Collagen I packs
together in thin ordered fibrils 10-300 nm in diameter, making them incredibly strong yet tensile, due to the
intermolecular nature of their covalent cross-links (Fig 3.1 C-D) (255). Such covalence only occurs during the
early stages of fibril development, when the N- and C- telopeptides are in a reactive site position, and not as a
tissue bed reaches maturity (257). This is the native tertiary conformation of collagen I and it’s fibres are the
building blocks for collagen fibril bundles (Fig 1.7 D). These collagen superstructures are prevalent on a large
scale in the body and exist in many types of tissues with diverse mechanical properties. While collagen I is a
major determinant of the architecture of a specific tissue site, it has been observed to be both directly and
indirectly involved in tissue specific functions including cell adhesion, proliferation, chemotaxis/migration,
differentiation, as well as an antigen in immunopathological conditions
(255,261-264).

1.6.3 Collagen crosslinking and fibrilogenesis
As aforementioned, collagen has been shown in vitro to undergo a self-assembly/polymerisation process,
spontaneously assembling into fibrils (256,265). However, the in vivo situation is vastly different. In mammals
there are two major classes of ECM collagen cross-linking enzymes, the lysyl oxidase (LOX) family (containing
5 genes, LOX and LOXL1 to -4) and the transglutaminase family (eight have been characterised), of which
LOX and the ubiquitous tissue Transglutaminase 2 (TG2) are the primary members of each family and essential
for collagen I fibrillogenesis in vivo (Fig 1.7 C) (266-268). Both TG2 and LOX expression are induced by
TGF-β (secreted by fibroblasts), which directly leads to increased cross-linking and reduced ECM degradation
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indirectly stimulating enhanced ECM deposition, including collagens, elastin, proteoglycans, laminins and
fibronectin, ultimately resulting in a greater tissue stiffness (269-271).

Disintegrin

BMP-1 and ADAMTS-2, -3, and -14

Fig 1.7 Structure of Collagen I. A. Procollagen I is the precursor to collagen I and contains two alpha-1 chains and one alpha-2
chains, assembled into a triple helix configuration. Procollagen peptidases cleave domains at the C- and N-terminals resulting in (B)
formation of mature Tropocollagen I (~300nm long and ~1.5 nm in diameter), which is then secreted from the cell. C. Collagen I
undergoes LOX and TG2 mediated cross-linking via aldol and aldol-histidine covalent reactions to form collagen I fibrils (up to 1 cm
long and ~500 nm in diameter). D. The formation of a robust collagen I bundle or fibre is the major component of the body’s ECM,
supporting cell and tissue architecture as well as having many important biological functions in cellular adhesion, survival, migration
and proliferation. Modified from (257).
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Collagen molecules generally bind to fibronectin and then to the plasma membrane of cells through α11β1and α2β1-integrins (256,272,273). This interaction has been shown to promote increased deposition of
collagen I and III fibers, forming large extracellular collagen networks (266). During wound healing, increased
biosynthesis is crucial for proper wound healing, where close cellular control over rapid collagen cross-linking
is required. In certain disease states such as keloids, hypertrophic scars, scleroderma and many cancer tissue
types, there is hyper-accretion of collagen bundling, forming desmoplastic, fibrotic tissue areas (274). Collagen
I is also significantly up-regulated in end-stage liver cirrhosis, eventually preventing the entry of blood and
oxygen to hepatic cells causing cell death. (275).

Furthermore, it is well established that many tumour types (including mammary, pancreatic and squamous cell
carcinomas) contain high levels of collagen I in the TME (276-278). Tumour progression and metastatis is also
positively correlated with collagen density and it has been demonstrated that stromal remodeling of collagen
and ECM collagen cross-linking facilitates invasion (279), particularly through LOX facilitation (264). As this
thesis involved effects on collagen crosslinking and ECM remodeling in the stroma of the TME, a summary of
the two main ECM cross-linking enzymes, LOX and TG2, follows.
1.6.4 Lysyl oxidase (LOX)
The Lysyl oxidase family is a quintet of extracellular matrix modifying enzymes, with important roles in
connective tissue formation, cellular adhesion, motility and migration, gene transcription regulation, and
senescence, as well as cancer progression (280). LOX, the main enzyme of the family, is a copper dependent
protein that covalently cross-links collagens (and elastin) within the ECM via converting lysine, histidine or
hydroxylysine residues of N- and C-terminal telopeptides of collagen into peptidyl aldehydes (281) (refer to
Fig. 1.7). These aldehydes then spontaneously condense with free lysine residues to form a variety of intra- and
intermolecular covalent cross-links (281). This reaction gives collagen additional mechanical stability and helps
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strengthen the surrounding ECM against degradation (255). As collagen fibril assembly is underway, LOX
activity is increasingly expressed, believed to be due to its capacity to bind highly conserved sequences that are
exposed on telopeptide regions of N- and C- terminals of fibrils (255). LOX expression is known to be upregulated by hypoxia-inducible factors (HIFs), along with TGF-β (269), and thus is often over-expressed in
hypoxic breast and pancreatic tumours, with poorer overall survival in patients with high LOX-expressing
tumours (282,283). Other fibrotic disorders where LOX is implicated are connective tissues of the heart (260)
and vasculature (284), lungs (264), skin (in particular keloid fibrosis and scleroderma) (274), kidneys (285),
liver (cancer and liver fibrosis) (286), mouth (gingival atrophy) (287), and the colon (281). The consequence
of correct LOX expression and resultant collagen cross-linking in homeostatic tissue is represented by the fact
that LOX-/- mice are neo-lethal due to a fragile diaphragm and cardiovascular system collapse (288). Mutations
in LOX, which can be recessive or as a result of nutritional copper deficiencies, are seen in Menkes disease and
Occipital horn syndrome (289,290). Further, Osteolathyrism, a condition caused by ingestion of legumes from
Lathyrus sativus, a plant rich in the LOX inhibitor β-aminopropionitrile (BAPN), reduces collagen cross-linking
ability and can be fatal (23). LOX is directly able to modify the ECM, and its overexpression leads to the
development of desmoplasia, with positive association reported between LOX, TIMP-1, SerpinB1 and MMP9 in human colorectal cancer patients, enhancing tumour cell invasion (291) (280,292). In addition, it was
recently demonstrated by Baker et al. (2013) that fibroblasts overexpressing LOX in vivo stimulate collagen
cross-linking and matrix stiffness in colorectal cancer through FAK activation (293). Further, when LOX
inhibitors have been used, reductions have been shown in the amount of activated fibroblasts, ECs, and a
significant decrease in desmoplasia and TGF-β expression (294).

1.6.5 Tissue transglutaminase-2 (TG2)
The transglutaminases are a family of (8 known) enzymes that occur both intra- and extracellularly in all
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mammals. Transglutaminases work by forming extensive cross-linked, mostly insoluble protein polymers, vital
for native tissue barrier formation and structural networks. TG2 [(78 kDa), also known as tTG, or tissue
TGase] is the most diverse and widespread of the transglutaminase family (295). This calcium dependent
enzyme catalyses the reaction between the group of ε-amino lysine residues in collagen I and the γcarboxamide group of glutamine residues in itself or other proteins (refer to Fig. 1.7), creating an inter- or
intramolecular isopeptide bond, highly resistant to mechanical stress and proteolysis (296). In addition to
collagen crosslinking ability of TG2, this ubiquitously expressed enzyme is a component of many cellular
compartments, including exosomes, and is an intrinsic component of the plasma membrane. Furthermore,
TG2 is able to catalyse many other biochemical reactions including GTP-binding/hydrolysing, deamidation and
isopeptidase activity (296). TG2 is abundantly expressed in the cytosol of skin, heart, liver and small intestinal
cells, while smaller amounts can also be found in the nucleus and mitochondria of cells (297).
Extracellularly, TG2 is known as nature’s biological glue and its expression is elevated in multiple cancer cell
types, implicated in drug resistance and metastasis due to its ability to promote EMT and stem cell-like
properties of tumour cell populations (298). Like SerpinB2, TG2 is induced under inflammatory conditions
and is deposited into the ECM after cell damage and stress to help in the remodelling and/or stabilisation of
several ECM proteins, binding with great affinity to fibronectin (299). TG2 is now one of the earliest
biomarkers of coeliac disease, stimulated mainly via TGF-β (300) and known to deamidate dietary gluten
peptides and aggregations, acting as a target auto-antigen in the immune response, essential for coeliac disease
pathogenesis (297,301). Interstingly, TG2 has been shown to have a positive feedback with TGF-β, increasing
it’s expression through NF-κB pathway activation (302). Extracellular TG2 increases cellular adhesion,
proliferation, migration, differentiation, ECM stabilisation, wound healing and signal transduction (298). For a
general review of the diverse roles TG2, refer to (303).
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1.6.5.1 SerpinB2 and TG2
It has previously been shown that SerpinB2 cross-links to fibrin(ogen) via TG2 (in trophoblasts), through
reaction with one of SerpinB2’s three Glutamines in the CD Loop (Gln83, Gln84 and Gln86) (304). Jensen et al.
(1993) stated that the TG2-catalysed/Ca2+-dependent anchoring of SerpinB2 to ECM structures could be
responsible for focally regulating fibrinolysis (181). In addition, they demonstrated that SerpinB2’s uPAinhibitory activity was not affected by cross-linking to fibrin(ogen), and activated peripheral blood monocytes
still efficiently inhibited uPA-mediated fibrin clot lysis, through secretion of SerpinB2 into clots (181).
Intracellular TG2 plays an important role in apoptosis and is known to use SerpinB2 as a substrate (182).
Recent studies have linked SerpinB2 and TG2 as downstream mediators in the anti-apoptotic response
triggered upon activation of TANK-binding kinase 1 (TBK1) (182). Studies by Delhase et al. (2012) show that
TBK1 induces SerpinB2 expression, which stabilises TG2, cross-linking and inactivating procaspase-3, in a
TNF-dependent manner (182). This study potentially provides explanation of the cytoprotective ability
conferred to SerpinB2 (305). It has also been shown that TG2 -/- mice are increasingly susceptible to cell death
in acute liver trauma (182), and reported symptoms of mild onset of diabetes through ageing, thought to be
related to insulin release disruption from pancreatic β-cells (295).
Interestingly, SerpinB2 has also been shown to be cross-linked to the cornified envelope of skin by plasma
transglutaminase (TG1) (306). TG1 is anchored within the inner plasma membrane of keratinocytes, and
activated with SerpinB2 in inflammatory conditions, such as congenital ichthyosis (306). Bechtel et al. (1996)
reported that not only was SerpinB2 a major PAS inhibitor within normal epidermis, but within lupus
erythematosus patients the increased epidermal SerpinB2 was not associated with an increase in epidermal uPA
or tPA (307). Their data led them to hypothesise that epidermal SerpinB2 may have other functions than
merely uPA inhibition (307). Further, Schroder et al. (2010) reported that SerpinB2−/− mice infected with
Schistosoma japonicum, which can cause schistosomiasis in the liver and other tissues incurring fibrosis, had
reduced collagen I fibrosis (as determined by collagen I picrosirius staining) versus wild-type (SerpinB2
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expressing) mice (158). Interestingly, in the two most researched areas that SerpinB2 and TG2 bind, i.e. the
skin (keratinocytes of the cornified envelope) and endometrium (endometrial cells, trophoblasts and the
decidua), there is a reported increased SerpinB2 expression associated with tumour promotion (139,211).
Whether there is a direct relationship within tumours of these tissues and SerpinB2 activity requires further
elucidation. In regards to SerpinB2 activity within endometrial tissue, this could potentially be an area of great
revelation for there are significant homologies between tumour biology and development.

1.6.6 SerpinB2 and TG2 in the TME and development
It has been shown that early embryonic cells share extremely similar phenotypes to tumour cells (308). Both
undertake deprogramming to a proliferative stem cell state and develop immortal and invasive stages (308).
These homologies were first speculated in 1892 by two French biologists, Lobstein and Recamier, but not
since advances in genetics and developmental biology has this been further elucidated (309). Studies now show
that embryonic development gene programmes are also being hijacked and used by invading tumour systems
(308). It has been demonstrated that signaling pathways in patterning and morphogenesis within embryo
development are co-ordinated by FGF, BMP, Wnt, Notch and Hedgehog signalling pathways (13). These
pathways have been reported to be reactivated during tumourigenesis and contributing to tumour cell EMT,
invasion and metastasis (14). Thus, through a functional and mechanistic understanding of trophoblast invasion
many insights into metastatic cancer cell invasion are being revealed (310). Moreover, it has been reported that
K-Ras mutation/over-activation coupled with developmental genetic elements (such as wnt-β-catenin, TGFand Hedgehog) above crucial temporal thresholds drives differentiated pancreatic cells into a de-differentiated,
ductal state (311,312). This has been shown to persist towards the formation of pancreatic epithelial neoplasia
(PanIN) and can eventually result in pancreatic ductal adenocarcinoma (PDAC) (313) (Fig. 1.8). Further indepth understanding could increase biomarker identification, new diagnostic techniques and future treatment
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options to control the advancement and dissemination of metastatic cancer (309).

It is known that trophoblast differentiation throughout first trimester pregnancy involves cell proliferation,
invasion and ECM remodeling (refer to Fig. 1.8). It is generally accepted that coordinated expression of
MMPs/TIMPs and tPA/SerpinE1 play the key roles in fibrinolysis during early stages of placentation and
separation of the placenta from maternal tissue at term (134,314). During pre-eclampsia, plasma tPA and
SerpinE1 levels are distinctly increased and there is an association with increased concentration and preeclampsia severity (123,315). Interestingly, SerpinB2 levels are significantly reduced in pre-eclampsia and
clinically the use of the ratio of high SerpinE1/SerpinB2 is associated with pre-eclamptic pregnancies [while the
reverse ratio is associated with normal pregnancy (123,315)]. In patients of intrauterine growth retardation,
uPA and SerpinB2 levels are prominently decreased, indicating that reduced uPA regulation and inhibition
decreases placental function and potentiates intrauterine growth retardation (123). As uPA and SerpinB2
appear mainly to degrade trophoblast cell-associated ECM during early stages of placentation (314), it has also
been proposed that cell membrane associated plasmin could impart directionality on migrating trophoblasts
through basement membranes and interstitial tissues (316). Zini et al. (1992) also observed both SerpinB2 and
SerpinE1 are secreted by trophoblasts in greater amounts than uPA (316), potentially to ensure critical uPA
regulation, however it is proposed that there could be additional roles concomitant with uPA inhibiton (316).
Further, trophoblast cell types (refer to Fig. 1.8) require the production of focal adhesions mediated by a
cytoplasmic tyrosine kinase named focal adhesion kinase (FAK) (317). Within endometrial invasion by a
blastocoele, FAKs are involved in trophoblastic cellular proliferation, migration/invasion, and ECM
remodeling, specifically expressed within villous cytotrophoblast and extravillous trophoblast (EVT) cells, colocalised with integrin α5 and MMP2 (317). Additionally, it has been shown that cell–ECM adhesion is
strengthened via TG2 cross-linking to integrin within cells causing receptor clustering, increasing integrins and
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syndecan-4 causing increased signaling and activation of FAK, ERK1/2, Rho/ROCK, AKT and PKCα (318320). This activity further stimulates TG2-mediated enhancement of cell adhesion and migratory processes
(320). Robinson et al. (2006) reported significant TG2 protein and mRNA present in stromal and trophoblast
cells from first trimester and at term, with higher levels appearing in third trimester (321). Further, it was
demonstrated that primary cultures of embryonic trophoblast, fibroblast and decidual stromal cells all produce
TG2 (321).

Fig. 1.8. Invasion of human trophoblasts and PDAC cell invasion. A. After blastocoele anchorage to maternal endometrial
BM, villous cytotrophoblast precursor cells proliferate in cell columns. Extravillous trophoblasts (i.e. interstitial cytotrophoblasts)
disconnect from cell columns and migrate into stromal areas of maternal decidua. Some interstitial cytotrophoblasts differentiate into
giant cells in deeper placental tissue areas, while endovascular trophoblasts (eCTB) within maternal arteries replace maternal ECs and
attain endothelial physiognomies. Adapted from (322). B. Within the pancreas, cells can acquire specific mutations that perpetuate
metaplasia and dysplasia, leading to pancreatic ductal cell proliferation, progressing down a pathway to PanIN and towards a
malignant phenotype. PDAC cells can reactivate developmental genes triggering BM degradation and EMT allowing invasion into the
ECM. Different modes of invasion can occur including mesenchymal, amoeboidal and collective cell streaming. Invasion is also
advanced with the assistance of stromal remodelling, paracrine signalling and growth factor secretion from carcinoma associated
fibroblasts (CAFs); further addressed in Chapter 4.

1.6.7 TG2 in cancer
In a tumourigenic system, TG2 expression causes activation of FAK and the downstream PI3K/Akt1 prosurvival pathway (320). Furthermore, Chau et al. (2005) reported that treating collagen I with TG2
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significantly increased cell attachment, migration and proliferation of both human osteoblasts and human
foreskin dermal fibroblasts, in comparison to native collagen I (323). Interestingly, the TG2-treated collagen
also had enhanced resistance to proteolysis over native collagen, due to increased cross-linking (323). Orban et
al. (2004) showed that TG2 supplemented collagen I gels exhibit increased mechanical strengthen of fibrillar
bundles, raising the denaturation temperature and burst pressure of gels, versus native Collagen gels (without
TG2 mediated polymerization) (324). Moreover, Fortunati et al. (2014) demonstrated that cross-linking of
collagen I by TG2 caused human osteoblasts to attach, spread, proliferate, differentiate and mineralise more
rapidly compared to cells seeded onto native collagen (325).
Moreover, there is increasing evidence of TG2 as a substantial player in tumour progression. TGF-β, TNF-α,
IL-1, IL-6 and NF-κB have all been shown to up-regulate TG2, driving inflammation and cancer progression
(296,326,327). TG2 has been shown to be up-regulated in the stroma of invasive ductal breast cancers
(328,329), and proposed as an independent risk factor for identifying patients at high risk of tumour
recurrence (330). In one of the most aggressive cancer types, pancreatic ductal adenocarcinoma [(PDAC) – the
focus of Chapter 4], Verma et al. (2006) showed that 42 of 75 (56%) tumour samples collected had higher
basal protein expression levels of TG2 compared with normal pancreatic duct tissue (331). Increased TG2
expression in PDAC was strongly associated with nodal metastasis and lymphovascular invasion (331). Verma
et al. (2006) also reported that TG2 induces activation of FAK and PI3K/AKT pathways, contributing to
PDAC drug resistance and a more invasive PDAC phenotype (331). Subsequently, Verma et al. (2008) showed
that siRNA down-regulation of endogenous TG2 abrogated the growth of PDAC tumours, through inhibition
of PDAC cell proliferation, angiogenesis, and Akt phosphorylation (327). In addition they also reported a
significant increase in gemcitabine efficacy with increased metastatic inhibition through TG2 knockdown (327).
Consequently, both LOX and TG2 significantly impinge upon disease states of tissue fibrosis involving collagen
I cross-linking malfunction. They are individually and dually expressed and secreted into the ECM by activated
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fibroblasts, directly leading to enhanced collagen cross-linking, stromal remodelling, EMT migration and
metastasis in cancer tissues (264,326,332). To this end, it is necessary to investigate their potential association
with the PAS (in particular, SerpinB2), specifically one of the main cell types that secrete these enzymes - the
fibroblast.

1.6.8

The Fibroblast & ECM remodeling

Fibroblasts are a heterogeneous population of cells of mesodermal origin and the most common cell type of the
connective tissue cell family (333). Fibroblasts are able to transform into any of the other members of the
family, including cartilage cells, bone cells, adipocytes, and smooth muscle cells (333). These transformations
are dependent upon the structural and chemical composition of the surrounding ECM, as well as an individual
cell’s specific shape and growth cycle (333). The –blast suffix refers to a more active and plastic cell, while
fibrocytes are considered less metabolically operational and unchangeable. Fibroblasts are generally
distinguished from fibrocytes by their abundance of cytosolic RER and relatively larger cell size (334).
Fibroblasts can synthesise and secrete collagens, collagenases, MMPs, TIMPs, uPA, uPAR, SerpinB2,
glycosamino- and proteo-glycans, reticular and elastic fibres, fibronectin, many types of growth factors [FGF2, TGF-β, PDGF, hepatocyte growth factor (HGF), insulin-like growth factors (IGFs), nerve growth factors
(NGFs), Wnt1 and EGF], cytokines (IL-1 and others), chemokines [(monocyte chemotactic protein 1 (MCP1)
and others], enzymes (LOX, TG2) and glycoproteins of the ECM (43,335-339). They provide the structural
stromal network and are actively involved in remodelling this area during pregnancy, wound healing, fibrosis,
cancer and other disease states (43). Originally considered a homogenous cell population (334), fibroblasts can
exist morphologically in many shapes and sizes, from flat, plump, to spindle- or stellate shaped (activated) with
multiple protrusions, processes and generally have a centrally placed oval or round nuclei, depending on the
tissues specific properties and functions in which they exist (340). Fibroblasts can exist in dormant/quiescent
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states as well as in an activated form (341). Their organ distribution and relative proportion of subpopulations
is known to have a considerable impact on the regulation of that specific tissues function in both health and
disease (341).
Moreover, fibroblasts have been shown to associate with tumour cells at all stages of cancer progression (43),
and their structural and functional contributions to this process are only now beginning to emerge (Fig 1.9).
Fibroblastic secretion of VEGF, TGF-β, GFs, chemokines and ECM facilitates the angiogenic recruitment of
ECs and pericytes (43,247). Fibroblasts are instigated to transition into an activated ‘myofibroblast’ state by
TGF-β, which ultimately leads to the pro-tumourigenic carcinoma-associated fibroblast (CAF) phenotype.
However, not all CAFs originate this way and the CAF phenotype can have multiple cells-of-origin, including
resident pericytes, ECs, adipocytes, epithelial cells and bone marrow-derived mesenchymal cells (BMDCs)
(42,342,343). CAFs engage in continuous molecular cross talk with tumour cells and have even been reported
to arrive at metastatic sites ahead of cancer cells (344).
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Cancerous

Fig. 1.9. Schematic representation of the biological activities undertaken by fibroblasts within the TME. Nontumourigenic or normal associated fibroblasts (NAFs) transition to activated fibroblasts, which ultimately lead to pro-tumourigenic
carcinoma-associated fibroblasts (CAFs). This figure also shows uPA/uPAR, VEGF-A and its receptor VEGFR-1, as contributing to
the TME. Soluble-secreted factors, such as TNF-α, are capable of eliciting multiple effects within the TME [TNF-α induces TGF-β
expression in lung fibroblasts (345)]; the figure depicts TGF-ß causing cells to undergo EMT/invasion and
proliferation/differentiation of CAF. TGF-β is known to up-regulate expression of SerpinB1 and SerpinB2, MMP-2, TIMP-1 and
plasmin (346). TGF-β up-regulates uPA in tumour associated macrophages (TAMs) (347) and stimulates uPA expression in cancer
cells (348), while uPA (via plasminogen activation) activates secreted latent TGF-β, creating a pernicious positive feedback loop
(349).

Traditionally, co-cultures of cancer cells with NAFs and CAFs have been used as in vitro models of EMT and
tumour invasiveness. In order to test fibroblast cell types within models of collagen crosslinking, stromal
remodeling and tumour invasion, more modern 3D systems are being employed.
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1.7

2D versus 3D in vitro models

Historically, assessment of both genetic and molecular mechanisms has been conducted on tumour cells
cultured on a flat monolayer (i.e. 2D in vitro system). However, pioneers in the cancer field demonstrated that
tissue context profoundly affects tumourigenesis and progression. In 1984, David Dolberg and Mina Bissell
demonstrated that the normal chicken embryonic microenvironment could override potent oncogenes [from
Rous Sarcoma Virus (RSV)] to cause malignant transformation, and that wounding promoted tumour
progression (11). Since that time it has been widely shown that tissue stroma can either promote or inhibit
tumour progression (350-352), (353). Advances within biotechnology and increased understanding of
biological tissue componency have made it both possible and ideal to develop 3D systems incorporating
numerous cell types and ECM molecules and substrates. These models are biomimetic and correctly
recapitulate the native in vivo scenario of tumour systems (354). It is now well known that cells behave
extremely different in a 2D system to that of 3D systems, where spatial limitations do not allow true
representation of cell-matrix interactions (354). 3D models show stark variances to 2D in regards to cellular
behaviours such as differentiation, proliferation, and gene expression (355-357), allowing for greater
assessment adequacy of complex in vivo whole organism approaches, where both cell–cell and cell-matrix
interactions generate signaling pathways and cellular responses (358). It has been shown that specific genes are
expressed in 3D, but not in 2D models. For example, Timpson et al. (2011) demonstrated that pancreatic
cancer cellular protrusions at the leading edge are RhoA-dependent in a 3D organotypic culture model, but not
in 2D cultures (359), and then further reported it’s expression in vivo (359,360). Linder et al. (2003) showed
that podosomes and invadopodia on migratory and invasive cells express high levels of actin, only observed in
3D and in vivo systems, yet not 2D models (361). It has also been shown that the classical focal adhesion
proteins, paxillin and vinculin, were present within focal adhesions in vivo at a concentration comparable with
cells within 3D matrices (362).
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It is now known that 3D systems recapitulate a gamut of autocrine, direct and indirect paracrine signaling and
cell type-specific behaviours as occurs in vivo, vital for cancer progression and not always observed 2D systems
(358).
The increased reliability of 3D systems in pre-clinical application for the assessment of therapeutics in
cytotoxicity, tumour progression, invasion and metastasis is unrivalled. Since the advent of 3D cancer models
there have been increases seen in drug resistance versus 2D models (363). Such resistance can be attributed to
many factors, one of which is limited diffusion through culture matrices facilitating hypoxia, shown to activate
cell-survival genes and preclude drug sensitivity (364). Such chemoresistance is often demonstrated in 3D
spheroid cultures first and then also observed in vivo (365). Another significant factor involved is the ECM and
remodeling, undertaken by stromal cells. A recent study by Yip and Cheul (2013) showed using a multicellular
3D culture that hepatic tumour cells displayed increased chemoresistance due to the stromal cells present in
their model (366). Talukdar et al. (2012) demonstrated in their 3D silk fibroin scaffold model that increased
drug was required for cytotoxic effects and invasion inhibition of triple negative MDA-MB-231 breast cancer
cells when compared with 2D cultures (367). In addition, 3D spheroids composed of either human or mouse
pancreatic ductal adenocarcinoma (PDAC) cells showed an increased in drug resistance compared with 2D cell
cultures, reflecting PDAC chemoresistance in vivo, believed to be due to integrin signaling effects (368). As
such, in order to produce reliable laboratory models for drug design and testing, 3D models are becoming the
gold standard.
One of the few downsides to some 3D culture systems is the decreased high-throughput nature in drug
screening, time constraints and cost. In addition, much effort is still needed to assure reproducibility, matching
of scorer analysis techniques, and automation in order to establish greater consistency. However, once a
promising anti-cancer drug is in the pipeline, 3D cancer models are an ideal pre-animal tool to expose any
flaws in drug efficacy or potential resistance mechanisms before commencing even more costly and timeconsuming in vivo systems (358).
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Additionally, it was recently proposed that cells can move rapidly through 3D fibrillar matrices via a 1D
migratory mechanism, attaching to single fibres, not mirrored in 2D matrices (369). This work illustrates that
cells interact and move within a wide range of dimensions in vivo from 1D, 2D and 3D, and as such it may be
necessary to consider utilising both 2D and 3D systems for tumour invasion assessment (358,369).
Nonetheless, the field is at a consensus that both the increased mimetic nature and utility of 3D systems in
modeling cancer behaviour in live tissue is a significant advantage over 2D models.

Moreover, as aforementioned (refer to section 1.9.3 and 1.10) collagen remodeling and cross-linking is a
major facilitator for tumour invasion, which means that pre-clinical cancer testing utilising collagen I is an
important element. It has been shown that increasing the number of fibroblasts within collagen matrices can
enhance tumour invasion. The addition of matrigel or cell-derived matrix (hyaluronic acid, laminins, FGF)
factors to collagen matrices can produce a realistic tissue bed and stimulate the specific sets of surface receptors
and activate signaling pathways as occurs within the TME (370). One such 3D investigatory apparatus is the
organotypic model.
1.8 The 3D organotypic model
This model allows one to decipher the molecular and cellular mechanisms encompassing tumour and stromal
microenvironment interaction. Once a matrix of fibroblasts and Collagen I is produced, it is considered
appropriately similar to the tissue of the fibroblast cell origin (371). Formation of the substratum depends
greatly upon the fibroblasts used and their ability to package and assemble collagen fibrils and bundles. Upon
this stromal matrix is then seeded epithelial carcinoma cells, imitating the in vivo monolayer of the majority of
early solid tumour tissue microenvironments. Once confluent, the carcinoma cells are then induced to invade
into the underlying stroma by a chemotactic air-liquid interface over a predetermined period of time (7-21
days) (Fig 1.10). Quantitation of reductions in the extent of invasion can be used as a measure of anti-invasive
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capacity of added compounds and assists in bridging the gap between traditional cell culture systems and animal
studies. Additionally, advanced microscopy techniques are providing new insights on how cells behave in their
native microenvironment thereby improving understanding of disease progression.

Tumour Cell
Seeding

Tumour cells

Fig. 1.10. Schematic of preparation and experimental progression of the 3D organotypic assay. A. Initial Collagen I
extraction from rat tails is performed via tendon dissection, acetic acid extraction, NaCl precipitation and dialysis into 17.4 mM
acetic acid, at physiological pH 7.4. B-C. Human or murine fibroblasts are co-cultured with harvested Collagen I and the matrices
are contracted over a pre-determined time course (7-21 days). D. Contracted matrices are then seeded with carcinoma epithelial
cells in 24-well plates and allowed to grow to confluency. E. After this time, matrices are partially submerged on top of a stainless
steel, sterile grid to create an air/liquid interface. The carcinoma cells are then induced to invade into the underlying stroma by the
chemo-attractive gradient and quantitation of reductions in the extent of invasion can be used as a measure of anti-invasive capacity of
added compounds.

The organotypic model directly utilises this dynamic reciprocity ideal and, in a cancer research setting, offers
researchers the foundations to explore the entire process of tumourigenicity, from ECM formation, stromal
remodelling, fibroblast migration, autocrine/paracrine and cell-type specific signalling, tumour cell
dissemination, migration and fibroblast-epithelial cell interaction. Invading tumour cells can be assessed for
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paracrine, autocrine or specific signalling proteins, which can ultimately provide greater in vitro fidelity to
support further in vivo models, reduce animal experimentation and increase drug discovery regimen (372).
Previously, such deep insight has been particularly challenging, as these tissues are fairly inaccessible to
experimental manipulation and optical observation. In the last decade there have been several novel
innovations in 3D culture experimentation, such as the organotypic model. In combination with the capacity to
isolate specific genes or proteins and manipulate individual microenvironmental factors, these systems have
facilitated the real-time analysis of live biological tissue specimen. These techniques can now be used to
visualise the cellular basis of fibroblastic migration, epithelial morphogenesis and migration modality, to test
the roles of specific genes in regulating cell behaviour and the nature of cell-ECM interactions within
equivalent carcinomatous tissues of the human condition. This is allowing for the elucidation of the
contribution of microenvironmental factors to normal and disease processes. Collectively, this novel model can
be used to answer fundamental biological questions and generate replacement human tumourigenic tissue,
affording the increased fidelity and applicability of novel therapeutic approaches.

1.9

Aims and Project Rationale

From a review of the current literature it can be seen that there are significant roles of SerpinB2 within the
TME of both primary and metastatic lesions. Overall, further understanding of the function of SerpinB2 in cell
migration, collagen cross-linking, tumour invasion and metastasis is required in order to investigate it’s
mechanistic roles in tumour progression and/or inhibition. There is potential for the development and future
utilisation of SerpinB2 based targeted therapies in the treatment of cancer and/or angiogenesis in patients with
uPA over-expressing cancer, thus an additional outcome of this project is to provide further rationale for
development of these novel therapeutics. The uPA binding properties of SerpinB2 has been exploited for
utilisation in targeted anti-cancer therapeutic design (227,373). SerpinB2-cytotoxin conjugates with improved
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pharmacokinetic properties hold promise for further development in this regard (129,130). However, a better
understanding of the ideal context and applicatory schedule of benefit for SerpinB2’s presence or absence
within the TME, should lead to increased efficacy in treating metastatic tumours. As this thesis is focused on
the role of the PAS in ECM remodeling, tumour invasion and metastasis, the cancers for experimentation were
chosen with relation to their expression of PAS components as well as their stromal environment and ECM
remodeling impingent on invasiveness. As Pancreatic ductal adenocarcinoma (PDAC) and triple negative breast
cancer (TNBC) both utilise the PAS and form solid tumour malignancies characterised by a high stromal
content, they were employed in this study. Thus, the overall aim of this thesis was to further investigate
whether the primary role of SerpinB2 in both PDAC and TNBC cell invasion is through a uPA inhibitory role
and/or additional mechanisms unrelated to protease inhibition. In order to investigate these potential
activities, the specific aims of this study were:
1.

To scrutinise the spatiotemporal effects of SerpinB2 expression, through development of lentiviral
systems to modulate SerpinB2 gene expression and GFP reporter gene applications in epithelial
and fibroblastic cell lines, respectively.

2.

To elucidate the effects of SerpinB2 in collagen cross-linking and ECM remodeling using wt &
SerpinB2-/- murine embryonic fibroblasts (MEFs) and functional imaging in a 3D organotypic
contraction model.

3.

To define the mechanism of SerpinB2 regulation in tumour invasion and metastasis in breast and
pancreatic tumour organotypic invasion models, utilising advanced functional imaging assessment.

4.

To investigate in vivo effects of modulated tumour cell SerpinB2 expression on tumourigenesis,
collagen ECM remodeling and local invasion in an allograft mouse model of pancreatic cancer and
a xenograft model of breast cancer.
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CHAPTER 2
PRODUCTION OF LENTIVIRAL VECTORS TO ASCERTAIN THE
SPATIOTEMPORAL EXPRESSION OF SERPINB2 WITHIN THE TME
2.1 INTRODUCTION
In order to elucidate underlying cell-specific effects of the spatiotemporal expression of SerpinB2 within the
TME, the expression of SerpinB2 within epithelial cells was manipulated, through the use of third-generation
lentiviral vectors. These lentiviral systems were utilised as they provide a fast and efficient means for
modulating gene expression and GFP knock-in for reporter gene applications in live cell imaging of collagen
remodeling and the TME (372).
2.1.1 Lentivirus
Lentiviruses belong to the large family, Retroviridae, spherical virions ~100 nm in diameter, with an outer
envelope displaying glycoproteins. Two copies of linear viral RNA genome (approximately 10 kb) are
enclosed, which contain three essential genes, gag, pol and env (374). The pol gene encodes three important
viral enzymes: reverse transcriptase, protease and integrase. The gag gene encodes for the structural proteins:
the capsid, nucleocapsid and matrix (375). Proteins are produced by a proteolytic separation of the gag-pol
precursor (376) (Fig. 2.1). The env gene codes for the viral envelope glycoproteins, which bind and attach to
target cell-surface receptors. Upon internalisation into a host cell, a pre-integration complex is formed (374),
which is then transported into the nucleus, allowing transduction within both dividing and non-dividing cells
(377,378). The viral enzyme integrase then initiates the proviral DNA integration within the host cell’s
genome. This process is made easier by long terminal repeats (LTRs), which can occur hundreds or thousands
of times at both the 5’ and 3’ ends, acting as promoters to aid in viral DNA synthesis, integration and
transcription regulation (379). Lentiviruses contain a complex genome, able to transduce a significant amount
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of RNA into the DNA of a mammalian cell, irrespective of cell cycle phase (380-383). This is a valuable feature
for utilising lentiviral vectors in modulating gene expression, with the ability to integrate and achieve long
term expression in biomedical research, making them attractive tools for gene therapy (384).
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HIV-1 Provirus

C

D

β-Glob

CMV

polyA

RSV

Packaging plasmid
pMDLg/pRRE

E

rev polyA

REV plasmid
pRSV-REV

G
RSV

gag

Promoter Transgene Promoter PRE
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Fig. 2.1 A. Structure of wild-type lentivirus. Two ssRNAs are present within the nucleocapsid, covered by a capsid. The outer
lipid membrane is formed from the host cell and is the surface is coated in glycoproteins. Lentiviruses contain the important viral
enzymes: integrase, protease and reverse transcriptase (description is provided in the text). B. The wild-type HIV-1 genome –
through differential RNA splicing, can obtain nine gene products. The viral LTRs, viral gene reading frames, Psi packaging signal (Ψ),
and rev-responsive element (RRE) are shown. C-F. The third generation lentiviral vector system. C. The packaging plasmid
(pMDLg/pRRE) contains both Gag and Pol genes under the stimulus of the CMV promoter and polyadenylation site (polyA) of the
human β-globin gene. D. Rev cDNA-expressing plasmid, pRSV-Rev. E-F. These vector plasmids contain HIV-1 cis-acting sequences
and an expression cassette for the transgene (cDNA or shRNA). Only the transgene is transported to target cells and no HIV-1 LTRs.
G. The envelope plasmid, pMD.G – a vesicular stomatitis virus (VSV) pseudotype. Co-transfection of all vectors into dividing and
non-dividing cells provides genomic integration of a specific transgene for gene expression modulation and concurrent
experimentation. Only significant sections of each construct are shown. Adapted from (385).

2.1.2 Lentiviral transfer vectors used for expression of cDNA and shRNA
Lentiviral vectors are based on the first viral vectors made by Nobel laureate, Paul Berg. Berg and colleagues
constructed hybrid viruses containing SV40 monkey virus and λ phage DNA segments, and were the first to
propagate their replication inside cultured monkey cells (386). To this day SV40 viral polyadenylation
sequences are used downstream of the 3' LTR of the latest generation lenti-vectors, as these greatly reduce the
chances of transcriptional interference (387).
Lentiviruses can be stably integrated into dividing and non-dividing cells for long term transgene expression,
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both in vitro and in vivo (379,382,388). Successful preclinical studies employed for treating Parkinsons,
Alzheimers and Huntingtons diseases have been undertaken, as well as for the correction of genetic disorders
such as immunodeficiencies and haemoglobin disorders (378,389,390). RNA interference has been readily
used as a robust tool to down-regulate specific gene expression. Lentiviral vectors enclosing short hairpin RNA
(shRNA) are extensively shown to induce efficient knockdown of specific individual and multiple cellular genes
(391) (Fig. 2.2), as well as utilisation for the creation of transgenic animals (392).
A large effort has been made in the field to remove all non-essential HIV-1 sequences for viral replication, thus
only viral proteins are transcribed within target host cells and the only genetic material that is incorporated
into the transfer vector is the transgene cassette with non-coding viral elements [such as LTRs, Psi packaging
signal, Rev responsible element (RRE)] (refer to Fig. 2.1). Another greate benefit of lentiviral vector systems
are their low immunogenicity invoked within the host. However, there have been reports of immune
responses directed against the VSV-G envelope (393). Due to the complexity of lentiviral vectors, and the
adverse risks of HIV gene incorporation, the third generation lentiviral vectors were formulated with three or
four plasmid lenti-vector production systems, with marginal sequence homology (394). At present, third
generation lentiviral vectors are the most readily used vector systems for delivery of short-interfering RNA
(siRNA) to cells (395) (refer to Fig. 2.1).
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Sense Strand

Antisense Strand

GGCAGGGTAGTTATCCTGATGCGATTTACATCTGTGGCTTCACTAAATCGCATCAGGATAACTACCT
CCGTCCCATCAATAGGACTACGCTAAATGTAGACACCGAAGTGATTTAGCGTAGTCCTATTGATGGA
Sense Strand
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SerpinB2 shRNA
Lentiviral infection

SerpinB2
shRNA
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shRNA

siRNA
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mRNA
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Cell membrane
SerpinB2 Gene Silencing

Fig. 2.2. Mechanism of RNA interference. To understand the effect of SerpinB2 knockdown, a lentiviral vector was created
with a sequence of SerpinB2 that was cloned into a pEN_TmiRc3 plasmid for use with the pSLIK system (single lentivector for
inducible knockdown). This lentivirus is then used to infect mammalian cells. In this process, SerpinB2 shRNA expressed from pSLIK
lentivirus forms a double stranded stem-loop structure, which is cleaved at the loop by the cytosolic enzyme, DICER. This cleavage
causes SerpinB2 shRNA to be integrated into the RNA-induced silencing complex (RISC). Herein, RISC guides the Serpin B2 shRNA
strand to its complementary mRNA target, cleaves the specific SerpinB2 mRNA sequence and then targets it for degradation coordinated by SLICER (396) .

2.1.3 Third generation lentiviral vectors
The overall difference between the second and third generation systems of lentiviral vectors is the increase in
the safety of their organisation. This has been achieved through splitting up the gag, rev and pol packaging genes
into two plasmids as well as splitting the gag/gag-pol gene into several parts (397). In addition, third generation
lentiviral systems have no tat regulatory gene and the development of the self-inactivating (SIN) vector was
accomplished by creating deletions in the 3 ́LTR (398,399). This abolished any LTR transcriptional activity,
thus reducing the risk to form RCL and minimising the chance of endogenous gene interference (399-401).
Third generation lentiviral vector systems utilise four-plasmids, as shown in Fig. 1.1, that contain HIV-1’s gag,
pol, and rev genes inserted between LTRs with promoter activity at both ends. Through separation of the
vector system into four plasmids [(three helper – one envelope (pMD.G) and two packaging vectors
(pMDLg/pRRE and pRSV-Rev) - and one transgene vector) refer to Fig. 2.3], there is a large increase
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required in the number of recombination events in order to form a complete replicative competent virus. In
this respect, to date there have been no reported cases of replication competent lentiviruses (RCLs) occurring
(385). With the addition of an extra plasmid, third generation lentiviral systems are potentially more difficult
to use because they require transfection with four separate vectors to create fully operative lentiviral particles.
Furthermore, third generation lentiviruses contain the incorporation of a central polypurine tract (cPPT) and a
post-transcriptional regulatory element from woodchuck hepatitis virus (WPRE) into the 3´end of the transfer
vector. This has been shown to improve transgene expression (402), increase transduction efficiency, nuclear
localisation and the total amount of RNA integrated into the targeted host cell genome (403) (404). Newer
generations of lentiviral systems have increased the application for viral vectors, including functional gene
restoration and animal transgenesis, standard cellular biology and cancer research, and other types of clinical
research (405). One of the latest lentiviral construction methods, based on a hybrid virus system, is the
Gateway® lentivirus vector system, by Invitrogen™ (CA, USA). This system was used in this project as it
offered a rapid and highly efficient site-specific recombination technology, through taking advantage of the
properties of bacteriophage lambda. Lambda recombination happens within specific attachment (att) sites: attB
on E. coli’s chromosome with attP on the lambda’s chromosome (406). These att sites have been wellcharacterised (407); upon lambda adherence and integration, recombination occurs between attB and attP
sites, giving rise to attL and attR sites (406) (refer to Fig. 2.1).
Moreover, within E. coli, the Tet repressor protein (TetR) negatively controls the tetracycline-resistance
operon (408). TetR blocks gene transcription through binding tet operator sequences (tetO) when
Tetracycyline is absent (409). In the presence of Tetracycline, TetR cannot bind tetO and gene transcription
can occur (410). Collectively, TetR and tetO are the foundation for the third generation Gateway® Tet vector
systems, regulating gene expression (411). The Tetracycline responsive promoter element of the Gateway®
TetR vector is inactive in the absence of tetracycline (or more frequently used, doxycycline). Once
doxycycline is applied to the culture media (at a concentration that does not otherwise affect mammalian cell
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behaviour), the tTA is allosterically modulated to bind to the CMV promoter and drive transgene expression
(375). Thus, when co-transfected into mammalian packaging cells with Gateway® Lenti transgene vectors, the
lentivirus produced to transduce target cells generates an effective apparatus to control the expression level of
a specific gene of interest simply through adjusting the concentration of doxycycline, the system’s inducer
(Fig. 2.3).
Transgene

pMDLg/pRRe

pRSV-Rev

pMD.G

Envelope & Packaging Vectors

HEK-293T Packaging cells

Lentivirus with
trasngene

Lentivirus
with TR

Target cells

- DOX

Expression OFF
No expression of transgene

+ DOX

Expression ON
Expression of transgene

Assay for recombinant
protein of interest

Fig. 2.3. Production of an inducible gene expression system. Co-transfection of envelope (pMD.G) and packaging vectors
(pMDLg/pRRE and pRSV-Rev)(Gateway® Tet vector Systems) into 293T cells are used to generate high-titre lentiviral particles
from both the pLenti3.3/TetR vector and pLenti6.3/V5-DEST vector, which contains the gene of interest. Target cells are then
simultaneously co-transduced with the two lentiviruses. After antibiotic selection and culturing for an additional 48 h (+/–
Doxycycline addition), the cells are harvested for recombinant gene analysis.
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As this project involved both increased and decreased expression of SerpinB2, as well as GFP knock-in for
reporter gene applications, different third generation lentiviral vectors were required to be constructed
(shown in Table 1).

Table 2.1. Third-generation lentiviral transfer vectors used for expression of cDNA and shRNA knockdown.
cDNA Transfer Vector

Cloning

Selection

Fusion tag

Citations

pLenti6.3/TO-DEST-V5
CMV (TO)

Gateway

Blasticidin S

C-terminal V5

(398)

pLV-eGFP

MCS

GFP fusion

C-terminal EGFP (398)

Cloning

Selection

BfuAI/Gateway

UbC-Neo/Venus

CMV CMV

shRNA Transfer Vector
pSLIK

Promoter

Promoter

TRE TRE

Citations
--

(412)

The specific aims of this chapter were to:
1.

Design and construct lentiviral vectors for the knockdown (shRNA) of SerpinB2; overexpression
(cDNA) of SerpinB2,

R380A

SerpinB2 (inactive RCL mutant), and their ΔCD loop counterparts,

SerpinB2 ∆CD loop and R380ASerpinB2 ∆CD loop.
2.

Optimise and characterise these vectors within MDA-MB-231 mammary epithelial carcinoma
cells.

3.

Stably transduce GFP into both wild-type and SerpinB2-/- Murine Embryonic Fibroblasts (MEFs)
for cell reporter functioning in proceeding experimental models, in Chapters 3,4 and 5.
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2.2 METHODS
2.2.1

Cell lines and culture conditions

The invasive triple-negative (HER2-, PR- and ER-) human mammary epithelial carcinoma cell line MDA-MB231 (luciferase expressing, referred to as MDA-MB-231) was originally purchased from American Type
Culture Collection (ATCC, VA, USA) was maintained in Roswell Park Memorial Institute medium (RPMI1640), supplemented with 10% fetal bovine serum (FBS), 10 mM HEPES buffer and 125 IU insulin, in a
humidified 5.0% CO2 atmosphere at 37 °C. Murine embryonic Fibroblasts (MEFs) originally isolated from
wild-type and SerpinB2-/- mice (203) were a gift from Dr Wayne A Schroder (QIMR Berghofer Medical
Research Institute, Australia). MEF primary cultures were then continually passaged in RPMI-1640 containing
10% FBS at 37°C with 5% CO2 until spontaneous immortality was obtained. Identity of wild-type and
SerpinB2-/- cells was confirmed by RT-qPCR (data not shown) and western blot. All experiments in this study
were carried out using immortalised cells (unless specified otherwise) that were passaged ≤10 times before
experimental use. Furthermore, passage-matched cells were used for the majority of experiments within this
study. All cell cultures were routinely tested in-house for absence of mycoplasma contamination using the
MycoAlert™ Mycoplasma Detection Kit (Lonza, Switzerland).
2.2.2 Generation of SerpinB2 cDNA and shRNA
Experimental design was carefully reviewed to minimise off target effects and to create the most efficient
means of stable knockdown or overexpression of SerpinB2.

In order to generate SerpinB2 lentiviral

constructs, full length His-tagged SerpinB2, inactive R380ASerpinB2 and their ∆CD loop forms, SerpinB2 ∆CD
loop and

R380A

SerpinB2 ∆CD loop, were created in our laboratory in pQE1 and pQE9 expression systems

(Qiagen, Netherlands), respectively (176). Plasmids were prepared using the Wizard Plus SV Miniprep system
(A1460, Promega) according to manufacturer’s instructions. Transfections were performed using midiprep
and maxiprep DNA only. Midiprep and Maxiprep DNA were prepared using the QIAGEN Plasmid Midi &
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Maxi Kit (12163, QIAGEN), according to manufacturer’s instructions. SerpinB2 plasmids were digested with
BamHI and PstI enzymes and checked for correct size via agarose gel electrophoresis. Constructs encoding a
hairpin targeting SerpinB2 were designed to knock down gene expression. SerpinB2 hairpins were created at
two regions within SerpinB2 mRNA sequence, and oligonucleotides were purchased and supplied by the
Garvan Institute’s ACRF Facility for the Molecular Genetics of Cancer (Darlinghurst, Sydney) (Fig. 2.4).
These DNA sequences were cloned into the pEN_TmiRc3 vector for use with the pSLIK system (412).

GTAACAACTCTCAGAGGAGCATTGCCCGTCAGACAGCAACTCAGAGAATAACCAGAGAACAACCAGCATTTCTTGCACT
ACAACTTGCTTAAGCTCTTACACTTCATAGTGAAGCTATGCACCACCGAGTGAAGCGATGTGGAACATTGGAAAGAGTG
GGCTTCCTTAGACAGACCTGGGCTTGAATCCCTGCTCCACTACCTACCAGCTGTGTGACCTTATACAAGTTACTTAATG
TTTCTGAGCATCAGGATATAATCTATAAAATAGGGAGAATCACCTCTACCTCATACAGATTCTGCAAAGATTAAACGAG
GAGAGGAGATTGAAACAATGGAGGATCTTTGTGTGGCAAACACACTCTTTGCCCTCAATTTATTCAAGCATCTGGCAAA
AGCAAGCCCCACCCAGAACCTCTTCCTCTCCCCATGGAGCATCTCGTCCACCATGGCCATGGTCTACATGGGCTCCAGG
GGCAGCACCGAAGACCAGATGGCCAAGGTGCTTCAGTTTAATGAAGTGGGAGCCAATGCAGTTACCCCCATGACTCCAG
AGAACTTTACCAGCTGTGGGTTCATGCAGCAGATCCAGAAGGGTAGTTATCCTGATGCGATTTTGCAGGCACAAGCTGC
AGATAAAATCCATTCATCCTTCCGCTCTCTCAGCTCTGCAATCAATGCATCCACAGGGAATTATTTACTGGAAAGTGTC
AATAAGCTGTTTGGTGAGAAGTCTGCGAGCTTCCGGGAAGAATATATTCGACTCTGTCAGAAATATTACTCCTCAGAAC
CCCAGGCAGTAGACTTCCTAGAATGTGCAGAAGAAGCTAGAAAAAAGATTAATTCCTGGGTCAAGACTCAAACCAAAGG
CAAAATCCCAAACTTGTTACCTGAAGGTTCTGTAGATGGGGATACCAGGATGGTCCTGGTGAATGCTGTCTACTTCAAA
GGAAAGTGGAAAACTCCATTTGAGAAGAAACTAAATGGGCTTTATCCTTTCCGTGTAAACTCGGCTCAGCGCACACCTG
TACAGATGATGTACTTGCGTGAAAAGCTAAACATTGGATACATAGAAGACCTAAAGGCTCAGATTCTAGAACTCCCATA
TGCTGGAGATGTTAGCATGTTCTTGTTGCTTCCAGATGAAATTGCCGATGTGTCCACTGGCTTGGAGCTGCTGGAAAGT
GAAATAACCTATGACAAACTCAACAAGTGGACCAGCAAAGACAAAATGGCTGAAGATGAAGTTGAGGTATACATACCCC
AGTTCAAATTAGAAGAGCATTATGAACTCAGATCCATTCTGAGAAGCATGGGCATGGAGGACGCCTTCAACAAGGGACG
GGCCAATTTCTCAGGGATGTCGGAGAGGAATGACCTGTTTCTTTCTGAAGTGTTCCACCAAGCCATGGTGGATGTGAAT
GAGGAGGGCACTGAAGCAGCCGCTGGCACAGGAGGTGTTATGACAGGGAGAACTGGACATGGAGGCCCACAGTTTGTGG
CAGATCATCCTTTTCTTTTTCTTATTATGCATAAGATAACCAACTGCATTTTATTTTTCGGCAGATTTTCCTCACCCTA
AAACTAAGCGTGCTGCTTCTGCAAAAGATTTTTGTAGATGAGCTGTGTGCCTCAGAATTGCTATTTCAAATTGCCAAAA
ATTTAGAGATGTTTTCTACATATTTCTGCTCTTCTGAACAACTTCTGCTACCCACTAAATAAAAACACAGAAATAATTA
GACAATTGTCTATTATAACATGACAACCCTATTAATCATTTGGTCTTCTAAAATGGGATCATGCCCATTTAGATTTTCC
TTACTATCAGTTTATTTTTATAACATTAACTTTTACTTTGTTATTTATTATTTTATATAATGGTGAGTTTTTAAATTAT
TGCTCACTGCCTATTTAATGTAGCTAATAAAGTTATAGAAGCAGATGATCTGTTAATTTCCTATCTAATAAATGCCTTT
AATTGTTCTCATAATGAAGAATAAGTAGGTATCCCTCCATGCCCTTCTGTAATAAATATCTGGAAAAAACATTAAACAA
TAGGCAAATATATGTTATGTGCATTTCTAGAAATACATAACACATATATATGTCTGTATCTTATATTCAATTGCAAGTA
TATAATAAATAAACCTGCTTCCAAACAACAATAAAAAAAAAAAAAAA
Fig. 2.4. mRNA sequence of SerpinB2 and shRNA hairpin mRNA sequences. Two hairpin loops (shRNA1 and shRNA2)
were created for SerpinB2 gene editing, and these are displayed within the SerpinB2 mRNA sequence, highlighted in green
(shRNA1) and blue (shRNA2), respectively.
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2.2.3 SerpinB2 expression clone generation
Using the purified SerpinB2 plasmids as described in Section 2.2.2, homologous recombination attachment
(att) sites, TGTTCAAACATGTTTTTTCGTCCGA (attB1) and TGGGTCGAAAGAACATG (attB2), were
attached with a kozak sequence - (gcc)gccRccAUGG, via O/N PCR. Two separate PCR experiments were
utilised in order to compare final purity of SerpinB2 expression clones using the pfu Turbo® (600250, Agilent,
CA, USA) and Phusion® (E0553, New England Biolabs, MA, USA) PCR kits. Both were made up to final
volumes of 50uL, using 50ng DNA for the pfu Turbo®, and 150ng DNA for the Phusion® PCR experiments.
The amplification was performed using the following parameters: initial denaturation at 98°C for 30 sec and
then 35 cycles of amplification consisting of 98°C for 10 s, 60°C for 10 s, and 72°C for 10 s. Primer sequences
for PCR amplification of SERPINB2 mRNA were GCATGTTCTTGTTGCTTCCA (forward) and
TTCAGCCATTTTGTCTTTGC (reverse).
2.2.4 Creation of entry vectors
Invitrogen Gateway® (California, USA) BP Clonase (11789-013) reactions were performed to create
pDONR221-SerpinB2 entry vectors. attB-SerpinB2 PCR products (30ng/µL) and pDONR plasmid (150
ng/µL) were incubated with BP enzyme mix for 2 h. Each reaction was then transformed into heat-shock
competent DH5α E. coli and grown O/N at 37°C. Cultures were grown and the plasmid DNA purified using
Wizard® Plus SV Miniprep DNA purification system (Promega). Correct insertion by gel digest and
sequencing using the following primers (3.2 pmol) M13 Fwd 5’ –GTAAAACGACGGCCAGT – 3’, M13
Reverse 5’ – CAGGAAACAGCTATGAC – 3’. Sequencing was undertaken as previously specified using 20 ng
per sample and genomic data was analysed using 4Peaks V1.8 software (Amsterdam, Netherlands). Sequences
were again analysed using Finch TV analysis program (Geospiza Inc, USA). Translated sequences were
BLASTed using blastx (NCBI; NIH, USA) in order to ensure correct sequences were maintained and in frame.
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2.2.5 Creation of destination vectors
The pDONR221 entry plasmids (50 ng) were incubated with Gateway LR clonase enzyme mix (11791-019)
and pLenti6.3/TO-DEST-V5 destination vector (150 ng) for 2.5 h at RT. Each reaction was then transformed
into DH5α E.coli as before and grown O/N on Ampicillin agarose at 37°C. Cultures were grown and plasmid
DNA was purified and sequenced as aforementioned in Section 2.2.4. Sequences were again analysed using
Finch TV analysis program, translated and then BLASTed versus their appropriate SerpinB2 template, again
using blastx. Once correct sequence homology was validated for each construct, lentiviral infections were
undertaken. A summary of the experimental procedure for lentivector production is illustrated above in Fig.
2.3.
2.2.6 Transient transfections using SerpinB2 mutant cDNA
Prepared destination vector cDNA was transiently transfected into adherent HEK-293T cells, in order to
ascertain if the produced SerpinB2 mutants could facilitate modified SerpinB2 expression. 5.0 x 105 HEK-293T
cells/well were plated in a 6-well plate. After 2 days, when cells had reached 90-95% confluency, 2 µg of
plasmid DNA was incubated with 10 µL Lipofectamine® 2000 (ThermoFisher) in 1.75 mL total volume OptiMEM media (31985-070, Life Technologies) for 10 min. After this time, the HEK-293T cells were transfected
with either 500 µL DNA/Lipofectamine mix, or 500 µL Opti-MEM for control wells. Media was changed in
all wells after 4-6 h (as Lipofectamine can be toxic to cells) with 2mL DMEM/10% FBS and cells were assayed
for transgene expression 48 h after this time.
2.2.7 Lentivirus production
In order to create lentiviral particles that could be used to infect mammalian cells of choice and produce stable
overexpression or knockdown of target genes, the destination vectors produced above were transfected into
the Human embryonic kidney cell line, HEK-293T. The destination vectors, pLenti6.3 LacZ (overexpression
control) and pLV411 shGFP (knockdown control), were a kind gift from colleague Dr Robert Shearer at the
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Kinghorn Cancer Centre, Sydney. All destination vectors, wt SerpinB2, full-length
∆CD loop and

R380A

R380A

SerpinB2, SerpinB2

SerpinB2 ∆CD loop as well as control vectors, LacZ (overexpression) and shGFP

(knockdown), were pre-incubated with Gateway packaging plasmids (pMDLg/pRRE, pRSV-Rev and pMD.G)
for 30 min at RT in Opti-MEM (31985-070, Life Technologies) and Lipofectamine®, then applied to HEK293Ts [CRL-3216, American Type Culture Collection (ATCC, VA, USA)] (2.0 x 106 seeded 24 h prior) in a
10 cm dish and incubated O/N at 37°C in 5% CO2. After 24h, Optimem media was changed with 10 mL fresh
DMEM/10% FBS (Gibco) and incubated for another 24 h. At this time, the lentivirus has been created and is
collected in 1 mL aliquots and stored at -20°C, or used to infect any mammalian cell line.
2.2.8 Viral titre optimisation for lentiviral transgene repression
To ascertain the ideal repression concentrations for the tetracycline repression of the CMV promoter, MDAMB-231 (Luciferase) cells were stably transduced using a two-vector expression system (A11144, Invitrogen).
β-galactosidase (β-gal, blue) (pLenti6.3 LacZ) expression construct was co-transduced with increasing levels of
the pLenti3.3TetR/CMV Vector. Three different dilutions of TR element construct were chosen for infection
– 1/10 (high repression), 1/100 (mid repression) and 1/1000 (low repression). After 72 h, antibiotic
selection was undertaken and 48 h post-induction of expression using 1 µg/mL doxycycline (Dox, 631311,
Clontech), 231 cells were incubated with X-gal at 37 °C for 2 h. This LacZ gene was was chosen as a suitable
control vector for the concurrent experiments as it is a extensively researched, reliable reporter gene and also
because translated β-gal would put similar amounts of ribosomal and overall cellular mechanical strain to overexpress.
2.2.9 Lentiviral infection
In order to infect adherent mammalian cell lines, each line was seeded (at 1.0 x 105 per well of a 6 well plate)
to be sub-confluent on the day of infection (~60% confluency). Cells must grow for at least 72 h before adding
antibiotic selection, thus cells were seeded at a density to ensure that they would not be over confluent too
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quickly. Infections were performed in a 6-well plate, with virus diluted in normal media at 1/50, 1/100 and
1/100 dilutions. This allowed for different dilutions of virus to be tried as if the viral construct packages
inefficiently (LTR bp length > 7kbp) then optimal concentration of the virus could be found. Viral dilutions
were made up in 10 mL of media with 8 µg/ml Polybrene (107689, Sigma). Media was aspirated from the
adherent cells and diluted virus added on top of the cells. After 24 h, viral media was replaced with fresh media
to remove any excess virus not up taken by the cells. After 72 h from addition of lentivirus, antibiotic selection
with Blasticidin S (R21001, Sigma) was added for overexpression pLenti constructs, at 6 µg/ml: initial
selection, or 3 µg/ml: maintenance; or G418 (10131027, ThermoFisher) was added for knockdown pSLIK
constructs (at 1 mg/mL: initial selection, or 0.5 mg/mL: maintenance) or sorting for fluorescent markers with
a FACS Vantage instrument (Becton Dickinson, USA) was undertaken. To initiate SerpinB2 (and other gene
construct) overexpression or knockdown, 1 µg/ml Dox was added to the media, to remove Tet repression
upon the promoter, allowing for SerpinB2 transcription (refer to Fig. 2.3). Gene knockdown was confirmed
by whole cell lysis, protein collection, western blot and immunofluorescence. Once selected, cells containing
SerpinB2 shRNA (and wild-type cell controls) were transduced with a VSV-G pseudotyped lentivirus encoding
pLV411 vector GFP. GFP-positive cells were then enriched by sorting with a FACS Vantage instrument
(Becton Dickinson, USA).
2.2.10 Characterisation
2.2.10.1 Western blotting
Total cell lysates were prepared in standard radioimmunoprecipitation assay buffer (RIPA) extraction
buffer supplemented with a protease inhibitor cocktail containing PMSF and EDTA (1183617001, Roche
Diagnostics). 20-30µg of protein from these samples were separated under non-reducing conditions by 10%
sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and transferred to PVDF membranes
(BioRad). The membranes were immunoprobed overnight at 4°C with antibodies against SerpinB2 (ab137588,
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Abcam, Cambridge, UK) and Actin (ab3280, Abcam) or GAPDH (TA150046, OriGene, Maryland, USA) as
per standard protocol (refer to Supplementary Antibodies Table of Appendix). The membranes were
incubated with the appropriate HRP-conjugated secondary antibody and then developed according to enhanced
chemilluminescence protocol (32106, ThermoScientific).
2.2.10.2 Immunofluorescence
For immunofluorescence analysis, MDA-MB-231 tumour cells (1.0 x 104 per well in a 6 well plate) were
grown on cover slips, in the presence or absence of Dox (1 µg/mL). Cells were fixed using 4%
paraformaldehyde for 10 min at RT and then blocked and processed with SerpinB2 antibody (Abcam), as
described in Supplementary Antibodies Table of Appendix (Table A1). Cover slips were then placed onto glass
slides mounted with Vectashield and cells imaged using a Leica DMI 6000 fluorescence microscope (Wetzlar,
Germany).
2.2.10.3 Proliferation assays
All assays were performed at 37°C and 5% CO2 using the IncuCyte ZOOM imaging system (Essen
BioScience). Cellular proliferation was measured using a confluence mask algorithm optimised for MDA-MB231 human mammary carcinoma cells. Wells were seeded with 1.0 x 104 MDA-MB-231 cells in a 24-well
plate in triplicate and monitored at 2 h intervals until confluence was reached. Proliferation was expressed as
percentage confluence over time.

2.3

RESULTS
2.3.1 Enzyme digestions and AGE

The PCR amplification of all SerpinB2,

R380A

SerpinB2, GFP and LacZ constructs yielded good product

concentrations. Restriction digest reactions were performed with PstI enzyme on PCR products (with attB
sites) of full length His-tagged SerpinB2, inactive R380ASerpinB2 and their ∆CD loop forms (as well as GFP and
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LacZ, data not shown). These were checked for correct size via AGE (Fig. 2.5). Analysis of the DNA bands
observed in the 1% agarose gel revealed dense bands migrating at ~1150 bp and ~1250 bp, consistent with the
expected sizes of

R380A

SerpinB2 ∆CD loop mutant and full-length

R380A

SerpinB2, respectively (Fig. 2.5, Lane

1,2). Another band migrating at ~1150 bp was also observed (Fig. 2.5, Lane 3), which is consistent with the
calculated size of SerpinB2 ∆CD loop.

Fig. 2.5. AGE analysis of PCR restriction digest reactions. Restriction digestions were performed with PstI enzyme,
fractioned on 1% agarose and stained with Ethidium bromide. Lane 1 – Inactive R380ASerpinB2 ∆CD loop cDNA, Lane 2 – Full length
R380A
SerpinB2 cDNA, and Lane 3 – SerpinB2 ∆CD loop cDNA.

2.3.2 Entry clone analysis
After incubation of PCR attB-constructs with pDONR entry vectors, subsequent transfection into DH5α E. coli
and O/N growth, entry clone DNA extraction and purification was undertaken. Sequenced samples were then
aligned and analysed as aforementioned in 2.2.4 (refer to Appendix E for raw sequence data). The sequences
were in correct alignment (refer to Fig. A.2-A.11), thus further homologous recombination (LR) assays could
be undertaken for transferal of SerpinB2 transgenes/shRNA into Gateway® destination vectors.
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2.3.3 Knock-in/overexpression constructs
Entry clone reactions were undertaken in triplicate for each overexpression construct to ensure that correct
sequences of each construct were maintained. Entry clone samples and their concentrations are shown in
Table 2.2.
Table 2.2. Overexpression entry clone concentration and DNA sequence analysis.

Entry Clone Sample
(pDONR221)

Concentration
(ng/µL)

Size (bp)

% Sequence Homology

Full length SerpinB2 - 1
766.7
4,031
100
R380A
SerpinB2 ∆CD - 1
573.2
3,932
100
R380A
SerpinB2 ∆CD - 2
511.1
3,932
100
Full length R380ASerpinB2 - 1
552.1
4,031
100
Full length R380ASerpinB2 - 2
517.4
4,031
100*
SerpinB2 ∆CD - 1
573.2
3,932
100
SerpinB2 ∆CD - 2
511.1
3,932
99.0
*Certain peaks were not as confident (<98%) as other constructs within cohort, samples in bold were chosen for further
use. % Sequence homology refers to alignment of vector transgene to native gene of interest, using ncbi BLAST.

2.3.1

Knockdown constructs

Knockdown entry clone reactions were also undertaken in triplicate for each SerpinB2 hairpin as
aforementioned in Section 2.3.2.1. Alignment and analysis revealed that peaks were quite confident and
several clones could be chosen for further use (refer to Appendix E for raw sequence data). Table 2.3 displays
the various clones with their concentrations and sequence homologies, matched to their respectively required
SerpinB2 shRNA hairpin codes.
Table 2.3. SerpinB2 knockdown entry clone concentration and DNA sequence analysis.

Entry Clone Sample
(pEN_TmiR_C3)

Concentration (ng/µL)

Size (bp)

SerpinB2 sh1 - A
341.7
4,295
SerpinB2 sh1 - B
393.4
4,295
SerpinB2 sh1 - C
371.0
4,295
SerpinB2 sh2 - A
392.4
4,295
SerpinB2 sh2 - B
429.3
4,295
SerpinB2 sh2 - C
200.3
4,295
*Sequenced peaks were not as confident as other shRNA samples within cohort.

% Sequence Homology
94
100 *
100
100
100 *
86
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2.3.4 Destination clone analysis
Gateway® LR recombination reactions were undertaken in duplicate for each destination construct in order to
limit errors in subsequent recombination reactions in an attempt to ensure that correct sequences of each
construct were maintained. Sequence alignment and analysis was undertaken on both forward and reverse
sequences of each construct. Robust peaks with good confidence (refer to Appendix E for raw sequence data)
were observed and correct sequence alignment was then confirmed [as aforementioned in Section 2.2.5 (refer
to Fig. 2.6-2.11)]. Thus, several clones were chosen for lentiviral packaging. Table 2.4 displays the various
clones that were utilised in this project, revealing their concentrations and sequence homologies, matched to
their respective SerpinB2 sequences. Forward and reverse sequences were performed and analysed to ensure
correct alignment of the entire sequence of each construct [versus template SerpinB2 (and ∆CD and
R380A

SerpinB2 forms)]. pSLIK SerpinB2 shRNA vcctor sequences are shown in Appendix E

(refer to Fig. A2-A8).
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Fig 2.6. pLenti6.3 SerpinB2 wt1 vector sequence. A. Nucelotide sequence analysis of destination vector, pLenti6.3 SerpinB2
wt1. B. Translated protein analysis of pLenti6.3 SerpinB2 wt1 construct versus translated wt SerpinB2 (Homo sapiens) sequence.
Plasmid sample was extracted from transformed DH5α E. coli and sequenced as described in section 2.2.2. Sequence analysis
performed using Finch TV and 4 Peaks analysis programs, compared to SerpinB2 template using blastx.
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Fig 2.7. pLenti6.3 SerpinB2 wt2 vector sequence. A. Nucelotide sequence analysis of destination vector, pLenti6.3 SerpinB2
wt2. B. Translated protein analysis of pLenti6.3 SerpinB2 wt2 construct versus translated wt SerpinB2 (Homo sapiens) sequence.
Plasmid sample was extracted from transformed DH5α E. coli and sequenced as described in section 2.2.2. Sequence analysis
performed using Finch TV and 4 Peaks analysis programs, compared to SerpinB2 template using blastx.
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Fig 2.8. pLenti6.3 SerpinB2 ∆CD1 vector sequence. Nucelotide sequence analysis of destination vector, pLenti6.3 SerpinB2
∆CD1. B. Translated protein analysis of pLenti6.3 SerpinB2 ∆CD1 construct versus translated SerpinB2 ∆CD (Homo sapiens)
sequence. Plasmid sample was extracted from transformed DH5α E. coli and sequenced as described in section 2.2.2. Sequence
analysis performed using Finch TV and 4 Peaks analysis programs, compared to SerpinB2 template using blastx.
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Fig 2.9. pLenti6.3 SerpinB2 ∆CD2 vector sequence. Nucelotide sequence analysis of destination vector, pLenti6.3 SerpinB2
∆CD2. B. Translated protein analysis of pLenti6.3 SerpinB2 ∆CD2 construct versus translated SerpinB2 ∆CD (Homo sapiens)
sequence. Plasmid sample was extracted from transformed DH5α E. coli and sequenced as described in section 2.2.2. Sequence
analysis performed using Finch TV and 4 Peaks analysis programs, compared to SerpinB2 template using blastx.
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Fig 2.10. pLenti6.3 R380ASerpinB2 full-length 1 sequence. Nucelotide sequence analysis of destination vector, pLenti6.3
R380A
SerpinB2 full-length 1. B. Translated protein analysis of pLenti6.3 R380ASerpinB2 full-length 1 construct versus translated wt
SerpinB2 (Homo sapiens) sequence. Plasmid sample was extracted from transformed DH5α E. coli and sequenced as described in
section 2.2.2. Sequence analysis performed using Finch TV and 4 Peaks analysis programs, compared to SerpinB2 template using
blastx. The red line undermarks the R380A mutation – arginine residue at position 380 with an alanine residue.
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Fig 2.11. pLenti6.3 R380ASerpinB2 full-length 2 vector sequence. A. Nucelotide sequence analysis of destination vector,
pLenti6.3 R380ASerpinB2 full-length 2. B. Translated protein analysis of pLenti6.3 R380ASerpinB2 full-length 2 construct versus
translated wt SerpinB2 (Homo sapiens) sequence. Plasmid sample was extracted from transformed DH5α E. coli and sequenced as
described in section 2.2.2. Sequence analysis performed using Finch TV and 4 Peaks analysis programs, compared to SerpinB2
template using blastx. The red line undermarks the R380A mutation – arginine residue at position 380 with an alanine residue.
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Fig 2.12. pLenti6.3 R380ASerpinB2 ∆CD1 vector sequence. A. Nucelotide sequence analysis of destination vector, pLenti6.3
SerpinB2 ∆CD1. B. Translated protein analysis of pLenti6.3 SerpinB2 ∆CD1 construct versus translated SerpinB2 ∆CD (Homo
sapiens) sequence. Plasmid sample was extracted from transformed DH5α E. coli and sequenced as described in section 2.2.2.
Sequence analysis performed using Finch TV and 4 Peaks analysis programs, compared to SerpinB2 template using blastx. The red
line undermarks the R380A mutation – arginine residue at position 380 with an alanine residue.
R380A
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Table 2.4. Lentiviral destination constructs, expression type, concentrations and DNA sequence analyses.
Transgene
SerpinB2 Wild-type 1
SerpinB2 Wild-type 2
SerpinB2 ∆CD loop 1
SerpinB2 ∆CD loop 2
Full length
R380A
SerpinB2
R380A
SerpinB2 ∆CD
loop
LacZ (Control)
SerpinB2 shRNA
(Hairpin 1)
SerpinB2 shRNA
(Hairpin2)
GFP shRNA
(Control hairpin)

2.3.5

Construct

Vector Size
(bp)

Transgene Size Concentration
(bp)
(ng/µL)

% Sequence
Homology

pLenti6.3/SerpinB2
pLenti6.3/SerpinB2
pLenti6.3/SerpinB2∆CD1
pLenti6.3/SerpinB2∆CD2
pLenti6.3/R380ASerpinB2

9,668
9,668
9,569
9,569
9,668

2,180
2,180
2,081
2,081
2,180

833.7
147.5
827.5
41.4
72.8

100
100
100
100
100

pLenti6.3/R380ASerpinB2∆
CD
pLenti6.3/LacZ
pSLIK/SerpinB2 1C1

9,569

2,180

702

100

10,822
12,273

3,064
67

637.9
186.7

100
100

pSLIK/SerpinB2 2A2

12,273

67

283.2

100

pSLIK shGFP

12,254

48

141.6

100

Transient transgene transfection of HEK-293T cells

Transient transfections were initially undertaken in order to reduce reagent and consumable use (that is
required for stable transduction experiments) while ensuring that the destination plasmids cDNA produced
were target specific and transgene expression was effective. Expression of SerpinB2, SerpinB2 ∆CD loop and
their

R380A

SerpinB2 mutant counterparts were assayed in the HEK-293T cell line after Lipofectamine

transfection (Fig. 2.13). As the gene expression of each construct was increased in HEK-293T cells, versus the
HEK-293T control cells (negligible levels of SerpinB2 expression), the destination vectors were deemed to be
functional, consistent with the predicted outcome from sequencing analyses (refer to Table 2.4). Constructs
chosen for further experimental use were full-length wild-type SerpinB2 construct 1 (refer to table 2.4), ∆CD
loop construct 2, (Fig. 2.1.3, Lane 4), full-length
R380A

R380A

SerpinB2 construct 1 (Fig 2.1.3, Lane 5), and

SerpinB2 ∆CD loop construct 1 (Fig. 2.1.3, Lane 7).
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Fig. 2.13. Western blot of upregulated SerpinB2 expression in HEK-293T cells. Transiently transfected HEK-293T
samples were fractioned by 10% SDS-PAGE, then transferred onto a PVDF membrane and probed with an anti-SerpinB2 antibody to
detect the expression of serpinB2 mutant constructs. Lane 1 – Recombinant SerpinB2, Lane 2 – HEK-293T control, Lane 3 –
SerpinB2 ∆CD loop construct 1, Lane 4 – SerpinB2 ∆CD loop construct 2, Lane 5 – Full length R380ASerpinB2 construct 1, Lane 6 –
Full length R380ASerpinB2 construct 2, Lane 7 – R380ASerpinB2 ∆CD loop construct 1, Lane 8 – R380ASerpinB2 ∆CD loop construct 2.
An anti-β-actin antibody was used as control (42 kDa).

2.3.6

LacZ infection for repression analysis

In order to reduce the chance of non-targeted gene disruption and to increase the likelihood of single transgene
integrations per cell, optimisation of the Tet repression system was undertaken. MDA-MB-231 cells were
stably transduced with a ß-galactosidase expression construct and increasing levels of the pLentiTetR Vector
(at 1/10, 1/100 and 1/1000 dilutions) (Fig. 2.14). After 2 h staining with X-gal, 48 h after Dox induction
(using 1 µg/mL), bright field microscopy images revealed stark differences in repression of the LacZ transgene
(Fig. 2.14). The transduction of the pLentiTetR Vector demonstrated that effective repression of a transgene is
possible with even a low dilution of virus (1/1000, Fig. 2.14A, far Right panels), however more concentrated
TR lentiviral infection increased repression of the LacZ vector, as expected (1/10 and 1/100, Fig. 2.14A, Left
and Middle panels, respectively). The control cells without lentiviral transduction had no ability to cleave Xgal, and thus produced no blue staining, ± Dox induction (Fig 2.14B, Left panels), while the MDA-MB-231s
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transduced singly with the pLenti CMV/(TO)LacZ vector show intense blue staining, ± Dox induction (Fig
2.14B, Right panels).

A

1/10

1/100

1/1000

+ DOX

- DOX

B

Control MM231

CMV(TO) LacZ only

+ DOX

- DOX

Fig. 2.14. Repression analyses for optimal transgene expression – MDA-MB-231 cells stably co-transduced with the pLenti
CMV/(TO)LacZ vector and various levels of the pLentiTetR Vector were incubated for 2 h with X-gal stain, 48 h post-induction of
expression using 1 µg/mL Dox, then imaged using bright field microscopy. A. Co-transduced 231 cells with decreasing dilutions (LR) of pLentiTetR Vector (± Dox addition). B. Left panels show Control 231 cells without any lentiviral transductions (± Dox);
Right panels show MDA-MB-231 cells singly transduced with pLenti CMV/(TO)LacZ vector (± Dox). Photomicrographs were
imaged at 10x magnification.
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2.3.7

Stable transductions of MDA-MB-231 cell line

Artificial destination constructs were prepared with SIN transgene vectors and the three Gateway® packaging
vectors (pMDLg/pRRE, pRSV-Rev and pMD.G) and Lipofectamine 2K, incubated for 30 min at RT, then
added into wells containing HEK-293T cells at 60% confluency. Following successful transient transfection
experiments, concurrent lentiviral infections were also performed upon MDA-MB-231 cells. After antibiotic
selection (72 h from infection), stably transduced MDA-MB-231s with knock-in SerpinB2,

R380A

SerpinB2 or

LacZ (control); knockdown constructs SerpinB2 shRNA (both hairpins) or shGFP control, were collected and
assayed using various modes for the evaluation of transgene modulation.
2.3.8 Western blotting - overexpression constructs

MDA-MB-231 (luc.) cells transduced with knock-in SerpinB2,

R380A

SerpinB2 or LacZ (control) lentiviral

vectors were also transduced in combination with either 1/10 TetR or 1/1000 TetR, in order to individually
evaluate the optimal repression for each gene expression lentiviral package. Three days after transfection and
antibiotic selection, reporter gene expression was examined using western blotting (Fig. 2.15A-D). After
confirmation of gene overexpression was achieved, cultures were kept under Dox conditions for at least ten
days in order to confirm that overexpression could be maintained (Fig. 2.15 A-D). It should be noted that
MDA-MB-231 cells do constitutively express SerpinB2, however this Dox inducible system revealed that all
constructs with Dox addition dramatically increased the expression of SerpinB2 or R380ASerpinB2 within MDAMB-231 cells, versus no Dox added control MDA-MB-231 cells. There was no significant difference observed
in the expression of SerpinB2 or

R3880A

SerpinB2 in using either a 1/10 (Fig 2.15 A,B) or 1/1000 (Fig. 2.15

C,D) dilution of TetR Vector. Once confirmation of SerpinB2 and

R3880A

SerpinB2 knock-in was achieved,

subsequent characterisation experiments could be performed.
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Fig. 2.15. Western blot of modified SerpinB2 expression in MDA-MB-231 cells using the pLenti system. Stably
transduced MDA-MB-231 samples (± Dox induction) were fractioned by 10% SDS-PAGE, then transferred onto a PVDF membrane
and probed with an anti-SerpinB2 antibody to detect the modified expression of SerpinB2. A. pLenti6.3/R380ASerpinB2 (TO) and
1/10 TetR (L-R) Day 2 -10 (-Dox), No TetR, R380ASerpinB2 Day 2 -10 (+Dox); B. pLenti6.3/SerpinB2 (TO) and 1/10 TetR (LR) Day 2 (-Dox), Day 2 (-Dox), Day 7 (-Dox), Day 7 (+Dox), Day 10 (-Dox), Day 10 (+Dox); C. pLenti6.3/R380ASerpinB2 (TO)
and 1/1000 TetR (L-R) Day 2 (-Dox), No TetR (-Dox), Day 7 (-Dox), Day 10 (-Dox), Day 2 (+Dox), Day 7 (+Dox), Day 10
(+Dox); D. pLenti6.3/SerpinB2 (TO) and 1/1000 TetR (L-R) Day 2 (-Dox), Day 7 (-Dox), Day 10 (-Dox), No TetR, Day 2
(+Dox), Day 7 (+Dox), Day 10 (+Dox). E –F. Ponceau S stained blot was used as a loading control.

2.3.9 Western blotting - knockdown constructs
MDA-MB-231 (luc.) cells were transfected with knockdown SerpinB2 shRNA (both hairpins) or shGFP
(control) lentiviral vectors in serum-free medium for 24 hours. These constructs were diluted at various viral
concentrations of either 1/50, 1/100 or 1/500, in order to evaluate the ideal amount for optimal SerpinB2
knockdown. Three days after transfection and subsequent Dox induction, reporter gene expression was
examined using western blotting (Fig. 2.16 A). It was observed that knockdown was achieved with both
hairpins using 1/50 and 1/100 dilutions (and Dox induction), yet there was no significant recorded
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downregulation effect on SerpinB2 expression using a 1/500 dilution of shRNA, in either hairpin (Fig. 2.16
A). After confirmation of SerpinB2 knockdown was observed, cell cultures were kept under Dox conditions
for up to 40 days (using only 1/50 and 1/100 lentiviral infected cells) in order to confirm that SerpinB2
knockdown could be maintained (Fig. 2.16 B). Western blot analysis revealed that knockdown was successful
in all cohorts over a 40 day period, however, there was a greater knockdown of SerpinB2 observed in the 1/50
samples of both hairpins (Fig. 2.16 B,D). These data demonstrate that through using the pSLIK lentiviral
vector, it was possible to introduce a tightly controlled miR-shRNA expression system for conditional
knockdown of endogenous SerpinB2 mammalian gene from a single viral infection and opened up the attractive
possibility of stable, robust, and reversible gene depletion in both primary and established cell lines for use in
ex vivo and in vivo model systems.

Fig. 2.16. Western blot of downregulated SerpinB2 expression in MDA-MB-231 cells using the pSLIK system. Stably
transduced MDA-MB-231 samples were fractioned by 10% SDS-PAGE, then transferred onto a PVDF membrane and probed with
an anti-SerpinB2 antibody to detect the modified expression of serpinB2. A. SerpinB2 shRNA1 Hairpins 1 and 2 (± Dox) at
lentiviral dilutions of 1/50, 1/100 and 1/500; B. SerpinB2 shRNA Hairpin 1 at lentiviral dilution of 1/50 over a 40 d time course
(± Dox); C. SerpinB2 shRNA Hairpin 1 at lentiviral dilution of 1/100 over a 40 d time course (± Dox); D. SerpinB2 shRNA
Hairpin 2 at lentiviral dilution of 1/50 over a 40 d time course (± Dox); E. SerpinB2 shRNA Hairpin 2 at lentiviral dilution of 1/100
over a 40 d time course (± Dox).
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2.3.10 Long term stability of gene modification
MDA-MB-231 cells were frozen and stored in liquid nitrogen. After more than a year, these cells were revived
and grown in culture to ensure that transduced cells were still viable and maintained stable expression of
transduced constructs. This was performed to ensure that future SerpinB2 knockdown or overexpression could
still be achieved. Cells were collected and assayed for SerpinB2 expression using western blot analysis (Fig.
2.17). It was clear that the SerpinB2 knockdown and R380ASerpinB2 overexpression constructs were still viable,
however this was not observed for the SerpinB2 overexpression construct (Fig. 2.17A).

Fig. 2.17. Long-term stability analysis of lentiviral constructs in MDA-MB-231 cells, using western blot analysis.
Stably transduced MDA-MB-231 samples were fractioned by 10% SDS-PAGE, then transferred onto a PVDF membrane and probed
with an anti-SerpinB2 antibody to detect the modified expression of serpinB2. A. (L-R) shGFP KD control (± Dox), SerpinB2
shRNA Hairpin 1 (± Dox), SerpinB2 shRNA Hairpin 2 (± Dox), LacZ OE control (± Dox), SerpinB2 OE (± Dox), R380ASerpinB2
OE (± Dox). A GAPDH antibody was used as loading control; B. Relative SerpinB2 protein expression, each lane normalised to its
respective GAPDH loading control lane.

The phenomena of the lower (~37 kDa) sized SerpinB2 band (observable in Lanes 3,4 and 5) is also observed
by other SerpinB2 researchers and is believed to be a cleaved form of SerpinB2. Performing a gel digest, or
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cutting out this band of interest to do an in-gel digestion with trypsin would be useful. Alternatively, to exactly
interpret this band, this band could be cut out, purified by HPLC and sequenced using Edman degradation
technology or HPLC/MS/MS sequence analysis. The loading controls revealed that this western blot should be
repeated in order to ascertain more quantifiable SerpinB2 knockdown occurring withn each hairpin.
2.3.11

Incucyte proliferation assay

As there appeared to be problems with the longterm stability of SerpinB2 overexpression constructs, SerpinB2
knockdown constructs were selected for further experimentation. To ascertain if the modulation of SerpinB2
expression (i.e. knockdown) influenced cell growth, the confluency of MDA-MB-231 cells was measured over
a period of four days using the IncuCyte Zoom live cell imaging system (Fig. 2.18). Results indicated that
SerpinB2 knockdown constructs did not significantly affect the proliferative rate of MDA-MB-231 cells, both
individually between Dox and No Dox addition, and versus shGFP control constructs (Fig. 2.18). It is possible
that the inefficient knockdown of SerpinB2 with the shRNA Hairpin 1 (1/100 dilution) potentially influenced
the proliferation rate (refer to Fig. 2.16 C, 1/100 dilution).
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Fig. 2.18. Effect of SerpinB2 modification on the growth of MDA-MB-231 cells. Stably transduced MDA-MB-231 cells
were seeded into individual wells of 96 well plates and then monitored over 4 days using the IncuCyte ZOOM imaging system.
Stably transduced constructs were induced with (± 1 µg/mL) Dox. Constructs tested were A. GFP shRNA (shGFP), B. SerpinB2
shRNA1 (sh1C1), and C. SerpinB2 shRNA2 (sh2A2).
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2.3.12

Immunofluorescence

In addition to western blotting, examination of MDA-MB-231 cells by immunofluorescence staining also
confirmed that the lentiviral vector overexpression and knockdown constructs had worked successfully (Fig.
2.19 and Fig. 2.20, respectively). Both SerpinB2 and

R380A

SerpinB2 pLenti constructs (after Dox addition)

effectively overexpressed SerpinB2 gene expression in MDA-MB-231 cells, when compared to the no Dox
controls, detected by immunofluorescence (Fig 2.19). Concomitantly, both SerpinB2 1/50 and 1/100
dilutions of shRNA hairpins (with Dox induction) considerably reduced the expression of SerpinB2 versus no
Dox controls, as observed by immunofluorescence (Fig 2.20). These studies validate the applicability of the
pSLIK system to introduce conditional SerpinB2 RNAi into MDA-MB-231 cells from a single viral infection
and allowed the modulation of SerpinB2 expression to study spatiotemporal expression of SerpinB2 in the 3D
organotypic model, and more complex systems (Chapters 3, 4 and 5).
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Fig. 2.19. Immunofluorescence imaging of overexpression constructs. Stably transduced MDA-MB-231 cells (± Dox) were fixed on glass slides and incubated with an antiSerpinB2 antibody and secondary-HRP fluorescent antibody to detect the modified expression of serpinB2. A. SerpinB2 ∆ CD loop transduced MDA-MB-231 cells, ± Dox; B. wild-type
SerpinB2 transduced MDA-MB-231 cells, ± Dox; C. R380ASerpinB2 ∆ CD loop transduced MDA-MB-231 cells, ± Dox; D. Full length R380ASerpinB2 transduced MDA-MB-231 cells, ±
Dox. Photomicrographs were imaged at 20x magnification.

84

Fig. 2.20. Immunofluorescence imaging of knockdown constructs. Stably transduced MDA-MB-231 cells (± Dox) were fixed on glass slides and incubated with an antiSerpinB2 antibody and secondary-HRP fluorescent antibody to detect the modified expression of serpinB2. A. MDA-MB-231 cells stably transduced with SerpinB2 shRNA1 at 1/50
dilution, ± Dox; B. MDA-MB-231 cells stably transduced with SerpinB2 shRNA1 at 1/100 dilution, ± Dox; C. MDA-MB-231 cells stably transduced with SerpinB2 shRNA2 at 1/50
dilution, ± Dox; D. MDA-MB-231 cells stably transduced with SerpinB2 shRNA2 at 1/100 dilution, ± Dox. Photomicrographs were imaged at 20x magnification.
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2.3.13 Stable GFP transduction of wild-type and SerpinB2-/- MEFs
In order to have cell reporter function in future experiments of this research project, wild-type and SerpinB2-/MEF cells expressing GFP were generated. This was achieved by lentiviral transduction using the VSV-G
pseudotyped lentivirus encoding pLV411 vector. After infection, 20-30% of wild-type and SerpinB2-/- MEFs
were GFP expressing (Fig. 2.21). GFP-positive MEFs were enriched by FACS sorting. Much cell gating was
employed during FACS sorting, for isolating viable cells as well as doublet discrimination, in order to detect
disproportions between cell size vs. cell signal. As Fibroblasts are morphologically heterogeneous, existing in
ellipsoid, stellate and epithelial shaped appearance, this was taken into consideration when gating, as two
distinct populations were observed [Fig. 2.21, A (i.)]. FACS MEF populations were collected, obtaining more
than 83% of (KO MEF) cells stably expressing GFP (while 85.7% wt MEFs had stable GFP expression). These
could then be used for imaging purposes in proceeding ex vivo and in vivo studies (Chapters 3,4, and 5). Further,
cloning was not necessary and there were two populations of MEFs that were of round or elliptical appearance
(identified through FACS sorting) and both were used for future experimentation (refer to Section 3.3.5).
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Fig. 2.21. FACS sorting of MEFs. Wild-type and SerpinB2-/- MEFs were stably transduced with pLV411 GFP vector and then
sorted via FACS flow cytometry. A. (i). Light scatter plot of entire unsorted wild-type MEF population. To discriminate between
healthy and damaged or dying cells, side scatter (SSC-A) and forward scatter (FSC-A) are plotted (P1); (ii). Panel displays the gating
of initial wild-type MEF purity, during sorting; (iii). Gated populations are based on forward scatter height (FSC-H) v Area (P2),
FSC –H v Width (P3) and Side scatter height (SSC-H) v width (singlet). To initially purify the population, gating for GFP-positive
cells was done using 530-nm laser (B530-A) against SSC-A; (iv). Panel displays the gating of wild-type MEF purity after sorting; (v).
Gated populations are based on SSC-A v B530-A (*GFP-POS) and final gating for GFP-positive cells was done using a 670-nm laser
(B670A) against B530-A; B. (i). Light scatter plot of entire unsorted SerpinB2-/- MEF population. To discriminate between healthy
and damaged or dying cells, SSC-A and FSC-A are plotted (P1); (ii). Panel displays the gating of initial SerpinB2-/-MEF purity, during
sorting; (iii). Gated populations are based on FSC-H v Area (P2), FSC –H v Width (P3) and SSC-H v width (singlet). To initially
purify the population, gating for GFP-positive cells was done using B530-A against SSC-A; (iv). Panel displays the gating of SerpinB2/MEF purity after sorting; (v). Gated populations are based on SSC-A v B530-A (*GFP-POS) and final gating for GFP-positive cells
was done using B670A against B530-A.
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2.4 DISCUSSION
This chapter outlines the development and validation of third generation lentiviral vectors for SerpinB2
modulation and GFP reporter gene applications. The production of these lentiviral vectors with a codonoptimised expression cassette under control of a TRE, CMV or (TO) promoter with high activity successfully
modified the expression of SerpinB2 in MDA-MB-231 cells, and knock-in GFP within MEF cells. The
Gateway® lentivirus vector system utilised in this project offered a robust and efficient tool for gene editing
studies. Incorporation of a central polypurine tract (cPPT) and post-transcriptional regulatory element from
woodchuck hepatitis virus (WPRE) in third generation lentviral vector systems has improved SerpinB2
transgene expression (402), versus earlier lentiviral systems used. This increase in transduction efficiency,
nuclear localisation and the total amount of RNA integrated into cell genomes meant that phenotypic
characterisations could be made much easier (403) (404), with increased reliability that effects were
consequences of SerpinB2 modulation.
All necessary elements required for the production of the lentiviral vectors were cloned into the four donor
plasmids and subsequently many high titre lentiviral stocks were produced. Homologous recombination
reactions were always performed in triplicate to ensure that sequence homology was maintained. Sequencing
consistently gave positive results, with evenly spaced peaks and a general lack of baseline 'noise' (refer to Fig.
2.6-2.11), proving that Invitrogen’s Gateway® system offers rapid, highly efficient site-specific recombination
methodology for gene editing. It is widely agreed that packaging of lentivirus inside HEK-293T cells proves to
be an extremely efficient medium for production of viral particles (413), and in this body of work offered the
best intermediate for reliable viral titres when comparing between constructs. For all SerpinB2, R380ASerpinB2,
SerpinB2 ∆CD loop, R380ASerpinB2 ∆CD loop, GFP, LacZ and several scramble control (not shown) constructs,
this system was effective in the production of lentiviral particles for subsequent infection of chosen mammalian
cell lines and targeted gene modulation. Transient transfections were undertaken preliminarily (refer to Fig.
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2.13), as these are straightforward to perform, versatile and avoid the time-consuming development and
reagent use required when creating stable cells lines. It also allowed for easy and rapid testing of the various
transgene constructs produced, and has been reported to be effective for testing viral pseudotypes (414). Since
the transient transfection system allows virus production for a limited time only and co-transfection may
increase the risk of recombination between the plasmids, stable packaging cell lines for SerpinB2 modulation
were sought, in addition to moving towards in vivo models. Previously, much research has been undertaken to
develop stable packaging cell lines for the production of lentiviral vectors (415-417). Lentiviral vectors are
known to package with various concentrations (MOI 50-1000) of lentivirus, thus in order to minimise off target
effects of gene insertion, such as non-targeted gene disruption, a single integration of virus per cell was optimal
(375). The viral transfer vectors used in this study encoded tetracycline-based inducer/repressor elements,
which are separate to the transfer vector, meaning that the inducible transgene could be independently titrated
to achieve various levels of transgene activation. An advantage of this system was that it could be used to make
cell lines with various base levels of repression for relatively comparable over-expression of multiple
transgenes. Therefore, to determine the optimal level of repression for virus production and transduction,
characterisation of the MOI of produced lentiviruses was determined by LacZ[-CMV(TO)] transduction of
MDA-MB-231 cells and subsequent growth on X-gal plates of different viral dilutions (Fig. 2.14). This method
was based on the amount of transgene copies per cell and allowed for evaluation of different dilutions to use in
subsequent experiments, in order to ensure that the number of integrated proviral genomes was not affecting
the tetracycline repression and thus not giving constitutive transgene expression without Dox treatment (418).
The pLenti6.3/TO-DEST-V5 vector was productively exploited to knock-in wt SerpinB2, full-length
R380A

SerpinB2 (and SerpinB2 ∆CD, R380ASerpinB2∆CD loop constructs) and LacZ into MDA-MB-231 cells (refer

to Fig. 2.15). Under tetracycline repression, this vector system was highly effective at overexpressing both
SerpinB2 and R380ASerpinB2. Validation by Western blot and immunofluorescence confirmed the efficacy of all
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lentiviral constructs produced (refer to Fig. 2.15-2.17 and Fig. 2.19-2.20, respectively). An essential
characteristic difference between third generation lentivectors to older viral vectors is that they contain regionspecific promoters. Many earlier lentiviruses used the constitutive CMV promoter to drive the ubiquitous
expression of a downstream transgene, not confined to just one subtype of cells (418). Thus, it has previously
been difficult to attribute whether phenotypic alterations caused by transgene transcription were due to
intentional targeted manipulation in chosen cells or inadvertent effects on non-target cells (419). The
generation of stable overexpression cell lines was time-consuming, however the ability to generate these within
the same vector type greatly facilitated progression. Stable packaging cell lines not only lessen variation
between vector stocks, but also reduce the likelihood of generating any forms of helper virus and allow
reproducible propagation of RCLs (420). In order to counteract the toxicity of lentiviral protease (421), which
abrogates constitutive vector production, inducible packaging cell lines were constructed, controlled with
tetracycline-inducible systems (416,422). The pLenti6.3/TO-DEST-V5 vector highlights the value of
restricting transgene expression within specific types of cells, with a selectable repressive element. Cotransducing these regulator and response viruses into target cells, creates a system that allows major control of
the expression level of a gene of interest by adjusting the concentration of the system’s inducer, Dox (418). In
order to be sure that the pLenti system was successful in producing increased expression of SerpinB2, both
western blot (Fig. 2.17) and immunofluorescence imaging (Fig. 2.19) were undertaken to confirm. These
assays validated the knock-in of constructs used and provided enough evidence that the generated cell lines
could be used for subsequent experimental models.
Concomitantly, the pSLIK system was efficaciously used to conditionally deplete the expression of SerpinB2
and GFP in MDA-MB-231 cells and MEF cells, respectively. Validation of both SerpinB2 shRNA knockdown
constructs produced were observed over a 40 day period (with Dox treatment) in cell culture (refer to Fig.
2.16). This was performed in order to ensure as much as possible that knockdown cell lines produced could be
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used in in vivo models with reliability that SerpinB2 knockdown would be maintained. The pSLIK system
supported robust RNAi mediated knockdown of SerpinB2 and there was no recorded evidence of leaky
expression from the TRE promoter. The Tet-inducible knockdown of SerpinB2 gene after transduction of cells
with a single pSLIK lentivirus provides an important experimental platform for analysing the downstream
effects on proliferation and the redundancy in signaling pathways associated with this gene. There is the
potential for low basal expression of miR-shRNA, which has been reported to be a challenge with highly potent
shRNA sequences (412). Shin et al. (2006) have reported that pSLIK’s vector topology and optimised TREdriven rtTA3 expression system counteract any problematic issues, driving fast integration and initiation into
RISC (412). The presence of Dox creates a positive feedback loop, which drives higher rtTA3, and ostensibly,
miR-shRNA expression (412).
In addition, subsequent cell confluency testing was recorded using the IncuCyte ZOOM digital imaging system,
in order to see effects on cell proliferation (refer to Fig. 2.18). It was noted that the SerpinB2 shRNA hairpin 2
(+Dox) MDA-MB-231 cell line had reduced doubling time. This result requires to be followed up as time
constraints unfortunately did not allow inquiry into further proliferation assays.
The pLV411 lentivirus expressed GFP as a transgene with minimal lentiviral cis-elements (LTR, packaging
signal, RRE) (398). This allowed for the GFP mRNA sequence to be transposed with greater reliability of MOI
as well as offering a good way to test the effectiveness of the promoter/enhancer elements in the pLV411
construct. After subsequent FACS sorting, a largely pure population of GFP-positive MEFs was produced (refer
to Fig. 2.21), which were utilised in concurrent experimental models. The standard time frame for each pooled
lentiviral infection in this study was approximately 2-3 weeks from the generation of the lentivirus to expansion
of each genetically modified cell line. MOI can fluctuate naturally between groups of packaged lentivirus, due
to differences in vector DNA quantity integrated during packaging, as well as the ability of chosen cells
packaging efficiency, passage number and time of harvest post infection (420,423). In order to counteract this,
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passage number was kept below five, harvesting was held time-period consistent and the same batch of
packaged lentivirus was used for all generated constructs.
This study provides a rapid and effective modus operandi for the generation of lentiviral vectors, for both
overexpression and attenuation of SerpinB2 gene expression. This work demonstrates specific transduction of
transgene expression, which could be used for the potential development of serpinB2 gene therapies, within a
cancer therapy approach. These data allow for further knowledge and insight to be gained when working with
this powerful inhibitor gene of the Plasminogen activation pathway. Lentiviral vectors provide a powerful
method to inducibly manipulate SerpinB2 (and GFP) gene expression in highly invasive breast cancer epithelial
cells (and fibroblasts). With both the ability to over-express and knockdown genes of interest in a temporal,
spatial, and cell-type specific fashion, this inducible genetic approach will allow for eventual understanding of
the differential roles of SerpinB2 in the tumour microenvironment, which underlies the enormous complexity
of tumour function and behaviour. GFP imaging in biomedical research is commonplace and extremely
important not only as a diagnostic tool, but also in monitoring the progress of therapy. Molecular imaging
provides a non-invasive opportunity to study diseases at the cellular or even the genetic level. In light of this,
recent developments in gene editing technology are offering newer alternatives to lentiviral transduction, which
minimise off-target effects, at the expense of time and cost. This study demonstrates the usefulness of lentiviral
gene modulation for several targeted therapy applications offering a versatile tool for imaging of live cell culture
and tumour microenvironment purposes. The progress of tumourigenesis and metastasis in carcinomatous
mouse models is necessary for drug discovery and elucidating molecular aspects of how cells behave in their
native microenvironment. This knowledge helps to improve our current understanding of disease progression.
In conclusion, this chapter’s work illustrates the versatile application of lentiviruses for SerpinB2 modulation,
and the constructs produced herein can be useful for the modification of SerpinB2 in other cell types and
research platforms, including those used to study tumour-stroma interactions within pancreatic and breast
cancer (chapters 4 and 5, respectively).
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CHAPTER 3
ELUCIDATING THE EFFECT OF SERPINB2 ON COLLAGEN
CROSSLINKING AND STROMAL REMODELLING THROUGH
APPLICATION OF THE 3D COLLAGEN CONTRACTION MODEL
3.1 INTRODUCTION
In order to understand the processes of stromal remodelling and collagen cross-linking within the TME,
extensive research into the structural and biological regulation of the ECM must be undertaken. As
aforementioned, the ECM is directly responsible for the homeostatic functioning of cellular and tissue functions
within the human body (refer to section 1.6). Strict control is essential for proper embryonic development,
angiogenesis, wound healing, pregnancy and normative organ functioning. During pathological conditions, such
as cancer, the dysregulated biochemical and biophysical functioning of the ECM perpetuates processes that aid
in tumour invasion, metastatic niche formation and metastases (249). Exactly how ECM composition and
remodelling is disrupted is still poorly understood, but is becoming increasingly accepted to be the crux for
success or failure of many clinical therapies. Thus, this chapter aimed to elucidate the role of SerpinB2 on
collagen matrix formation and stromal interactions within a TME context, through the use an advanced ex vivo
3D ECM model system. This novel model is based on the contraction of a type-1 collagen matrix, using human
or murine fibroblasts (359), and was introduced to our laboratory by Dr Paul Timpson, Lab Head of Cancer
Invasion and Metastasis at The Kinghorn Cancer Centre, Garvan Institute of Medical Research (Darlinghurst,
Sydney). The primary function of this assay within a cancer research context is to mechanistically understand
the process of ECM formation, tissue stiffness and collagen cross-linking, fibroblast/tumour association,
tumour progression, migration and therapeutic efficacy of drug testing, as well as reducing the numbers of
animal models by closing the gap between in vitro and in vivo research. Cell biology research has relied heavily
on cell culture systems utilising cells grown on plastic in a 2-dimensional (2D) plane, which unfortunately do
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not capture many effects of the tissue microenvironment as observed in vivo, including cell morphology,
polarity and junctions, cellular interaction between the ECM and other tumour or stromal cells, and
mechanotransduction, which affects intracellular signalling and cell fate (424). In the human situation, cancer
invasion and metastasis occur in a complex 3D environment, with both autocrine and paracrine feedback loops
in constant interplay from the surrounding host tissue and stroma. This governance of both cancer and stromal
cell behaviour is both exceedingly complex and critical within the events that lead to dissemination and spread
of a primary tumour thus, the use of 2D models are not comparable to the in vivo situation, creating conflicting
results (358,425,426). The 3D organotypic model allows one to use the powerful fibroblast cell (discussed in
more detail below) from nearly all tissue locations, which is the main cell type involved with the desmoplasia
and fibrosis seen in invasive tumours (249,263,280). According to the type of tissue under investigation, a
recapitulative ECM can be created utilising primary or immortalised fibroblasts, including those stably
transduced with fluorescent markers. In this way, both stromal and tumour cells can be labeled in order to
visualise cell-cell interactions during invasion. By mimicking the 3D TME, it is possible to couple in vitro and in
vivo drug development with greater efficacy, utilising powerful advanced imaging techniques, with real-time,
non-invasive imaging approaches for innovation of both biomarker target-based and phenotypic-based drug
discovery experiments. In order to construct this TME, the 3D foundation substratum is produced by cultured
fibroblasts, which actively contract collagen I into fibrils and bundles. Collagens have more than fifty binding
partners in vivo, believed to be due to the requirement of such diversity of fibril patterns, ranging from parallel
bundles in tendon and ligament, to orthogonal lattices in cornea, and interlocking weaves in blood vessels, skin,
and bone (256). In healthy tissue this is beneficial, however, having such a large number of binding partners can
have detrimental impacts in diseased tissue states. In the last decade there have been several novel innovations
in 3D culture experimentation, such as the 3D organotypic model. In combination with the capacity to isolate
specific genes or proteins and manipulate individual microenvironmental factors, these systems have facilitated
the real-time analysis of live biological tissue specimen. These techniques can now be used to visualise the
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cellular basis of fibroblastic migration, epithelial morphogenesis and migration modality, to test the roles of
specific genes in regulating cell behaviour and the nature of cell-ECM interactions within equivalent
carcinomatous tissues of the human condition. This is allowing for the elucidation of the contribution of
microenvironmental factors to normal and disease processes. Collectively, this novel model can be used to
answer fundamental biological questions and generate replacement human tumourigenic tissue, affording the
increased fidelity and applicability of novel therapeutic approaches. Through combining advanced imaging with
3D systems, it is now possible to provide more informative and disease-relevant platforms for cancer behaviour
and drug discovery.
3.1.1

Imaging 3D systems

In order to characterise and capture the continuous cellular and molecular narrative involved in tissue
development and remodelling, advanced imaging in 3D cultures is being developed and helping to extend the
frontiers of medical science (372). 3D Imaging of live (and fixed) tissue is typically undertaken overnight using
an inverted microscope and requires constant control of temperature, humidity, 02 and CO2 levels, and
evaporation (427). As such, there are many new challenges involved to accurately visualise live cells in 3D cell
cultures, techniques such as bright field and phase microscopy are usually not feasible as 3D culture tissue is
often thick and light is not as easily transmitted through the specimen (428). In addition, to effectively visualise
3D cultures in a non-destructive manner, epi-illumination (light detected in a backward direction) imaging
techniques are preferred for the observation of 3D tissue structure and dimensional characteristics (428).
Different microscopic systems can be used in complementation for detection of fluorescent markers, cell/tissue
autofluorescence, backscattered light, as well as label free proteins that are non-symmetrical (e.g. collagen I
fibres) (428). Such imaging systems used in this study included second harmonic generation (SHG), two-photon
(TPM) and multi-photon microscopy (MPM), and scanning electron microscopy (SEM) (Fig. 3.1).
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Fig. 3.1. 3D imaging systems. Diagrams of (A) second harmonic generation microscopy; (B) multi-photon microscope; (C) scanning electron microscope, and schematics of the signal
paths of each system from the source, upon tissue sample and back to the detector for image generation. Images modified from http://www.leica-microsystems.com and
http://binoculas.net.
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3.1.2

Second harmonic generation (SHG)

In biomedical science, SHG microscopy is used for high-resolution, non-linear optical imaging that does
not require fluorescent labeling for image detection (429). Instead, this technique involves two-photon
fluorescence imaging, where a laser focuses two high-intensity photons upon a non-centrosymmetric
tissue specimen to generate frequency-doubled light: the formation of one photon with twice the energy
(and thus, frequency) yet half the wavelength of the initial photons (429) (Fig. 3.1A). In 1971, Fine and
Hansen established SHG as a dynamic microscopic technique for visualisation of collagenous tissue
samples (430). SHG differs from TPM in that it does not lose any photon energy after tissue absorption.
The reason for this is because there is substantially less absorption into non-centrosymmetric tissue and
thus, there is negligible thermal, photobleaching or phototoxic damage, valuable for live-imaging
purposes (431). In addition, SHG imaging offers several advantages for live cell and tissue imaging as near
infrared wavelengths of incident light can be used, meaning one can image deeper into thick tissues
without any image loss or distortion. SHG laser photons are emitted coherently (432) and occur at noncentrosymmetric loci (433), such as collagen I fibres (434), myosin filaments (435), and in cellulose
(436). Because SHG light is coherent, it is different to fluorescence microscopy in that it can capture
dynamic information about the spatial organisation of molecules and tissue beds. Through the use of a
high energy, short-pulse femtosecond laser and the correct filters, SHG excitation light can be easily
isolated from the frequency-doubled emission signal (429). This means that pinholes are not required and
very high axial and lateral resolution equivalent to confocal imaging can be obtained (429). In this regard,
SHG microscopy has been extensively used to analyse tissues of the cornea and lamina cribrosa sclerae,
both consisting primarily of collagen I (437). Within tissue specimen containing collagen I, SHG radiates
from the shell of collagen fibrils, rather than from the core (434). The SHG signal may relate to the
supporting element of each collagen fibril and thus, collagenous specimen can be resolved by directly
imaging the backward-propagating SHG signal, which is an extremely useful tool for research within 3D
live systems containing collagen I (434).
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3.1.3 Multiphoton microscopy (MPM) imaging
MPM uses two pulsed long-wavelength photons to excite a fluorophore within a tissue sample. The two
photons must simultaneously hit the fluorophore in order to excite an electron into a higher energy state,
causing it to decay and emitting a fluorescent signal (438) (Fig. 3.1B). A MPM is different from a conventional
fluorescence microscope, as the MP wavelengths of both excitation photons are longer than the wavelength of
the resulting emission photon (438). MPM uses a raster pattern of focused laser light to generate an image,
creating an optical section effect (439). Several advantages exist to multiphoton microscopy over confocal
microscopy, including increased penetration depth with less damage to live tissue, higher contrast without bulk
fluorescence, as well as all fluorescence light from the focus point being collected by the detector. The longer
the emitted photon wavelength (typically infrared) the less damage there is to live tissue, meaning imaging can
be undertaken for extended time periods without photobleaching or phototoxicity damage (439). In twophoton fluorescence microscopy (TPM), the synchronised absorption of two photons with half the frequency of
the absorption spectrum of a fluorophore is necessary for fluorescence emission. The likelihood of simultaneous
absorption of two photons within the natural light spectrum is small (calculated to be 1 event/106 years) (439).
Thus, TPM fluorescence usually utilises a mode-locked laser, where photons are emitted at high intensity for
extremely short (femtosecond) time periods (439). This technique allows for a multi-colour 3D image to be
taken within tissue up to 70–100 µm deep, and also for time-lapse imaging. TPM was utilised within this study
as it can both facilitate deeper imaging into specimen and visualise fibrillar ECM networks using SHG signals.
Additionally, many novel techniques are being applied to MPM and TPM systems to help improve working
length of biological samples without toxicity as well as attaining higher resolution images. Finally, 3D tissue
samples can be prepared for ultrastructure imaging by scanning electron microscopy (SEM).
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3.1.4 Scanning electron microscopy (SEM)
This technique has been used in cell biology since the early 1920’s; however, as technology and methodology
(cryogenic) has become increasingly better, sharp increases in resolution have been gained, specifically for
biological matter. SEM produces a focused beam of electrons that interact with atoms in a sample, emitting a
multitude of signals that contain information about the sample's surface topography, crystalline structure,
chemical composition and electrical behaviour (440) (Fig. 3.1C). The types of signals produced by SEM include
secondary electrons, back-scattered electrons, characteristic X-rays, light (cathodoluminescence) and specimen
current and transmitted electrons (440). For biological matter, secondary electrons and back-scattered
electrons are readily detected for image generation. The electron beam is scanned in a raster scan pattern
predominantly (refer Fig. 3.1C), and the beam's position is combined with the detected signal to generate an
image (440). SEM can achieve high resolution from >1 µm down to ~1 nm, and specimens can be observed in
high or low vacuum, and at a wide range of cryogenic or elevated temperatures (441). The angle at which an
electron beam contacts with the surface of a specimen is largely responsible for the resolution of the image as
electron repulsion happens in a vast array, which must be optimised during each sample run. SEM was utilised
in this project as it offered the ability to attain high-resolution ultrastructure information about the collagen
networks formed in stromal matrices during fibroblast mediated ECM contractions.

3.1.5 SerpinB2 in the ECM
In order to facilitate proper ECM contraction, fibroblasts must appropriately regulate the PAS pathway. The
combined signalling and proteolytic outputs of the PAS pathway activate a plethora of downstream events
driving ECM degradation, cell proliferation, adhesion and migration (89). Negative regulation of this pathway
occurs at several levels, including inhibition and clearance of protease activity by naturally occurring inhibitors,
such as SerpinB2 (19,25). Elevated tumour SerpinB2 expression is linked with prolonged survival, decreased
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metastasis, or decreased tumour growth in many cancer types (19,442,443). However, specific mechanisms
have not been addressed. Therefore, to identify the role of SerpinB2 in collagen cross-linking and stromal
remodelling it is necessary to interogate and dissect the role of the PAS pathway in collagen fibrillogenesis and
ECM development. Through modulation of PAS activity in a context-dependent manner it should be possible
to demonstrate the necessity of PAS activity in regulating cell-stromal interactions driving fibroblast adhesion
and migration, collagen integrity and ECM remodelling.
Thus, the specific aims of this chapter were to:
1.

Construct stromal equivalent collagen I matrices using fibroblasts with modified SerpinB2

expression.
2.

Characterise the ultrastructural properties of these matrices using advanced microscopy

techniques, including second harmonic generation (SHG), multiphoton microscopy (MPM) and scanning
electron microscopy (SEM) analyses.
3.

Identify and ascertain differences between the fibrillogenesis and stromal remodelling of matrices,

in order to understand potential influences upon invasive capacity of epithelial breast and pancreatic
carcinoma cells in proceeding experiments (Chapter 4 and 5).

3.2

METHODS
3.2.1 Cell lines and culture conditions

Human skin derived telomerase-immortalised fibroblasts (TIFs) (359) were maintained in Dulbecco's modified
Eagle's medium (DMEM) supplemented with 10% FBS with 100 U/mL penicillin and 100 µg/mL
streptomycin in a humidified 5.0% CO2 atmosphere at 37°C. All cell cultures were routinely tested in-house
for absence of mycoplasma contamination using the MycoAlert™ Mycoplasma Detection Kit (Lonza,
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Switzerland). Spontaneously immortalised GFP-positive wild-type and SerpinB2-/- mouse embryonic fibroblasts
(MEFs) were previously generated and cultured as described in Chapter 2 (section 2.2.1).
3.2.2

Flow cytometry

Expression of cell surface uPA and uPAR was analysed by indirect immunofluorescence using dual color flow
cytometry (LSRFortessaTM, Becton-Dickinson), propidium iodide (PI) was used to exclude non-viable cells as
previously described (444). Data was analyzed using FlowJo software version 7.6.5 (FlowJO LLC, USA)
comparing specific antibody binding to isotype controls to account for nonspecific binding (refer to
Supplementary Antibodies Table of Appendix – Table A1).

3.2.3 Wound healing assays
Wild-type and SerpinB2-/- MEF migration differences were tested in 2D, prior to 3D model experimentation.
All assays were performed in a humidified 5.0% CO2 atmosphere at 37°C using the IncuCyte ZOOM imaging
system (Essen BioScience, USA). Wells were seeded with either wild-type or SerpinB2-/- MEFs at even density
(25,000/well) in triplicate in an uncoated ImageLock 96-well plate (Essen BioScience) and allowed to attach and
spread over 16 h in RPMI containing 10% FBS. After a subsequent wash step with phosphate buffered saline (PBS),
the wells were refreshed with RPMI in the presence or absence of 10% FBS. Scratch wounds were generated with
the Woundmaker tool and images taken every 2 h. Images were processed using IncuCyte ZOOM system (10 x
objective) and wound regions were measured using automated analysis. Relative Wound Density (%, value of 0 =
no migration, value of 100 = completed migration, when the cell density inside the wound is the same as the cell
density outside the initial wound) was analysed as a percentage (± SEM).
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3.2.4 3D organotypic contraction assay
Contraction of collagen I matrices by either TIFs, wild-type or SerpinB2-/- MEFs were performed essentially as
previously described (359). Briefly, rat-tail tendon collagen was extracted with 0.5 M acetic acid to a
concentration of 2.0 mg/ml. The purity of the isolated collagen I was verified by SDS-PAGE. Contraction to a
3D matrix was stimulated by mixing fibroblasts (5.0 x 105 – 1.0 x 106 per 12 matrices) into neutralised (pH
7.4) collagen I solution and placing into 35 mm petri dishes (2.5 mL/dish). For use in this assay, TIFs were
required to be quiescent, by leaving in culture for 4-14 days after confluency without change of media, while
MEFs were used immediately upon reaching confluency. Detached polymerised matrices were then allowed to
contract for 12-14 days (unless specified otherwise) in complete media (DMEM, supplemented with 10% FCS
and pen/strep), refreshed every 2-3 days. It is of note that differences in overall matrix contraction time were
observed due to different cell types used, or batch-to-batch variation in collagen I. This was controlled for by
using the same collagen in triplicate experiments. Protein concentration was determined by performing SDSPAGE alongside known concentrations of commercial collagen I (Sigma-Aldrich) and quantified via
densitometry analysis.
Moreover, much literature has recently reported that doxycycline (Dox) is also an MMP inhibitor, decreasing
MMP activity in wound healing (445), endometriotic lesions (446), reducing myocardial infarction size (447),
as well as inhibiting MMPs and reducing brain damage after cerebral ischemia through attenuating hypertensive
vascular remodelling in peripheral and cerebral vasculature (448). Therefore, supplement experiments were
undertaken where either PBS (Control), 500 nM SerpinB2 ∆CD loop, R380ASerpinB2 (on ∆CD Loop backbone)
or 20 µg/mL Dox were added to the media of contracting matrices, refreshed every two days. Dox is a broad
spectrum inhibitor of MMPs, particularly MMP2, MMP9 (448), thus, Dox was used to elucidate the effect of
MMP inhibition in collagen matrix contraction. Quantification of contraction rate was measured using
photomicrographs and analysed by ImageJ (NIH, USA). After contraction, the matrices were fixed in 10%
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neutral buffered formalin (NBF) for 2 days and either analysed or processed immediately, or kept in 70%
ethanol at RT for 1-2 days before paraffin embedding or analyses. FFPE samples were then used for histological
and microscopic analyses.
3.2.5 Histological analysis
Samples fixed in 10% NBF were processed using the Leica Peloris Dual Retort tissue processor (Germany).
Histological staining was performed on 4 µm sections that had been deparaffinised in xylene and rehydrated
using graded ethanol washes (70% - 100% EtOH). Haematoxylin and Eosin and picrosirius red (Polysciences,
USA, #24901-250) staining were performed on a Leica Autostainer XL. Immunohistochemistry was
performed used the Leica Bond RX system. Refer to Appendix Table 1 for antibody details. For scoring of
invasive index, migration modality, cell cluster and immunohistochemistry staining, ten images per sample
were acquired using a bright field microscope (Leica DM4000).
3.2.6

Ultrastructural SHG imaging

Live collagen I matrices or 20 µm sections of fixed contracted matrices, or tumours, were imaged using a 203
0.95 NA water immersion objective on an inverted Nikon TE-2000 microscope body. The excitation source
was a Ti:Sapphire femto-second laser cavity (Coherent Chameleon Ultra II, USA), coupled to a LaVision Biotec
Trim-scope scan-head. 840 ± 20 nm excitation wavelength/420 ± 10 nm emission wavelength was used to
collect collagen 1 SHG signal. ImageJ was used to calculate percentage area detected by SHG signal per optical
slice within a volume, after conversion to a binary image based upon a manually determined threshold value.
3.2.7 Tracking of fibroblast movements in matrices
Fibroblast motility through live collagen I matrices was computed by tracking cell position versus time with
Imaris 8.0 (Bitplane, USA), using the cell-detection (built-in spots) and isosurface tracking routines (130 - 160
cells were tracked per experiment). Cells were selected for analysis if the cell centroid moved greater than one
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cell diameter over the 14 h time course and blebbing cells were excluded. Visual confirmation was also used to
exclude any cells displaying oscillations or shape changes to minimise artefacts associated with automated
analysis. All cells were tracked in z-planes in the central part of the matrix (typically where the matrix was
thickest for wild-type MEF matrices) to avoid any potential edge effects. GFP-tagged wild-type and SerpinB2-/MEFs were detected using 488 nm excitation wavelength.
3.2.8 SEM imaging
Fixed matrices were sliced and clamped in a cooling chamber consisting of a 25mm x 10mm brass block with a
sample chamber groove. The brass holder containing each sample was plunged into a bath of liquid nitrogen for
40 – 45 sec and then fractured with a liquid nitrogen cooled blade, to expose a cross-section surface which was
flush with the surface of the brass block. The cooled holder with the fractured sample was then inserted into a
JEOL 6490LV scanning electron microscope equipped with a secondary electron detector and a backscattered
electron detector (scintillator type) using acceleration voltages between 10 and 20 kV. Images were recorded
with an integrated JEOL digital image acquisition system, undertaken at the Australian Institute for Innovative
Materials (AIIM), the UOW Electron Microscopy Centre (EMC), North Wollongong Australia.
3.2.9

Pilot proteomic analysis of wild-type and SerpinB2-/- MEF matrices

10 µm section of FFPE wild-type and SerpinB2-/- fibroblast mediated collagen I contracted matrices (n = 3)
were sent to our collaborators, Dr Oliver Shilling and Dr Zon Weng Lai, at the University of Freiburg,
Germany. Sections were deparaffinised with xylene and rehydrated in a decreasingly graded ethanol series,
transferred into microreaction tubes and prepared for LC-MS/MS analysis by Dr Shilling and Dr Lai, as
described in (449). LC-MS/MS analysis was performed on an Orbitrap XL (Thermo Scientific) mass
spectrometer (MS) coupled to an Ultimate3000 micro pump (Thermo Scientific). The MS was operated in data
dependent mode and each MS scan was proceeded by five MS/MS scans. LC-MS/MS data was obtained in raw
format and converted to the mzXML format, using msconvert (86). For spectrum to sequence assignment X!
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Tandem (version 2013.09.01) was used (449). The proteome database consisted of mouse and rat tissue
reviewed

canonical

uniprot

sequences

(without

isoforms)

downloaded

from

UniProt

(http://www.uniprot.org). Two different searches were conducted for light and heavy labelled peptides and
mass tolerance for quantification was 0.02 Da. XPRESS data was log2-transformed yielding fold change (Fc)–
values (449). Protein abundance was considered to be significantly altered if protein abundance increased or
decreased with an average Fc-value > 0.70 or < −0.70.

3.2.10 Statistical analyses
Unless specified otherwise, data is presented as the mean (± SEM) of at least 3 independent experiments
performed in either triplicate or sextuplet. Differences in the mean of two samples were analysed by an
unpaired t-test. Comparisons of more than two groups were made by a one-way (or two-way) ANOVA with
post hoc Holm-Sidak (or other post hoc) analysis for pairwise comparisons and comparisons versus control. P
values < 0.05 were considered statistically significant. Unless stated otherwise, data and statistical analyses
were performed using GraphPad Prism (version 6.0, USA).

3.3

RESULTS
3.3.1 Collagen I preparation

Collagen I is sequence conserved between rat and human, thus rat tails are the most convenient source for
collagen I extraction within the laboratory, with a high content found in the tendon (four per tail). In order to
ensure that the extracted collagen from rat-tails was in fact collagen I, a 7.5% SDS-PAGE was undertaken
(Fig 3.2). Three bands can be observed in lanes 1 and 2, consistent with the sizes of collagen I monomers,
alpha-1 chain [alpha-1(I) chain (139 kDa)] and alpha-2 chain [alpha-2(I) chain (129 kDa)]. As collagen I is a
triple helix consisting of one alpha-2 chain and two alpha-1 chains, the third band present is the dimeric form
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(~270 kDa) of alpha-1. Once confirmation of collagen I purity was achieved, proceeding contraction
experiments using fibroblasts could be undertaken.

Fig. 3.2. SDS-PAGE analysis of a representative sample of purified rat tail collagen I. 7.5% non-reducing SDS-PAGE
showing, Lane 1 – 0.5 µg collagen I; Lane 2 – 1 µg collagen I.

3.3.2

PAS expression in fibroblast lines

To determine PAS protein expression levels within the cell lines used for matrix formation, uPA and uPAR
expression was undertaken using flow cytometry, and SerpinB2 expression by Western blot analysis (refer to
section 2.2.10.1 for methodology) (Fig 3.3). Both wild-type and SerpinB2-/- MEFs expressed cell surface uPA
(Fig 3.3B,C), however uPA fluorescence shift was 2.3-fold less in the SerpinB2-/- MEFs versus wild-type MEFs
(P < 0.0001, Fig 3.3E). uPAR was significantly expressed on both SerpinB2-/- and wild-type MEFs, versus IgG
isotype controls (Fig 3.3B,C), however there was no significant uPAR fluorescence shift recorded between
SerpinB2-/- MEFs and wild-type MEFs (P = 0.2927, Fig 3.3F). TIF cells showed little to no expression of these
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PAS activators, relative to IgG isotype controls (Fig 3.3C). Western blot analysis revealed that TIFs and wildtype MEFs both expressed moderate levels of PAI-2 (translated SerpinB2), while SerpinB2-/- MEFs were devoid
of SerpinB2, as expected (Fig 3.3D).

Fig. 3.3. Flow cytometry analysis of cell surface uPA and uPAR expression. A. Wild-type MEFs, B. SerpinB2-/- MEFs, and
C. TIFs. Insets show the geographical mean of fluorescence intensity (± SEM, n = 3). D. Western blots showing expression of
SerpinB2 in TIFs, SerpinB2-/- and wild-type MEFs. Blots were reprobed for actin as equiloading controls.

3.3.3 Differences in MEF migration/2D wound healing
The rate of proliferation of wild-type versus SerpinB2-/- MEFs was not significantly different in 2D systems [data
not shown; reported by (167)]. Conversely, there was a significant difference observed in MEF cell migration as
observed in 2D scratch wound assays, where the ability of SerpinB2-/- MEFS to polarise and migrate into the
wound space over 24 h was significantly impaired under serum containing conditions, compared to wild-type
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MEFs (P < 0.0001) (Fig. 3.4, A). This effect is not due to differences in MEF proliferation as aforementioned,
and also observed in the serum free conditions of the assay (P < 0.0001) (Fig. 3.4, B).

Fig. 3.4. Comparative time-course of migration of wild-type SerpinB2 versus SerpinB2-/- MEFs measured using IncuCyte
ZOOM (Essen Biosciences). Cells (25,000/well) were added to an uncoated ImageLock 96-well Plate and allowed to attach and spread
over 16 h in RPMI containing 10% FBS. After a subsequent wash step with PBS, the wells were refreshed with RPMI in the presence (A) or
absence (B), of 10% FBS. Scratch wounds were generated with the Woundmaker tool and images taken every 2 h. Images were processed
using IncuCyte ZOOM system and wound regions were measured using automated analysis. Relative Wound Density (%, value of 0 = no
migration, value of 100 = completed migration, when the cell density inside the wound is the same as the cell density outside the initial
wound). Each point represents the mean of 24 wells with the vertical bars showing the SEM. Generated by time-lapse imaging (Incucyte, 10
x objective) over time.
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3.3.4 Fibroblast contracted collagen I matrix formation and integrity
Primarily, TIFs were used to verify that these cells could indeed contract collagen over a period of 12 days,
forming robust dermal equivalent extracellular matrices (359). SEM imaging was then utilised to show the
ultra-structure of these matrices (Fig. 3.5), revealing robust matrix integrity. Both surface (Fig 3.5A-E) and
sagittal (Fig 3.5F-J) images were taken, revealing robust fibroblast-collagen contracted matrices, with
homogenous collagen cross-linking, large fibril networks and dense matrix formation. This innovative
technique was thus shown to be an ideal model for understanding collagen crosslinking and stromal remodeling,
as well as for the elucidation of the effects of PAS on this process.
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Fig 3.5. SEM ultrastructure analysis of TIFs matrices. SEM images show surface (A-E) or sagittal section (F-J) of TIF
contracted collagen I matrices. Fixed sections were prepared (as described in section 3.2.7) at day 12 of contraction. Homogenous
isotropic collagen cross-linking and large fibril networks in horizontal orientation can be seen in the surface section images
(particularly images A-C). Solid matrix formation can be observed and TIFs (denoted by arrows) can be seen directly connected to
the collagen networks.
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Stromal expression of SerpinB2 is consistently linked to progression in a number of tumour types, as
aforementioned. Therefore, to confirm the role of stromal SerpinB2 in regulation of the ECM and involvement
with collagen fibrillogenesis, TIFs were substituted for wild-type or SerpinB2-/- MEFs to drive matrix
contraction. Interestingly, matrices formed by SerpinB2-/- MEFs showed significant differences in the rate of
collagen contraction to those generated by wild-type MEFs (Fig. 3.6). After a 12-day contraction period, wildtype MEF-contracted collagen I matrices were on average 2.3 x smaller than those contracted by SerpinB2-/MEFs (Fig. 3.6D). This corresponded to a 58% reduction in the rate of matrix contraction in the absence of
SerpinB2 (Fig. 3.96). This phenomenon was further characterised by a series of detailed structural analyses
performed to interpret matrix integrity and organisation during matrix formation by either wild-type or
SerpinB2-/- MEFs. SHG analysis of collagen coverage and density showed that wild-type fibroblasts formed a
robust matrix composed of stable, covalent cross-linked collagen I, with homogenous density (Fig. 3.6A,
Supplementary movies 1 and 2). Conversely, SerpinB2-/- fibroblasts formed disordered collagen networks with
heterogeneous collagen I density and decreased diffusive hindrance (Fig. 3.6B; Supplementary movies 3 and 4).
Quantification of SHG signal through z-stacks of each matrix showed a significant decrease in collagen coverage
in the absence of SerpinB2. Maximum collagen coverage of 30% was observed in wild-type matrices at a depth
of 20 µm, decreasing to 13% at a depth of 80 µm (Fig. 3.6C). In contrast, maximum collagen coverage only
reached 10% in SerpinB2-/- matrices at the same 20 µm depth (Fig. 3.6C). 3D imaging of the SHG signal
through matrices showed the stark differences between matrices constructed with SerpinB2 (Fig. 3.6F,
Supplementary movie 5) or in the absence of SerpinB2 (Fig. 3.6G, Supplementary movie 5). The decreased
diffusive hindrance recorded in the SerpinB2-/- MEF matrices shows the reduction in proper collagen I network
formation, however more detailed ultra-structure characterisation was employed.
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Fig 3.6. SHG imaging and quantification of wild-type and SerpinB2-/- MEF matrices. A-B: Maximum projection through
0 – 80 µm z-stack of SHG signal intensity of collagen I matrices formed with either (A) wild-type or (B) SerpinB2-/- MEFs; C. Total
collagen coverage (quantified by intensity of SHG signal) within matrices formed by either wild-type or SerpinB2-/- MEFS, inset:
Mean collagen coverage at SHG signal peak. Values shown are means ± SEM from 3 separate matrices (n = 9), statistical analysis
performed using an unpaired t-test; D. Photographs showing collagen I matrix contraction over 12 days in the presence of either
wild-type or SerpinB2-/- MEFS; E. Changes in area (mm2) of collagen matrices shown in (D) over the 12 day contraction period.
Values shown are means ± SEM from 3 separate matrices (n = 9); F-G 3D z-projections of multiphoton SHG imaging of matrices
contracted by either (F) wild-type or (G) SerpinB2-/- MEFs, over a 12-day time course, demonstrating collagen crosslinking ability.

To this end, SEM imaging was undertaken and showed extensive fibril coverage, strong outer matrix structure
and homogenous (isotropic) collagen distribution in the wild-type matrices (surface view Fig. 3.7A-E, sagittal
view Fig 3.8A-E). Conversely, SerpinB2-/- MEFs formed disordered (anisotropic) collagen networks, with SEM
revealing dense collagen bundles distributed in an unregulated fashion, resulting in poor collagen network
integrity (surface view Fig. 3.7F-J, sagittal view Fig 3.8F-J). Hence, SerpinB2 expression by stromal fibroblasts
is necessary for structural integrity in an ex vivo model of extracellular collagen matrix formation.
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Fig 3.7. SEM ultrastructure surface analysis of MEF matrices. SEM ultrastructure analysis showing surface of either wild-type
(A-E) or SerpinB2-/-MEF (F-J) contracted collagen I matrices. Fixed sections were prepared (as described in section 3.2.7) at day 12
of contraction. Robust matrix formation can be observed in wild-type matrices (particularly images B,C and E), while SerpinB2-/matrices show a malformed surface topography, with loose uncross-linked collagen (shown with a red *). MEFs (denoted by arrows)
can be seen directly in the matrices, showing cell-cell contact and connected to the collagen networks in wild-type matrices, however
this is considerably less in SerpinB2-/- MEF matrices.
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Fig 3.8. SEM ultrastructure sagittal section analysis of MEF matrices. SEM ultrastructure analysis showing sagittal sections
of either wild-type (A-E) or SerpinB2-/-MEF (F-J) contracted collagen I matrices. Fixed sections were prepared (as described in
section 3.2.7) at day 12 of contraction. Collagen cross-linking of wild-type matrices can be observed with tighter networks and small
pore size (A-E), while decreased collagen networks and decreased diffusive hindrance (large pore size) within SerpinB2-/- MEF fibril
networks can be observed (F-J). Top of matrix is marked (B and G) with a dotted line and direction towards bottom of matrix
marked with a red arrow.
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3.3.5 Stromal SerpinB2 effects on MEF migration and ECM remodelling
The prominent differences shown above in ECM construction raised further questions into the individual cell
specific effect within these matrices. Thus, in order to further understand the effect of SerpinB2 on matrix
contraction, MEFs with stable GFP expression (refer to Chapter 2, section 2.3.7) were used to visualise their
behaviour during collagen contraction. At day 6 - when matrix contraction was well underway (refer to Fig.
3.9), SHG and multiphoton imaging was undertaken over a 14 h period. Dramatic differences in the
morphology and behaviour of wild-type versus SerpinB2-/-MEFs were observed (Fig. 3.9A). Morphologically,
wild-type MEFs appeared larger than SerpinB2-/- MEFs, and were recorded consistently with higher motility,
moving freely throughout the matrix, while SerpinB2-/- MEFs were virtually immobile (11.2 µm/s ± 0.4
versus 3.3 µm/s ± 0.1, respectively) (Fig. 3.9B and C; Supplementary movie 6). Notably, several wild-type
MEFs were observed undergoing mitosis/cytokinesis, but this was not observed in SerpinB2-/- MEFs
(Supplementary movie 7). Despite this, no difference in proliferation rate was observed between wild-type
versus SerpinB2-/- MEFs in 2D systems [data not shown, reported by (167,198)]. Wild-type MEFs were
predominantly multipolar, with dynamic cycling of numerous, short cellular protrusions. In contrast, SerpinB2/-

MEFs were predominately bipolar - with fewer but longer and more stable protrusions observed (Fig. 3.9D -

H). Hence, the behaviour of MEFs within the contracting collagen matrix is significantly altered in the absence
of SerpinB2, and this altered behaviour is likely responsible for the observed structural changes in matrices
formed by SerpinB2-/- MEFs.
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Fig. 3.9. Overnight 3D imaging of MEF migration and ECM remodelling. A. Migration of wild-type or SerpinB2-/- MEFs
through collagen I matrices was tracked over 10 h at the midpoint of matrix contraction (day 6). collagen (magenta) was detected
using SHG and wild-type or SerpinB2-/- MEFs were detected through stable GFP expression. Cell tracks are marked by a vector tail
(white); B-C. Polar plots denoting cell directionality (x,y distance) and total displacement (µm) of either (B) wild-type or (C)
SerpinB2-/- MEFs through collagen I matrices over the time course (14 h) of the experiment; D. Average motility of wild-type or
SerpinB2-/- MEFs through collagen I matrices was computed by tracking cell position over time (n >130 for each, individual values
are shown with bars representing mean ± SEM.); E. Average number of protrusions per cell across the course of the experiment; F.
Average length of protrusions per cell across the course of the experiment. Statistical analyses were performed using unpaired t-tests.
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3.3.6 Pilot proteomic analysis of wild-type and SerpinB2-/- MEF matrices
In order to begin to elucidate specifically the proteins present within this complex ECM remodelling process, a
pilot LC-MS/MS analysis was performed on matrices derived using wild-type or SerpinB2-/- MEFs (Fig. 3.10).
Interestingly, there were many proteins that were significantly decreased within SerpinB2-/- MEF matrices
versus wild-type MEF matrices (Fig. 3.10), potentially responsible for the reduced contraction rate, increased
overall diameter of matrices, lack of matrix integrity and decreased collagen cross-linking observed throughout
(refer to Fig. 3.6-3.8). Those proteins found to be significantly less abundant were, and not limited to, LOX
(2.6-fold less), collagen alpha-1(I) chain (0.8-fold less), collagen alpha-2(I) chain (1.2-fold less), EMILIN-1 (1fold less), Biglycan (1-fold less), and SPARC (0.7-fold less) (Fig. 3.10). In addition, there were many proteins
that were significantly increased within SerpinB2-/- MEF matrices, possibly in attempts at retaining functional
roles for matrix integrity and collagen cross-linking, through SerpinB2 absence. Those proteins found to be
significantly up-regulated were, and not limited to, Superoxide dismutase-1 [(SOD-1) 3.19-fold increase],
Fibrinogen (2.28-fold increase), Zinc finger protein [(ZFAT) 2.2-fold increase], Actin-related protein 2/3
complex subunit 1B [(ARPC1B) 2.12-fold increase], and Actin (0.73-fold increase) (Fig. 3.10).
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Fig. 3.10. LC-MS/MS data analysis. Normalised Fc values of proteins significantly altered within the SerpinB2-/- MEF matrices
versus wild-type MEF matrices. Protein abundance was considered to be significantly altered if protein abundance increased or
decreased with an average Fc-value > 0.70 or < −0.70.

3.3.7 Exogenous SerpinB2 effects on SerpinB2-/- MEF collagen contraction
SerpinB2 was lentivirally knocked back in to SerpinB2-/- MEFs as well as wild-type MEFs, using the pLenti6.3
vector system. However, after transduction and selection, the cells were phenotypically altered, displaying an
epithelial-like phenotype with irregular lamellopodial protrusions (data not shown). The doubling time of both
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transduced lines were also significantly decreased versus untransduced controls, and eventually the cells died.
Thus, in order to determine whether the absence of SerpinB2 affected collagen cross-linking, via inability to
inhibit potential uPA mediated effects on contraction, exogenous SerpinB2 was utilised in these SerpinB2-/MEF mediated collagen I contraction experiments to ascertain whether the re-introduction of SerpinB2 could
re-instate contraction rates, collagen cross-linking ability and proper fibrillogenesis, as observed within wildtype MEF matrices. Unfortunately, full length SerpinB2 was not available, thus SerpinB2 ∆CD loop, which
maintains full uPA inhibitory activity (176), was used in its place, along with a PBS vehicle control and
R380A

SerpinB2 ∆CD loop as a uPA non-inhibitory control. As aforementioned, much literature has recently

reported that Dox is also an MMP inhibitor (MMPs -2 and -9), while not causing cell death or effects on
proliferation. Thus, contraction assays were setup using SerpinB2-/- MEFs in the presence of 500 nM SerpinB2
∆CD loop, 500 nM

R380A

SerpinB2 ∆CD loop, PBS or 20 µg/mL Dox. There were no significant differences

recorded upon the rate of matrix contraction using PBS, SerpinB2 ∆CD loop or R380ASerpinB2 ∆CD loop (Fig
3.11A,B), suggesting that SerpinB2 mediated uPA inhibition does not affect collagen cross-linking, but it is an
intrinsic effect of SerpinB2 on cell behaviour. However, in the presence of 20 µg/mL Dox, matrices did not
contract from the original size of the 35 mm petri dish (Fig 3.11A,B). This shows that through Dox induced
MMP inhibition, SerpinB2-/- fibroblasts are not able to form viable collagen cross-linked networks and remodel
the ECM. This suggests, not surprisingly, that impeded MMP -2 and -9 activity interferes with ECM
remodelling within SerpinB2-/- MEF-collagen I matrices.
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Fig 3.11. 3D organotypic of SerpinB2 restoration effects on SerpinB2-/- MEF matrices. A. Photographs showing
SerpinB2-/- MEF collagen I matrix contraction over 21 days in the presence of either PBS Control, 500 nM SerpinB2, 500 nM
R380A
SerpinB2 and 30 µg/mL Dox; B. Changes in area (mm2) of SerpinB2-/- MEF collagen matrices shown in (A) over the 21 day
contraction period. Values shown are means ± SEM from 3 separate matrices.

This novel result is only preliminary in its findings, however, SEM imaging revealed that there were few, if any
collagen fibrils in the Dox treated matrices (surface view Fig 3.12I-L, sagittal view Fig 3.13I-L), whereas
extensive fibrillar collagen networks were observed within both SerpinB2 ∆CD loop (surface view Fig 3.12AD, sagittal view Fig 3.13A-D) and R380ASerpinB2 ∆CD loop (surface view Fig 3.12E-H, sagittal view Fig 3.13EH) treated SerpinB2-/- matrices. Additionally, there appeared to be thicker bundling of collagen in the SerpinB2
∆CD loop matrices versus those formed in

R380A

SerpinB2 ∆CD loop matrices Fig 3.13D,H). This observation
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could be due to higher uPA/uPAR expression effects on collagen cross-linking, as MMPs are required for
remodelling and their presence is definitely required more than absence, as observed in Dox treated matrices
(Fig 3.11A,B, Fig 3.12I-L, and Fig 3.13I-L).

Fig 3.12. SEM ultrastructure surface analysis of SerpinB2-/- MEF matrices. SEM ultrastructure analysis showing surface of
SerpinB2-/-MEF contracted collagen I matrices in the presence of either 500 nM SerpinB2 ∆CD loop (A-D), 500 nM R380ASerpinB2
∆CD loop (E-H), or 20 µg/mL Dox (I-L). Fixed sections were prepared (as described in section 3.2.7) at day 21 of contraction.
Collagen cross-linking can be observed in SerpinB2-/-MEF matrices formed in the presence of SerpinB2 ∆CD loop and R380A500 nM
SerpinB2 ∆CD loop (images A-H), while SerpinB2-/- matrices in the presence of Dox do not show evidence of adequate collagen
cross-linking.
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Fig 3.13. SEM ultrastructure sagittal section analysis of SerpinB2-/- MEF matrices. SEM ultrastructure analysis showing
sagittal sections of SerpinB2-/-MEF contracted collagen I matrices in the presence of either 500 nM SerpinB2 ∆CD loop (A-D),
R380A
500 nM SerpinB2 ∆CD loop (E-H), or 20 µg/mL Dox (I-L). Fixed sections were prepared (as described in section 3.2.7) at day
21 of contraction. Substantial collagen cross-linking in SerpinB2-/-MEF matrices was observed in those contracted in the presence of
SerpinB2 ∆CD loop and R380A500 nM SerpinB2 ∆CD loop with fibrillar organisation (C and D, F and H) evident, albeit with
significant decreased diffusive hindrance (large pore size). SerpinB2-/- matrices contracted in the presence of Dox did not show any
evidence of collagen I fibrilogenesis or collagen I bundle formation (I-L).
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3.4

DISCUSSION

Indisputably, loss of ECM homeostasis is a key factor in tissue fibrosis and cancer progression (23).
Interestingly, both of these pathologies are heavily shown to aid the other, shaping the way for malignant
transformation, as cancer-associated fibrosis and desmoplasia are incriminated in primary tumour growth and
metastases in many cancer types (23,249,263,353,450). Understanding ECM function within stromal
formation and the TME is thus vital for the emergence of better treatment strategies and therapeutic options.
As SerpinB2 has been linked to cancer inhibition as well as progression [(213) see Chapter 1, refer to section
1.5], we utilised SerpinB2 both genetically and pharmacologically for studies in 3D collagen I matrix
contraction assays. The 3D matrix consists of collagen I, which is cross-linked into fibrils and contracted over a
period of 7-21 days by both human and murine fibroblasts. The collagen was prepared by acetic acid extraction,
which unlike enzymatic digestion, preserved the N- and C-terminal telopeptide reactivity aiding in collagen
cross-linking (359,451). The acetic acid extraction method resulted in pure collagen I stocks that had robust
polypeptide reactivity, as re-constituted collagen I successfully formed robust fibroblast-contracted matrices,
confirmed by SEM (refer to Fig. 3.5). As collagen I has a homologous sequence between rat and human, rattails were sourced for collagen I extraction. Either from fresh or frozen starting material, adolescent rat tails
were used, because collagen cross-linking is more labile in younger animals (N- and C- telopeptide residues
available for aldol-lysine cross-linking) (359), thus essential for this technique. As stated by Timpson et al.
(2011), collagen cross-linking is more labile in younger animals, thus collagen I was extracted from adolescent
rat tedons and re-constitution occurred with higher fidelity (358,359,372). The collagen contraction assays
utilising (both TIF or MEF) stromal fibroblasts were undertaken with success and proved that this is a highly
useful model for assessing the impact of SerpinB2 on collagen cross-linking, matrix formation, stromal
remodelling, as well as specific drugs which can be aimed at increasing or inhibiting these processes
(358,359,372).
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Initially, matrix formation with TIFs occurred over 12 days and indicated the ability of the collagen I extracted
in-house to be used in this system and revealed that this assay would be not only a viable model (refer to Fig.
3.5), but also a robust tool for further interrogation of PAS activity in stromal formation. After successful pilot
experiments with SerpinB2 expressing TIFs, the effects of genetically modified murine fibroblasts on collagen
matrix contraction were conducted. The striking and somewhat unexpected effect of SerpinB2 absence on
matrix integrity over a 12-day period suggested that SerpinB2 has a dramatic effect on collagen cross-linking
(refer to Fig. 3.6-3.8). Significant decreases were observed in SerpinB2-/- MEF matrix contraction rates, overall
diameter, matrix integrity, collagen coverage and fibril network formation (refer to Fig. 3.6-3.8). SHG and
SEM analyses of matrices formed by SerpinB2-/- MEFs revealed dysregulated, anisotropic dispersal of collagen I,
compared with the ordered, isotropic distribution observed in matrices formed with wild-type MEFs (refer to
Fig. 3.6-3.8). Further, collagen matrices formed using wild-type MEFS formed robust matrices, with
homeostatic fibrous layers, suggestive of good cell-cell cross talk, leading to proper fibril bundles formed due to
stable covalent collagen I cross-linking, and apposite ECM construction. These large network coverings
displaying an ordered ECM are normative of healthy tissue. Conversely, matrices prepared using SerpinB2-/MEFs revealed that collagen I was not being crosslinked properly, with areas of large porosity in collagen
networks. One of the major reasons for such profound differences in matrix construction is because there
appeared to be poor cell-cell and cell-matrix communication, evidenced by many gap and overlapping regions
of crosslinked collagen within the matrices, and a general lack of adequate bundle formation. This resulted in
defunct construction of collagen I bundles, with unordered collagen matrices observed. Without proper
fibrillogenesis and ordered collagen networks, the ECM contained larger pores (collagen cross-linked
improperly) and where fibrils did form, there were denser bundles that were dispersed in an anisotropic fashion
(refer to Fig. 3.7-3.8). This finding is supported in a different model of SerpinB2 deficiency. As
aforementioned (refer to section 1.6.5), Schroder et al. (2010) reported that SerpinB2−/− mice infected with
Schistosoma japonicum had reduced collagen I fibrosis versus wild-type (SerpinB2 expressing) mice (158),
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suggesting that SerpinB2 is necessary for the fibroblast-dependent redistribution of collagen fibres around
wound matrix contraction. The next challenge was to visualise the fibroblasts in collagen matrices to get a more
in depth idea of the cellular behaviour. Improved MP microscopy techniques allow for continuous cell tracking
exploring the subtle dynamics of biological processes in collagen cross-linking, fibroblast migration and stromal
remodelling. To improve the imaging consistency and reliability, MEFs were modified to express GFP (refer to
Chapter 2). This increased the ease of fibroblast detection by working in a spectrum with little collagen
autofluorescence. Coupled with SHG detection, a solid framework was utilised where both collagen and
fibroblast signals were captured separately (refer to Fig. 3.9), revealing stark differences between wild-type and
SerpinB2-/- MEFs, suggesting that SerpinB2 is important in regulating fibroblast migration, necessary for matrix
remodelling (Fig. 3.9). The significantly decreased motility of SerpinB2-/- MEFS together with the striking
differences in cellular protrusion dynamics in these cells, suggest that the effect of SerpinB2 on matrix
remodelling is primarily through regulation of MEF cellular adhesion and motility/migration. Fibroblast
migration and cross-linking ability in this model somewhat mimics the proliferation/granulation and
remodelling (but not re-epithelialisation) stages of wound healing. Proteases are important in these stages,
particularly MMPs [stimulated by IL-1, TNF and TGF-β (452)], and uPA/plasmin are vital in a wound healing
environment in order to break down the clot(s) as fibroblasts move into the area and start depositing collagen
(452,453). Additionally, uPA/plasmin are important for keratinocyte migration to the area. MMPs are not
constitutively expressed in cells in this environment, requiring regulation (452). SerpinB2 has a role in this
context and moreover, in our models we propose that SerpinB2 potentially modulates MEF migration through
stabilising TG2, binding via one or more of SerpinB2’s three glutamine residues in the CD loop of its structure.
SerpinB2 is known to be present on the focal adhesions of cells (454), thus interactions could be occurring with
integrins and FAKs, potentially assisting fibroblasts during stromal remodelling and collagen crosslinking.
Verma et al. (2006) reported that overexpression of catalytically active TG2 induced FAK and PI3K/Akt
activation and siRNA mediated down-regulation of TG2 attenuated FAK phosphorylation in PDAC cells (331).
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Further, they showed, via immunopreciptation and confocal microscopy, that activated FAK was colocalised
with TG2 at focal adhesion points (331). This novel result proposes that elevated expression of TG2 induces
constitutive activation of FAK. Given that TG2 is one of the major classes of collagen cross-linking enzymes, it
is possible that SerpinB2 is utilised to assist in collagen fibrillogenesis, binding with fibronectin, fibrin(ogen) and
other ECM molecules to achieve greater cell-matrix adhesion, communication and stability. Tissue stiffness in
keloid fibrosis has been shown to increase expression of SerpinB2 (455). Suarez et al. (2013) showed that
knockdown of SerpinB2 in keloid fibroblasts significantly reduced the intracellular expression of extracellular
matrix components, α-SMA, fibronectin and collagen I (455). Further, SerpinB2 knockdown did not influence
the viability or metabolic activity of keloid fibroblasts (455), as observed in MDA-MB-231 cells from Chapter 2
(see section 2.3.6.4). However, it has been reported that SerpinB2-/- MEFs are less able to withstand
proteotoxic stress (198). In scleroderma and keloid fibrosis SerpinB2 is known to interact with FAKs, via
integrin binding (455). FAK is a cytoplasmic tyrosine kinase encoded by the PTK2 gene (456), mediating
integrin signalling during cellular adhesion and migration, as integrin binding enhances FAK phosphorylation
(456). As its name would suggest, FAK is heavily localised to focal adhesions, coordinating the motility of a cell
by inducing actin polymerisation and the throughput of cell-ECM contact and signalling (457). In vitro culturing
of cells increases the levels of tyrosine phosphorylation in their focal adhesions, enabling proper adherence to
culture flasks (457). FAKs have been implicated in the development of fibrosis, following mechanical force
stimuli of inflammation, fibroblast activation and ECM (458). Myofibroblast differentiation has been shown to
be initiated by TGF-ß and dependent on cell adhesion and integrin signalling via FAK (459). Mechanical tension
induces α2β1-integrin expression, helping bind the cell cytoskeleton with the ECM, which in turn causes FAK
formation between fibroblasts and collagen (460,461). FAK phosphorylation causes α-actinin stabilisation,
inducing actin polymerisation and the throughput of cell-ECM contact and signalling (457). This increase in
integrin binding consists of clustered, ECM-bound integrins, FAK and cytoskeletal adaptor proteins (such as
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paxillin) within the cytoplasm (462), which not only mediates cell anchorage to the ECM, but also instigates
‘outside-in' signalling cascades, which activate downstream pathways, regulating cell survival processes (462).
In particular, increases in ECM stiffness in tumour and stromal tissue leads to increased integrin clustering
(463), resulting in enhanced mechanotransduction that subsequently initiates cell migration (464). There is
extensive crosstalk between integrins and TGF-beta signaling, where TGF-beta affects integrin-mediated cell
adhesion and migration through regulating integrin expression (465). Conversely, integrins directly stimulate
TGF-beta activation and reciprocal TGF-β-integrin signalling is implicated in normal physiology, as well as in a
variety of fibrotic diseases, cancer and wound healing (465). In addition, TGF-β has been shown to up-regulate
MMP-2, TIMP-1, SerpinB1, SerpinB2, and also plasmin (346). As aforementioned, TGF-β also increases
expression of fibronectin, collagen, elastin, proteoglycans as well as LOX and TG2 by fibroblasts, leading to
increased ECM synthesis, collagen cross-linking, decreased ECM degradation and overall ECM deposition and
tissue stiffness (269). With respect to the observations seen in the real-time overnight imaging of wild-type
MEF and SerpinB2-/- migration in collagen I matrices, it is tempting to hypothesise that such decreased tissue
stiffness in SerpinB2-/- matrices potentially was caused through reduced integrin induction, reducing FAK
activation and α-actinin stabilisation, meaning cell-ECM contact and signalling would be dramatically
decreased, not allowing SerpinB2-/- MEFs to adhere or migrate as well as their wild-type counterparts (refer to
Fig. 9; Supplementary movies 6 & 7). Furthermore, within SerpinB2-/- MEF matrices, excess activity by the
uPA/uPAR system should lead to enhanced migration, cellular adhesion and proliferation mediated by uPAR
binding to integrin receptors, EGF receptor, HMW kininogen, caveolin and the G-protein-coupled receptor
FPRL1 (104). Although not tested within this thesis, overnight imaging revealed a reversed phenotype, which
may mean that without adequate SerpinB2 regulation of uPA/uPAR complexes, signalosome interaction by
uPAR and it’s plethora of tyrosine- and serine-protein kinase partners (Src, FAK, Rac, ERK, JAK/STAT,
MAPK) (103), could be impaired.
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Proteomic analysis by Dr Zon Weng Lai revealed a (normalised) three-fold decrease of LOX within SerpinB2-/MEF collagen matrices versus wild-type MEF matrices (refer to Fig. 3.10). This is a key finding and may be the
major reason for such significant reductions in matrix contraction rates reported in collagen cross-linking and
overall matrix integrity of SerpinB2-/- MEF matrices. To date there is no direct association between LOX and
SerpinB2 published in the literature, revealing that this is a potentially novel result and one that certainly
requires further investigation.
3.4.1 Hypothetical effects of SerpinB2 in the ECM
A potential link between LOX and SerpinB2 is via the FAK signalling pathway and this possible corollary link
for collagen cross-linking and stromal remodelling would be mediated by integrin binding. A schematic of this
proposed mechanism is shown in Fig. 3.14 It is well known that secreted LOX can interact with FAKs,
increasing cell-to-matrix adhesion (282). Miller et al. (2005) previously reported that LOX facilitates MCF-7
breast cancer cell migration and cell-matrix adhesion formation through a hydrogen peroxide-mediated
mechanism (HIF-1α), where LOX works upstream of the FAK/Src signalling pathway (282,466). As
aforementioned, it was recently reported that fibroblasts overexpressing LOX stimulate FAK activation in vivo,
causing increased collagen cross-linking and matrix stiffness in a colorectal cancer model (293). Many
tumourigenic studies show decreased FAK activation with LOX inhibition (466,467) (282). Hypothetically,
without SerpinB2, surplus uPA/uPAR activity may not allow adequate regulation of MMP activity, thus
collagen exposure of telopeptides could be impaired, disabling LOX’s post-translational activity in collagen
cross-linking. Further, it has been reported that as collagen fibrils are being formed, LOX is involved in
collagen linearisation, and fibril organisation (468). This requirement for LOX expression to facilitate collagen
bundle formation could potentially be one of the reasons for the 3-fold decrease seen in the LC-MS/MS
proteome analyses of SerpinB2-/- MEF derived versus wild-type MEF constructed collagen matrices (refer to
Fig. 3.10). It is interesting to speculate that potentially there exist signaling mechanisms between
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TG2/SerpinB2 and LOX to facilitate collagen oligomerisation, where SerpinB2-/- MEFs might have have
decreased integrin (α2ß1) binding (without TG2-fibronectin/fibrin/integrin bond et), reducing FAK (Vinculin,
Paxillin and FAK) activation/phosphorylation, attenuating actin re-organisation and eventually ECM
remodelling, causing changes in cellular adhesion, proliferation, migration and cell survival. Conversely, as
more collagen was being cross-linked in the wild-type matrices (where SerpinB2 stabilised TG2), LOX was
activated moreso, thus helping to linearise the fibrils. Future experiments are essentially required to investigate
further. Interestingly, actin-related protein 2/3 complex subunit 1B (ARPC1B) was present at twice the
amount compared to that of wild-type matrices, as assessed by LC/MS. This increase was potentially to account
for the decreased LOX pathway activity (refer to Fig. 3.10) as ARPC1B is a subunit of the Arp2/3 complex,
involved in regulation of actin polymerisation and formation of branched actin networks. Welch et al. (1997)
showed that Arp2/3 complex is localised to the lamellipodia of both stationary and motile fibroblasts and
suggested that this complex promotes both actin assembly in lamellipodia and could facilitate lamellipodial
protrusion (469). This 2-fold increase in SerpinB2-/- MEF ARPC1B level is potentially associated with the 0.73fold up-regulation of actin within SerpinB2-/- MEF matrices (refer to Fig. 3.10) and may be a compensatory
mechanism to stimulate proper fibroblast lamellipodial protrusion for adequate ECM remodelling. An
explanation for this is not clear, but would most likely involve intracellular signaling cascades. EMILIN1 was
also reportedly decreased (1-fold down-regulated) within SerpinB2-/- MEF matrices (refer to Fig. 3.10). This is
interesting as EMILIN1 is a component of elastin fibres and reported to affect actin and paxillin distribution
associated with cell polarity, ECM stress fibre formation and signalling (470). Numerous cell types migrate on
EMILIN1 (471), however trophoblasts attach to EMILIN1 most efficiently (versus other cell types) and migrate
using α4β1 integrin without any stimulus, induction or activation (472). Further, Spessotto et al. (2006)
showed ordered haptotaxis (directional motility) in trophoblasts was significantly more efficient toward
EMILIN1 compared with fibronectin (472). In addition, Biglycan was also found decreased (1-fold down-
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regulated) within SerpinB2-/- MEF matrices (refer to Fig. 3.10). Biglycan is a small, leucine rich ECM
proteoglycan that binds with collagen I fibrils in vivo (473). Altogether, these data corroborate the extensive
differences in cell-cell and cell-ECM communication observed in SHG, MPM and SEM experiments. To this
end, SerpinB2 might be a key upstream regulator (with LOX and TG2) of extracellular matrix remodelling and
collagen cross-linking (Fig 3.14).

Fig 3.14. Schematic of SerpinB2, LOX and TG2 in the ECM. A. Potential molecular links between SerpinB2, LOX and TG2 in
ECM remodelling and collagen cross-linking activities. Collagen and fibroblasts interact via focal adhesions, where SerpinB2 regulates
MMP (through uPA/plasmin), promoting ECM accumulation. SerpinB2 also modulates cell migration mediated by integrins. LOX
cross-links collagen within the ECM and promotes FAK and Paxillin activation, increasing cell motility and cell-ECM adhesions. TG2
binds to collagen via fibronectin, utilising secreted SerpinB2 (when present) as a stabiliser, mediating the binding, and affording
enhanced cell-matrix communication and stability. B. In homeostatic tissue beds, collagen molecules interact with the cell via
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fibronectin binding, which connects with the plasma membrane through α11β1- and α2β1-integrins. When ECM remodelling is
initiated, biochemical and mechanical signalling from the ECM occurs through integrin receptors and leads to activation of a large
number of pathways, particularly FAK [FAK, and integrin are both required for normal development: FAK, and integrin knockout
mice are embryonic lethal (474,475)]. This and other kinase signalling cascades [Ras, Akt, ERK, Rho, Jun-N-terminal kinase (JNK)]
can induce cytoskeletal alterations and lead to gene transcription changes in the nucleus. TGF-ß is relased into the ECM, activating
collagen cross-linking enzymes, LOX and TG2, as well as SerpinB2 and B1, uPA/uPAR, MMPs. Lox is known to cause collagen
linearisation. The modulation of both proteases and protease inhibitors is under disordered regulation in fibrotic/tumourigenic tissue
beds, where inflammation and hypoxia activate increased expression of many matrix remodelling enzymes and proteins, leading to
increased mechanical remodeling of the ECM. The contractile activity of the cells depends on activation of a number of pathways,
including the Rho pathway, for assembly of stress fibres, integrin clustering, focal adhesion hyper-activation and increased tractional
force at cell– matrix interface (463,476).

Concurrently, secreted protein acidic and rich in cysteine (SPARC), a matricellular glycoprotein that binds
collagen and Ca2+, was observed to be 0.73-fold less abundant in SerpinB2-/- matrices versus wild-type (refer to
Fig. 3.10). SPARC is primarily involved in initiating nucleation during bone mineralisation (477) however,
SPARC has also been reported to be secreted in non-ossifying tissues (478), during both ECM formation and
tissue repair, arbitrating ECM remodelling, matrix turnover, and cell-ECM interactions (479,480).
Interestingly, zinc finger protein (ZFAT) was also twice as abundant within SerpinB2-/- matrices (refer to Fig.
3.10), which could potentially be present in such concentration in order to facilitate zinc-dependent MMP
processes (481).
Furthermore, proteomic analysis of the MEF-collagen I matrices revealed that SOD-1 was 3.2-fold more
abundant in SerpinB2-/- matrices, potentially as a stress protein. SOD-1 is an important enzyme during
apoptotic signaling and oxidative stress, most notably involved in the mitochondrial death pathway and cardiac
myocyte apoptosis (482). Studies by Lee et al. (2015) reported that SerpinB2 loss lead to an inability to
compartmentalise aggregating proteins and a reduced capacity of the ubiquitin-proteasome system, causing a
proteotoxic phenotype (198). Thus, without SerpinB2, potentially a proteotoxic stressed environment may
have activated SOD-1 in order to regulate apoptotic signaling and cell death. Fibrinogen was increased in
SerpinB2-/- matrices (α-chain 0.84-fold more abundant, β-chain 2.28-fold more abundant), associating SerpinB2
expression with fibrinogen modulation (refer to Fig. 3.10). It has been reported that fibrinogen cleavage
products can regulate cell adhesion and spreading, involved in chemotactic activities, and acting as mitogens for
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several cell types (483). Further, Sahni et al. (2004) reported that fibrinogen binding to FGF-2 via αVβ3,
induced expression of uPA, uPAR, and SerpinB1 in endothelial cells (484). SerpinB2 might crosslink to
collagen via TG2 mediated fibronectin/fibrin binding, and this increase in fibrinogen observed in SerpinB2-/matrices may be a direct attempt at SerpinB2-/- MEFs to facilitate collagen cross-linking using fibrinogen. In the
absence of SerpinB2, TG2 potentially utilises fibronectin as a substrate for cross-linking to the α-chain of fibrin,
which is why there is substantially less α-chain fibrinogen than β-chain fibrinogen. If true, this could also explain
the decreased presence of anastellin (a peptide of fibronectin), as well as through plasmin degradation (36).
Conversely, supra-expression of fibrinogen could be facilitating SerpinB1 expression, in order to regulate
uPA/uPAR, and thus MMP activity. Alternatively, it may be that fibrinogen is two-fold more abundant within
SerpinB2-/- MEFs due to the unnecessary formation of fibrin networks, which would only then be broken down
by plasmin. This again demonstrates the similarity of this model with a wound-healing environment, except
that fibrin network formation and breakdown is not required as the haemostasis stage is not present. It appears
in our model that SerpinB2 helps to create ECM formation, separate to its uPA inhibitory functional acitivity.
Both collagen I and fibronectin confer mechanical strength to tissue beds (357) and fibronectin is found in tissue
stroma as well as in the extracellular matrices of cultured cells (485). Fibronectin can be cross-linked via plasma
transglutaminase to itself and the α-chain of fibrin. Mosher et al. (1979) previously have shown plasma
transglutaminase-mediated crosslinking of fibronectin to alpha 1 type-1 collagen occurs at 37 °C and
demonstrated that fibronectin-fibrin and fibronectin-collagen binding and cross-linking are highly related
(486,487). Interestingly, there were no expression differences recorded by LC/MS in TG2 abundance. This
could potentially be due to the fact that the matrices were analysed once fully contracted, thus TG2 may have
fulfilled all specific purposes and was not present in detectable concentrations. This is potentially the case for
certain proteases, such as MMPs, and may have been down regulated by the time the LC/MS analyses
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occurred. Future experiments should analyse matrices at various stages of matrix contraction in order to
determine whether this affects the detection of different proteins or levels of certain proteins (i.e. LOX).
Moreover, it has previously been shown that increased LOX expression results in increased collagen
linearisation and tissue stiffness in pre-malignant tissue (485). Erler et al. (2009) demonstrated the crucial role
LOX has in matrix remodelling in pre-metastatic niche formation, where tumour secreted LOX protein causes
ECM remodelling and matrix stiffening in peri-tumour regions (485). This was actively aided by bone-marrowderived cell (BMDC) recruitment and facilitated metastatic tumour cell colonisation and growth (485).
Further, Erler et al. (2009) showed that matrix stiffening with LOX increased invasiveness of myeloid
(CD11b+) precursor BMDCs and also increased MMP activity (485). The importance of LOX cannot be
overlooked, as this enzyme is vital for collagen cross-linking in ECM remodelling within pre-malignant tissue,
stroma of early tumour invasion, pre-metastatic niche formation and at metastatic lesion sites. Recently, it was
reported that prolonged exposure to hypoxia deactivates CAFs, leading to reduced collagen I organotypic
contraction and decreased both ECM remodelling and stiffening of collagen I matrices (488). They showed that
the ability of CAFs to remodel and invade matrices was impaired under hypoxic conditions, leading to HIF-1α
stabilisation, reduced αSMA and periostin expression, decreased myosin II activity, abrogating CAF-mediated
invasion of cancer cells (488). It would be interesting to see the expression of SerpinB2 in their models as they
did not observe a difference in collagen cross-linking or oligomerisation in hypoxia (488). A potential path of
tumourigenesis, invasion and metastasis utilising LOX and SerpinB2 is proposed herein (Fig. 3.15).

134

Fig. 3.15. Schematic of the roles of PAS and LOX in collagen cross-linking and ECM transformation from
homeostatic tissue beds to pre-malignant, tumourigenic and metastatic tissue sites. SerpinB2 helps facilitate TG2collagen I binding in the ECM. Premalignant and tumourigenic tissue increases secretion of soluble cytokines and chemokines, leading
to inflammation, increasing local expression of SerpinB2. SerpinB2 aids the site with anti-plasmin/MMP activity in ECM remodelling,
as well as anti-apoptopic roles. As tissue becomes more hypoxic, LOX is increasingly expressed, leafing to excess collagen
crosslinking and bundle formation around the tumour. Both SerpinB2 and LOX are present on focal adhesions of tumour cells,
facilitating increased ECM remodelling, and affording enhanced cell-matrix adhesion, communication and stability, allowing for
tumour cell migration. Tumour secreted LOX causes peritumoural ECM stiffening and formation of a pre-metastatic niche for
primary tumour cells to migrate easier. SerpinB2 is down-regulated as tumour cells undergo metastasis, increasing uPA/uPAR. BM:
Basement membrane. Adapted from (249).

Much research has been conducted into MMPs, as they are heavily increased in the inflammatory response,
normal tissue remodelling, wound healing, angiogenesis and cancer (481). The sustained presence of MMPs in
stromal remodelling combined with increased ECM production and deposition, leads to the destruction of
normal ECM and its replacement by invasive tumour-stromal ECM (23). Thus, MMPs are anti- and protumourigenic, and ECM degradation and remodelling occurs via MMP regulation, which increases TME signals
stimulating cellular proliferation and migratory mechanisms (23). These data align with the inadequate results
of MMP inhibitors reported in cancer clinical trials where severe side effects and severe toxicity from both
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short (e.g. marimastat) and long term (e.g. BMS-275291) dosing were reported (489). The reason for such
disappointing trials is thought to be due to a functional redundancy between MMP family members (23),
meaning that a combinatorial approach might be required for clinical efficacy. However, next generation MMPi
antibodies are being created with higher binding for specific MMPs (particularly membrane anchored MMPs)
offering renewed hope that this could be a renewed therapeutic pipeline(490,491). Conversely, within
dermatology, there are two Dox drugs approved by the United States Food and Drug Administration, for adult
periodontitis (Periostat), and rosacea (Oracea) (445). Both are administered as a 20 mg (twice daily) or 40 mg
dose (slow-release) of Dox for MMPi and anti-inflammatory/anti-collagenolytic effects (445).
Moreover, MMPs have been shown to regulate FGF-2, VEGF and PDGF cell signalling, controlling cell
growth, inflammation and angiogenesis (23). This is of particular importance because MMP expression and
activity is highest in cells resident within the TME, and if there is not regulation of their expression, cytokine
signalling can quickly move out of control. collagenase-1 (MMP1) degrades collagen IV (main constituent of the
BM) and its expression is increased in highly metastatic cancer cells (492,493). Additionally, overexpression of
MMP2 in transformed mammary epithelial cells and overexpression of MMP3, MMP11, MMP12 and MMP13
have been demonstrated in tumour stroma (494,495). As SerpinB2 is an upstream inhibitor of MMP1, MMP2,
MMP3, MMP9, MMP12 and MMP13 (via uPA-plasmin inhibition) (496-499), its presence in the stroma
biochemically modulates ECM remodelling. Thus, the ability to regulate MMP expression is of clinical
significance and this study’s finding highlights the important nature of MMPs in the ECM. In this chapters work,
the effect of (20 µg/mL) Dox in the system, showed the importance of MMPs in ECM construction (refer to
Fig.’s 3.11-3.13). There was zero contraction seen in the Dox cohorts. This result shows that MMPs are
positive and negative regulators of stroma formation, vital for collagen breakdown, and necessary in the process
of ECM remodelling. Interestingly, as of yet there are no reports or research evidence to show that Dox acts as
a TIMP inhibitor (500). As the widely accepted primary extracellular biochemical function of SerpinB2 is
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inhibition of uPA activity, the potential role of proteolytic activity in collagen matrix remodelling was
considered. However, as the effect of SerpinB2 ∆CD loop addition to contracting SerpinB2-/- MEF collagen
matrices had no effect on contraction versus PBS or

R380A

SerpinB2 ∆CD loop controls, this result potentially

shows that contraction is independent of uPA activity (refer to Fig.’s 3.11-3.13). Interestingly, LOX is
extracellular, and TG2 is both intra- and extracellular. Hence, there may be a response using full-length
SerpinB2 exogenously versus SerpinB2 ∆CD loop, in SerpinB2-/- MEF collagen I contraction experiments.
Thus, this experiment needs to be further elucidated, with incorporation of full-length wild-type SerpinB2.
Furthermore, another reason for the lack of compensation observed in SerpinB2-/- MEF contracted collagen
matrices by exogenous SerpinB2 addition could be related to the already irreversible effects of decreased LOX
expression by the SerpinB2-/- MEFs. SerpinB2 may be a key upstream regulator for LOX and TG2 and other
matrix proteins. Therefore, without its intracellular presence, the modulation of not only proteases and
protease inhibitors is under disordered regulation, but potentially also LOX and TG2 expression. Thus, within
the contraction experiments, the reintroduction of SerpinB2 exogenously is potentially too late, as a difference
mechanism of action between intracellular and extracellular SerpinB2 maybe occurring.
However, the question whether uPA/PAS activity is necessary for matrix remodelling remains, as MMP
inhibition by Dox clearly effected the contraction of collagen I by SerpinB2-/- MEFs (refer to Fig. 3.11).
Though, undetectable levels of uPA/uPAR on TIFs suggest this in unlikely, and MMPs can be produced
without uPAS activity. Notably, the immortalised fibroblasts (TIFs) normally used to drive efficient matrix
contraction for organotypic experiments (i.e. similar to that observed with wild-type MEFs) express significant
levels of endogenous SerpinB2 (Fig. 3.3), pointing moreso to intracellular signalling mechanisms affecting ECM
remodelling.
As aforementioned in Chapter one (refer to section 1.7.1), Valiente et al. (2014) reported that increased
SerpinB2 (and SerpinI1) expression is required for lung and breast metastatic cells to infiltrate the blood brain
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barrier (BBB) (213). Cell adhesion to the surface of capillaries within the brain is attributed to increased
SerpinB2 expression and shown to protect metastatic cells from astrocytic FasL apoptosis and L1CAM
inactivation, facilitating further metastases (213). The pro-survival effects of SerpinB2 and cell adhesion and
binding stability through integrins may allow enhanced cell-matrix attachment and help metastatic cells
infiltrate the brain. This study allows one to ponder that perhaps the unique composition of the brains ECM
(lecticans, proteoglycans, hyaluronic acid and tenascin family adhesive/anti-adhesive proteins) confers
resistance to tumour invasion (501). Matrix proteins (especially type-1 collagen) common in other tissue beds
are absent in the adult brain (501) and this unique composition of ECM may be responsible for the such cell
motility activities, including tumour cells of non-neuronal origin. More cell migratory functions of SerpinB2
are addressed in section 1.9.5. In contrast, Yu et al. (2002) reported that SerpinB2 transfected THP-1
monocytes showed reduced adhesive properties and a decreased proliferation rate (172).
Interestingly, a study by Da Silva et al. (2015) reported there was no significant increase in LOX expression in
astrogliomas (AGI, AGII and AGIII) compared to matched normal brain tissue samples (502). However,
glioblastomas (GBMs), a more malignant astrocytoma, exhibited significantly enhanced LOX expression (502).
The paradoxical difference in LOX expression between astrocytomas is of note, though da Silva et al. (2015)
reported increased LOX expression, with increases from AGI-GBMII, which facilitated increase migration and
angiogenesis within their models. It would be fascinating to see if SerpinB2 was expressed in these brain cancer
cells, potentially working to facilitate both anti-plasmin activity and also cell-matrix adhesion.
Lastly, the results of this chapter demonstrate that ECM production and collagen deposition is influenced
dramatically by SerpinB2 with regards to the development and remodelling of matrix architecture, from
collagen cross-linking, tissue stiffness and porosity. The use of multiphoton-based SHG imaging in this study
aided the investigation of ECM attributes and allowed for quantitative examination of collagen coverage and 3D
modelling of organotypic matrices in real-time.
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In the future, SerpinB2-/- 3D models could be imaged using imaging systems, such as FRAP and FLIM–FRET,
to analyse SerpinB2-FAK co-localisation in fibroblast migration during matric contraction experiments. In
addition, these imaging techniques could examine anti-uPA drugs that target the ECM, thereby offering early
validation before more time-consuming, expensive and complex in vivo assessment. Additionally, there is a dire
necessity for increased research and imaging of the stroma around primary, peri-tumoural, micrometastatic and
metastatic sites, as this area remains poorly understood. This would be ideal for testing SerpinB2-/- tissues, as
these are recapitulative of most advanced tumour systems and would be especially beneficial for the
development of new combinatorial treatments targeting uPA/uPAR and/or the stroma of inoperable tumours.
Cancer therapies are increasingly targeting ECM remodelling enzymes in an effort to prevent changes in ECM
homeostasis that promote tumour progression, and aiding in chemotherapy efficacy (23). However, the
development of anti-fibrotic therapies for cancer treatment (such as imatinib, dasatinib and nilotinib) are not
straightforward (503). Premature attempts to treat hypertrophic fibrosis and keloidal scars utilised the potent
LOX inhibitor, BAPN, to reduce collagen cross-linking (23). Although these trials effectively reduced collagen
cross-linking and associated scarring when applied upon the skin, clinical testing was stopped due to toxicity
issues (23). Studies have reported that LOX inhibition reduced primary tumour growth and
mechanotransduction in breast cancer (504). Although LOX is an encouraging therapeutic biomarker for fibrotic
diseases and cancer, targeting specific ECM enzymes involved in stromal remodelling while avoiding unwanted
side effects is extremely difficult and pursuing a single molecule within a large disease network can cause
adverse side effects. Additionally, there can also be compensation by other ECM members, which can
potentially lead to drug resistance. The TME has many overlapping molecules and pathways that help maintain a
dysfunctional order. Thus, the field needs to elucidate all linkages within a specific network and every key
individual and collective members response to dynamic modulation of the TME. This is a huge task and will
only be achieved through worldwide, multi-disciplinary collaborations in order to attain a greater
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understanding of how microenvironmental cues are driving fibrosis and stromal remodelling in tumourigenic
systems. Through advancements in imaging technologies, utilised in this study, great insight is being gained to
help elucidate these networks, and innovative imaging techniques are enabling accurate monitoring, imaging
and quantification of the ECM when specific molecules are attenuated genetically or through drug dosage.
Together, these technologies can help dissect both the spatial and temporal dynamics of the ECM in a TME
setting, and promote understanding of the underlying mechanisms that influence cell-ECM interactions.
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CHAPTER 4
INVESTIGATION INTO THE EFFECTS OF MODULATING SERPINB2
EXPRESSION ON PANCREATIC TUMOURIGENESIS AND LOCAL
INVASION
4.1 INTRODUCTION
Pancreatic ductal adenocarcinoma (PDAC) represents ~92% of all pancreatic cancers and is the deadliest of all
solid malignancies, with a 1-year survival rate of less than 20% and a 5-year survival rate of less than 5%
(505,506). This is because approximately 85% of PDAC patients present with advanced stages of disease where
local invasion or metastasis has occurred, or the primary tumour is surrounding arteries and is therefore
inoperable (507). Further, prognosis remains poor even for those patients who do have surgery as tumour
regrowth occurs ~85% of the time, meaning only 25-30% of patients are alive five years post-surgery (508).
Thus, established approaches to PDAC therapy (i.e. resection and gemcitabine treatment) are largely
ineffective and have severely limited impact on metastatic disease. Advances in adjuvant and metastatic
chemotherapeutic regimens have resulted in modest improvements in outcome, but pancreatectomy remains
the single most effective and the only potentially curative modality for the ~20% of patients suitable for such a
procedure. Current treatment strategies for PDAC therefore remain ineffective and require urgent attention.
4.1.1

Genetic aberrations in the lead up to PDAC

Pancreatic duct epithelial cells undergo extensive atypical transformations in the lead up to PDAC morphology
(509).

Persistent epithelial de-differentiation and reactivation of embryonic/developmental signalling pathways,

such as wnt-β-catenin, TGF-β and Hedgehog (Hh), contribute to a proliferative and anti-apoptotic phenotype
of ductal epithelials, altering cell plasticity and increasing genetic variability (Fig. 4.1) (311,312). Considerable
research has been conducted to determine the molecular foundations of PDAC. The almost universal K-Ras
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mutation in over 90% of PDAC tumours, means that there is a constitutively active state of downstream
signaling, through an inability to hydrolyse guanosine triphosphate (GTP), essential for signal transduction with
G-proteins (494) (510). It is reported that K-Ras mutation/over-activation coupled with developmental
genetic elements [wnt-β-catenin, Hedgehog (Hh)] above crucial temporal thresholds drives differentiated
pancreatic cells into a de-differentiated, ductal state (313). This persists towards formation of pancreatic
epithelial neoplasia (PanIN) and can eventually result in PDAC. The high degree of molecular heterogeneity
associated with PDAC makes identification of suitable candidates for targeted therapy challenging (511).
Approximately 2–10% of PDACs are associated with hereditary factors (312,512,513), however most are
associated with somatic mutations of tumour suppressor genes p53 (75%) (514,515), p16/CDNK2A (~95%
mutated and ~5% epigenetically silenced) (516), INK4A (~95%) (517), and SMAD4 (55%) (518). There are
many large-scale genomic studies, such as the Australian Pancreatic Cancer Genome Initiative (APGI) [the
Australian branch of the International Cancer Genome Consortium (ICGC)], which have been established in
order to expand knowledge of the wider landscape of mutations associated with pancreatic cancer (511,519).
It is widely agreed that PDAC development arises from non-invasive, preneoplastic lesions (520). The
materialisation of PanINs are the most common and extensively studied putative precursors to PDAC. PanINs
are histologically classified into three stages of increasing cellular and nuclear abnomality (Fig. 4.1), and it has
been found that each PanIN stage correlates with an increase in mutation frequency and gene association (521).
PanIN1 lesions recurrently acquire a mutation in K-Ras (~20–40%), experience telomere shortening (~90%)
(522), and have increased expression of HER2/neu (523), while PanIN2 more frequently harbour mutations in
p53, SMAD4, and p16 (521,524). As these ductal lesions progress to a stage 3 PanIN, the ducts experience
much higher mutations in K-Ras, p53, SMAD4 (and SMAD4 deletion) with additional mutations common in
DPC4 and BRCA2 (523,525) (refer to Fig. 4.1). Further, Moriya et al. (2005) reported that K-Ras and SMAD4
regulate HER-2 expression in PanINs (523), which is known to dramatically increase signal transduction of
kinase pathways MAPK, PI3K/Akt, and JAK-STAT, to name a few (526,527). This combination of genetic
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elements creates a hyper cascade of downstream signaling, ultimately causing increases in genetic variability and
cellular differentiation and activity.

Fig 4.1. Pancreatic epithelial neoplasia — PDAC initiation and progression. A. Illustration of the gross anatomy of the
pancreas (showing a PDAC in the pancreatic duct) indicating its close anatomical relationship with the duodenum and common bile
duct. B. De-differentiated ductal cells can become PanINs, where β-catenin signalling is over-activated in parallel with increasing
expression of Hh ligand and K-Ras, which temporally activates target genes in stromal cells of the developing desmoplastic response.
Gene plasticity is altered and mutations can occur more frequently, causing ductal formation towards a PDAC state. Adapted from
(313).

For these cell types, the reprogramming and dedifferentiation of their epithelial status into a 'ductal' cell type is
required to undertake the PanIN–PDAC lineage. Initially, K-Ras was proposed as the instigating genetic lesion
of PDAC, due to its widespread mutation frequency in patients. However, this was not successfully
investigated until the development of transgenic models to assess such an hypothesis. Many pancreatic mouse
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models have since been developed to understand which pancreatic cell types can develop into PDAC when
mutant K-Ras is expressed (528,529).

Hingorani et al. (2003) were the first to produce the Pdx1-Cre;LSL-K-RasG12D/+ model (530). This Creinducible conditional allele [lox-stop-lox KrasG12D (LSL-K-RasG12D )] targeted to the endogenous K-Ras locus,
allowed for expression of constitutively active K-Ras under both temporal and spatial control (530). This model
unfortunately did not isolate a specific cell type, but instead targeted mutant K-Ras to most cells from all three
epithelial lineages of the pancreas (ductal, acinar, islet). Nonetheless, the lesions slowly progressed through the
entire human PanIN spectrum over increasing age of the mice into advanced PDAC disease, with a median
survival of 15 months (530). This study suggested that K-Ras activation is a necessary tumour-initiating event in
pancreatic carcinomatous states and that specific events are required for human PDAC progression. Based on
this LSL-KrasG12D model, three representative studies of invasive PDAC models have been reported (531-533).
However, more recent models have been modified from the original Cre recombinase models, in order to
begin to determine pancreatic cell type co-expression in the development of PDAC when mutant K-Ras is
expressed. Hingorani et al. 2005 developed the LSL-K-RasG12D/+;LSL-Trp53R172H/+;Pdx- 1-Cre model,
where the concomitant expression of both K-RasG12D with Trp53R172H manifested in the initiation of
pancreatic tumourigenesis and widely metastatic PDAC (532). In addition, within this model, neither telomere
shortening nor mutation of other major tumour suppressor gene pathways was required for the formation of
ductal glandular histology, consistent with human PDAC patient histology (532). This model is both highly
recapitulative of the human situation and also greatly hastens the development of locally invasive and largely
metastatic PDAC, ideal for research purposes. Through using this strategy in 3D organotypic and xenograft
models, observation into the effects of tumourigenesis, stromal remodeling and local invasion within the
significant desmoplastic changes that occur in the PDAC TME could be made.
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4.1.2

Desmoplasia in PDAC

PDAC generally arises in the head of the pancreas and within the developing TME, production of a dense
stroma rich in collagen fibres, ECM proteins, fibroblasts and inflammatory cells, cytokines, chemokines,
growth factors and ECM metabolising enzymes creates a fibrotic milieu, termed the desmoplastic reaction (450)
(263) (refer to Fig. 4.1). It is only within the last five to ten years that the mechanisms contributing to this
complex matrix process in PDAC have slowly started to be both elucidated and appreciated. This mechanical
barrier surrounding the tumour is the defining reason why PDAC is one of the most drug-resistant forms of
cancer. The main role in the formation and turnover of this near impenetrable stroma is assigned to the
pancreatic stellate and fibroblast cells (discussed further below), leading to an increase in type I and V collagen
and fibronectin, which could provide a valid reason for such poor drug penetration seen in PDAC treatments
(534). This fibrous matrix surrounding PDAC also accumulates large amounts of hyaluronan, which increases
interstitial fluid pressure and constricting tumour vasculature (535,536). Under these circumstances hypoxia
and nutrient deficiency is in full effect, making it difficult for chemotherapy diffusion from the blood into the
tumour, as well as leading to the selection of the most aggressive tumour cells through clonal expansion of
resilient tumour populations (537).
Imamura et al. (1995) have reported that both lymph node and liver metastases have a similar increase in ECM
proteins to that of PDAC desmoplastic tissue and that comparable amounts and type of collagens in PDAC
desmoplasia are also features of alcoholic chronic pancreatitis and tumour-associated chronic pancreatitis tissue
(276). Desmoplastic reaction in PDAC creates an inflammatory/immune cell front at the peripheral invasive
edge of tumours (263). Morphological analyses of this sparse cell infiltrate in PDAC specimens has been shown
to consist mainly of mast cells, macrophages, lymphocytes and plasma cells (538). Esposito et al. (2003) found
that poorer survival was associated with PDAC patients who had higher numbers of mast cells in the stroma.
These authors suggest the reason for this trend could be that mast cells secrete vascular endothelial growth
factor [VEGF], largely responsible for facilitating angiogenesis (538). It is of note that there are contradictions
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in the field about PDAC stroma and its influence on vasculature, invasion and metastasis [(353) also discussed
below].
The presence of pancreate stellate cells (PaSCs) in the desmoplasia of PDAC are now recognized as playing an
important role in the TME. PaSCs are a subset of pancreatic cancer-associated fibroblasts, which provide prosurvival signals to PDAC tumours (539). Homeostatically, PaSCs are a common cell feature of the exocrine
pancreas and are usually located within the periacinar space, existing in a quiescent state (540). They have long
cytoplasmic processes, which are used to encircle the base of the pancreatic acinus (263). When in a quiescent
state, PaSCs exhibit a low rate of proliferation and small amount of ECM production. However, within
pancreatic disease progression, these cells help facilitate and renovate tissue sites, after transforming from their
normal quiescent state into an activated ‘myofibroblastic’ state (540). Once activated, PaSCs become
significantly more proliferative, migrate towards areas of inflammation and produce ECM proteins, cytokines,
chemokines, and growth factors (450,541). Apte et al. (1998) were the first to isolate PaSCs (542), and showed
that these produced the ECM proteins that comprise the stroma of PDAC, as well as demonstrating the
presence of activated PaSCs in the tumour stroma (450). They found that activated PaSCs were indeed the
specific cellular source of ECM proteins and that these cells expressed α-SMA and co-localised with mRNA
encoding procollagen, within PDAC stroma (450).
Thus, much evidence has come to light that PaSCs have a mutually beneficial relationship in PDAC etiology,
resulting in an overall increase in growth rate of pancreatic tumours and potentially helping to facilitate their
metastases. In this regard, studies have shown that culture supernatants from human pancreatic tumour lines
can stimulate PaSC proliferation and their production of ECM proteins (543). This is believed to be due to the
ability of pancreatic tumour cells to produce and secrete PDGF, TGF-β and FGF-2, which promote the
activated state and proliferation of PaSCs as well as increasing ECM production (450). Furthermore, Bachem et
al. (2005) showed that the growth rate of PDAC cells injected subcutaneously into nude mice markedly
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increased when co-injected with PaSCs and that PDAC tumours grown with both cell types exhibited a
desmoplastic reaction also observed in the human situation (543).
Of major interest to this project is the knowledge that PaSCs and PDAC cells both have the ability to produce
matrix metalloproteinases and tissue serine proteases, specifically those generated by PAS (544). Moreover, the
stroma of the PDAC TME is now widely believed to be the major facilitator of tumour invasion and metastasis
(43). The field’s relatively limited understanding of tumour-stromal interactions in PDAC is likely hindering
the development of effective therapies and there is a strong imperative to better elucidate these processes. In
that regard, this chapter focused on the role of uPAS in stromal remodelling, tumour growth and local invasion
in PDAC.
4.1.3

uPAS in PDAC

PDAC has been reported to express significantly high levels of uPA and uPAR, which also potentially play a
major role in PDAC invasion and metastasis. One of the first studies on the role of uPAS in PDAC was
conducted by Takeuchi et al. (234). In 1993, their group analysed 97 PDAC specimen and found uPA
expression predominated in 76 of these (a total of 78.4%), which correlated with shorter survival (234).
SerpinB2 was present in 79 carcinoma specimens (81.4%) and was found to be significantly lower in PDAC
specimen from patients with peritoneal metastasis (P < 0.02) (234). Further, higher SerpinB2 expression was
associated with significantly higher survival than negative or weak PDAC SerpinB2 expression (P < 0.05) (234).
Harvey et al. (2003) reported high uPA expression in PDAC cells in 93% of patients and also in surrounding
stromal cells in 87.5% of patients, however, they recorded no uPA expression in normal pancreatic tissue
distant from the PDAC site (233). A study by Xue et al. (2009) reported that the overexpression of uPAR
predicted short survival in PDAC patients and that uPAR siRNA inhibited PDAC cell proliferation, migration
and promoted apoptosis (545). Asuthkar et al. (2013) examined the role of uPA in the generation of PDAC
cancer stem cells (CSCs), concluding that uPA interacts directly with transcription factors (Lhx2, HOXA5 and
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Hey) to promote PDAC CSCs (546). In addition, Asuthkar et al. (2013) showed decreased tumourigenicity and
increased gemcitabine sensitivity after suppressing uPA in PANC-1 and Mia-PaCa-2 cells (546). Winter et al.
(2015) directly analysed uPA blood serum concentration in 90 PDAC patients and found a threefold increase of
uPA serum concentration in patients with PDAC (3,23 ng/ml), compared to the control group (1.01 ng/mL; P
< 0.01) (117). Further, they reported that higher uPA serum concentration was observed in patients with
shorter survival time as well as significant differences between uPA levels of lower and greater concentration
(than 2 ng/ml) and overall survival time (117).
Thus, the presence of uPA, uPAR and SerpinB2 in both fibroblasts and PDAC cells raises the question of how
functionally relevant the PAS is within PDAC tumourigenesis, stromal remodelling, and tumour invasion and
metastasis. Stromal expression of SerpinB2 has been linked to reduced disease progression and improved
patient outcome in PDAC (19,238). In addtition, SerpinB2 expression in esophageal squamous cell carcinoma
associated fibroblasts (CAF) correlated with prolonged patient survival (232). Elevated tumour SerpinB2
expression is commonly linked with prolonged survival, decreased metastasis, or decreased tumour growth in a
number of other cancer types (19), including three small-scale studies in human PDAC (238,442,443).
However, specific mechanisms have not been addressed and there is much to gain through looking at the cell
specific effects of SerpinB2 modulation of the PDAC TME. Through the development of 3D organotypic
culture systems (refer to section 3.2.3) (358), mouse models of pancreatic cancer that closely recapitulate the
human disease (547), and mouse models of SerpinB2 deficiency (198), this may provide a unique and powerful
opportunity to dissect the role of the PAS in the PDAC TME. By combining these models to modulate PAS
activity in a context-specific manner, this chapter aimed to demonstrate that uPA activity is necessary for
PDAC invasion ex vivo and in vivo and that SerpinB2 regulates tumour-stroma interactions driving stromal
remodelling, collagen integrity, PDAC tumour growth and local invasion.
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Thus, the overall aim of chapter four was to investigate the effects of stromal SerpinB2 modulation on PDAC
growth, local invasion and progression in our in vitro and in vivo models. The specific aims of chapter four
were to:
1.

Interrogate the ICGC data for uPA expression analyses with PDAC patients

2.

Utilise the 3D organotypic invasion model to functionally assess the effects of SerpinB2 upon
tumour cell invasion, migration and clustering.

3.

Characterise the influence of SerpinB2 upon local invasion and tumour growth in a mixed cell
allograft mouse model of PDAC.

4.

Characterise the collagen properties of wild-type and SerpinB2 modified tissue from both in vivo
and ex vivo models using advanced microscopy techniques (including IVIS, SHG, multiphoton
imaging and SEM analyses), immunofluorescence and uPA enzymatic assays.

4.2 METHODS
4.2.1 Proteins and antibodies
Recombinant human SerpinB2 and SerpinB2R380A inactive mutant were purified and characterised as
aforementioned. High molecular weight (HMW) human and murine uPA was purchased from Molecular
Innovations (USA). Refer to Table 1 of Appendix for all antibody details.
4.2.2 Gene expression survival analysis
Collaborations with Dr Mark Pinese and Dr Marina Pajic at the Kinghorn Cancer Centre (Darlinghurst, NSW)
afforded our laboratory access to outcome data and gene expression measurements from the APGI PDAC
cohort (511). These data are available from the ICGC DCC (https://dcc.icgc.org/). Gene expression
measurements were undertaken by our collaborators at at the Kinghorn Cancer Centre from bulk tumour,
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performed on the Illumina Human HT-12 V4 platform, and were processed using the Bioconductor lumi
package (v 2.18.0), using "bgAdjust.affy" background subtraction, "vst" transformation, and "quantile"
normalization. Outcome data were current as of March 2016. The influence of log-expression on diseasespecific survival was examined separately for each probe. Martingale residual plots were used to assess
functional form, and no departures from linearity were observed. The prognostic significance of each probe
was then evaluated by likelihood-ratio tests, comparing a Cox model with probe log-expression as a linear
predictor, against a marginal model. Multiple testing correction was performed by Holm's method. All data
processing was performed in the R environment (version 3.1.1, survival package version 2.37-7). Analysis of
gene alteration frequencies in PAS components across various tumour types in the TCGA database was
performed using the cBioPortal for Cancer Genomics (442,443).

4.2.3 Cell lines and culture conditions
The invasive murine pancreatic ductal adenocarcinoma cell line, PDACp53R172H/+ (and referred to as PDAC
hereafter), harvested from Pdx1-Cre, LSL-KRasG12D/+, LSL-Trp53R172H/+ mice (547), were maintained in Dulbecco's
modified Eagle's medium (DMEM) supplemented with 10% FBS with 100 U/mL penicillin and 100 µg/mL
streptomycin in a humidified 5.0% CO2 atmosphere at 37°C. Human TIFs and wild-type and SerpinB2-/- MEFs
were generated and cultured as described in section 3.2.1.
4.2.4

Flow cytometry

Expression of cell surface uPA and uPAR was analysed by indirect immunofluorescence using dual color flow
cytometry (LSRFortessaTM, Becton-Dickinson) and PI used to exclude non-viable cells (444). Data was analysed
using FlowJo software version 7.6.5 (FlowJO LLC, USA) comparing specific antibody binding to isotype
controls to account for nonspecific binding. Antibody details and dilutions are described in Table 1 of
Appendix.
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4.2.5

3D organotypic invasion assay

Invasion of PDAC cells through collagen I matrices contracted by either TIFs, wild-type or SerpinB2-/- MEFs
were performed as described in detail in section 3.2.2. After contraction, 2.0 x 105 PDAC cells were seeded on
top of the matrix in 24-well plates and grown for 2-3 days or until confluent. The matrices were then
transferred to a liquid-air grid interface for invasion, as previously described (359). Matrices were refreshed
every 2-3 days with DMEM supplemented with 10% FBS with 100 U/mL penicillin and 100 µg/mL
streptomycin ± compounds (500 nM SerpinB2, 500 nM

R380A

SerpinB2 or PBS control). After 14 days, the

matrices were fixed in 10% NBF for 2 days and kept in 70% ethanol at room temperature prior to embedding
and sectioning as described in section 3.2.2. Sections were then processed for histological and microscopic
analyses.
4.2.6

Mixed cell allograft model

Subconfluent PDAC cells and MEFs were harvested and resuspended in cold PBS, pH 7.4. 7.5 x 105 MEFS
(wild-type or SerpinB2-/-) were mixed with 2.5 x 105 PDAC cells (totalling 1 x 106 cells in 100 µL at a 3:1
MEF:PDAC ratio) and injected subcutaneously into the rear flank of four week old female BALB/cFox1nuAusb mice (5 per group). Tumour volume was quantified using a digital vernier caliper while mice were
conscious and calculated using the equation, xy2/2 (548). Mice were monitored daily in compliance with the
Garvan/St Vincent’s Hospital Animal Experimentation and Ethics Committee guidelines (approval #13/17).
Mice were anesthetised seven days post injection and analysed using an IVIS fluorescence/luminescence
imaging platform. After euthanasia, tumours were dissected into 3 parts and either formalin fixed or frozen for
further processing and analyses.
4.2.7

Histological analysis

Dissected tumour sections from mixed allografts above were fixed in 10% cold NBF and processed and
embedded in paraffin using the Leica Peloris Dual Retort tissue processor (Germany). Histological staining was
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performed on 4 µm sections deparaffinised in xylene and rehydrated using graded ethanol washes.
Haematoxylin and Eosin (H&E) and picrosirius red (Polysciences, USA, #24901-250) staining were performed
on a Leica Autostainer XL. Immunohistochemistry was performed using the Leica Bond RX system. Refer to
Table 1 of Appendix for antibody details. For scoring of invasive index, migration modality, cell cluster and
immunohistochemistry staining, 10 images per sample were acquired using a bright field microscope (Leica
DM4000).
For immunofluorescence analysis, pancreatic tumour allograft cryosections (4 µm) were cut and air-dried on
glass slides. Sections were then fixed in 100 % acetone for 10 min at -20 °C and air-dried. Rehydrated sections
were blocked and processed with antibodies as described in figure legends and Table 1 of Appendix. Slides
were then mounted with Vectashield containing DAPI (Vector) and cells imaged using a Leica DMI 6000 SP8
laser scanning confocal fluorescence microscope (Germany). Staining specificity was shown with isotype
controls.
4.2.8

In vivo allograft local invasion scoring method

Single and collective cell invasion into local tissue (subcutaneous fat, muscle and skin) was analysed by
histoscore on 4 µm H&E stained sections. Local invasion was quantified as shown in Fig. 4.2, and scored by
three separate researchers.
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Fig. 4.2. In vivo allograft local invasion scoring method. Representative photomicrograph images defining quantification system of local invasion by either wild-type or SerpinB2-/MEF:PDAC tumours. Single and collective cell invasion into local tissue (subcutaneous fat, muscle and skin) was analysed by histoscore on 4 µm H&E stained sections. No invasion was
quantified as 0; single cell invasion into local tissue was scored as 1, collective cell invasion as 2, and in the event where the tissue was completely penetrated by tumour, a score of 3 was
given. Arrows show invasion of tumour cells into specific tissue area. Quantification of local invasion was scored blind by three separate researchers.
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4.2.9

SHG and SEM imaging analysis

20 µm FFPE sections of 3D matrices or tumours were analysed using SHG and SEM imaging systems as
described in section 3.2.6 and 3.2.8, respectively.
4.2.10

uPA activity assay

Activity assays were performed as previously described (176). Briefly, frozen tumour samples were
defrosted on ice and homogenised in 10 mM Tris (pH 8.0), 0.15 M NaCl, & 0.1% Triton X-100. Total
protein levels were determined and lysates diluted to 3 mg/mL in 100 µL reaction buffer (20 mM
HEPES, pH 7.6, 100 mM NaCl, 0.5 mM EDTA, 0.01% (v/v) Tween 20) containing 0.25 mM uPA
fluorogenic substrate (Z-Gly-Gly-Arg-AMC – Chemicon, USA). Fluorescence was measured over time at
37 °C using a POLAstar plate reader (OMEGA) and activity determined against a murine uPA standard.
4.2.11

Statistical analyses

Unless specified otherwise, data is the mean (± SEM) of at least three independent experiments
performed in either triplicate or sextuplet. Differences in the mean of two groups were analysed by an
unpaired t-test. Comparisons of more than two groups were made by a one-way (or two-way) ANOVA
with post hoc Holm-Sidak (or other post hoc) analysis for pairwise comparisons and comparisons versus
control. P values < 0.05 were considered statistically significant. Unless stated otherwise, data and
statistical analyses were performed using GraphPad Prism (version 6.0, USA).
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4.3 RESULTS
4.3.1

APGI PDAC gene expression survival analysis

The PAS has previously been shown to drive invasion and metastasis in numerous cancer types (19). In the
specific context of pancreatic cancer, expression of various individual components of this system have been
associated with differential survival/outcome in a small cohort of PDAC patients (238,549). Therefore, the
association of mRNA expression of PAS components (PLAU, PLAT, PLAUR, SERPINB2, SERPINE1) and
disease-specific survival in a large cohort of resected PDAC (APGI) were analysed (Fig. 4.3) (511). Increasing
PLAU expression was significantly associated with poorer survival (1.6 years reduced) following
pancreatectomy (Cox model coefficient 0.387; likelihood ratio P = 0.00019, n = 141, Fig. 4.3A and B).
Further, at the genomic level, PAS component genes (PLAU, PLAUR, SERPINB2) were found to be frequently
altered in PDAC (22% of cases, Fig. 4.3C). Interestingly, genomic alterations of the enzyme (PLAU), receptor
(PLAUR), or inhibitor (SERPINB2) of the PAS pathway appeared to be mutually exclusive in PDAC (Fig.
4.3D). Mutual exclusivity of genomic alterations within a particular pathway are strongly predictive of a role
for that pathway in driving tumourigenesis (550). Together, these data suggest a functional role for the
uPA/SerpinB2 axis in PDAC progression. These genomic data imply that PDAC invasion could be facilitated by
PAS, and thus needed to be interrogated through various experimental models.
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Fig. 4.3. PAS expression in human PDAC after pancreatectomy. Hazard ratio (A) and overall survival (B) in relation to uPA
expression for a cohort of patients with resected PDAC (n=141). Standard error of the fit is shown as a light blue band, and the
distribution of PLAU expression in the cohort as a grey density distribution. 10th, 50th, and 90th percentiles of the PLAU expression
distribution are indicated by vertical green, blue, and orange lines, respectively. The Cox model predicted survival paths for these
three percentiles of PLAU expression are further illustrated in (B). Inset lines denote the extended survival time of 1.6 years for
patients in the 10th percentile for PLAU expression versus patients in the 90th percentile of PLAU expression distribution. C.
Alteration frequencies of the PAS component genes PLAU, PLAUR and SERPINB2 across various cancer types in TCGA database; D.
Mutual exclusivity of PLAU, PLAUR and SERPINB2 genomic alterations in pancreatic tumours in TCGA database (n=90).
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4.3.2

PDAC cell invasion in the 3D organotypic culture model

To further assess the role of uPA and SerpinB2 in PDAC invasion, the 3D organotypic culture system described
in Chapter 1 (refer to Fig. 1.11) was employed. In this model, invasion of PDAC cells into the fibroblastcontracted collagen I matrix was induced by a chemotactic air-liquid interface (359). PDAC cells are an
appropriate functional model for understanding the role of PAS in pancreatic cancer as they express cell surface
uPA/uPAR (refer to Fig. 4.7E). This model closely recapitulates the interaction between cancer cells, stromal
cells and the ECM (547). In order to determine the effects of altered matrix integrity in the absence of stromal
SerpinB2 (matrices outlined in Chapter 3) on migration and invasive capacity of pancreatic tumour cells, a 14day invasion using the air-liquid interface method was undertaken. PDAC cell invasion through matrices
formed by SerpinB2-/- MEFs doubled compared to wild-type (27.2 % ± 1.9 versus 55.2 % ± 1.8; P < 0.001)
(Fig. 4.4A-C). Furthermore, a significant difference in invading PDAC cell morphology and migration mode
was observed in matrices formed by SerpinB2-/- MEFs. PDAC cells invading through wild-type matrix exhibited
a predominantly mesenchymal migratory mode (>70% of cells) (Fig. 4.4A, D) while PDAC cells in SerpinB2-/matrices displayed a predominantly amoeboidal phenotype (>80% of cells) (Fig. 4.4B, D).
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Fig. 4.4. PDAC invasion through wild-type and SerpinB2-/- MEF/collagen I matrices. A-B: Photomicrographs of pancytokeratin stained sections of organotypic cultures showing invasion of PDACs through collagen I matrices formed in the presence of
either (A) wild-type or (B) SerpinB2-/- MEFs; C. Invasion index - calculated as the percentage of PDACs invading the matrix relative
to PDACs present in the layer overlaying the matrix; D. Migration mode analysis - PDAC cells were scored as displaying either
amoeboidal, mesenchymal or collective migration modes; E. Cluster analysis – Clusters per field of view (FOV) were scored when ≥3
PDAC cells were together in a complex. C-E analysis was performed on images taken at sites of maximal invasion after 14 days, using
10 fields of view. Individual values are shown with bars representing mean ± SEM from 3 separate matrices. Statistical analyses were
performed using unpaired t-tests; F-G: Maximum projection of SHG signal intensity of collagen matrices formed with either (F) wildtype or (G) SerpinB2-/- MEFs (bars = 100 µm); H. Total collagen coverage (quantified by SHG) within PDAC invaded matrices
formed with either wild-type or SerpinB2-/- MEFS, inset: Mean collagen coverage at SHG signal peak. Values shown are means ±
SEM from 3 separate matrices (n = 9), statistical analysis performed using an unpaired t-test.
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These observations were supported by increased expression of E-cadherin in PDAC cells within SerpinB2-/matrix, but not in wild-type matrices (Fig. 4.5). Expression of E-cadherin is required for epithelial cell
adhesion mechanisms, forming adherens junctions to bind epithelial cells tight together and to the tissue bed
(551). E-cadherin down-regulation reduces cellular adhesion strength within a tissue bed, resulting in increased
in cellular motility and migration. As PDAC cells in the wild-type matrices exhibited a decreased expression of
E-cadherin, this potentially allowed them to break adherens junctions and separate from the monolayer,
acquiring the classic epithelial-mesenchymal transition (EMT) to invade down into the collagen matrix.
Further, there was a significant increase in PDAC cell clustering observed within matrices prepared with
SerpinB2-/- MEFs compared with wild-type MEFs (6.2 ± 0.6 clusters versus 3.1 ± 0.7; (P < 0.0001) (Fig.
4.4E). This cluster phenotype coupled with significant E-cadherin expression, suggested that collective invasion
did not require EMT within SerpinB2-/- collagen matrices, and revealed PDAC cellular control of CDH1 (Ecadherin encoding gene).

Fig. 4.5. PDAC invasion through wild-type and SerpinB2-/- MEF/collagen I matrices. A-B: Photomicrographs of ECadherin stained sections of organotypic cultures showing invasion of PDACs through collagen I matrices formed in the presence of
either (A) wild-type or (B) SerpinB2-/- MEFs.

Moreover, fibroblast led PDAC invasion was observed in both wild-type and SerpinB2-/- MEF/collagen I
matrices (Fig. 4.6), which is a novel result for SerpinB2-/- MEF constructed matrices, however well-known to
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occur in the TME and reported by others (344,552). Additionally, ultrastructural SEM analyses observed
fibroblast constructed tunnels in both wild-type and SerpinB2-/- MEF/collagen I matrices, which potentially
provides insight into one of the pathways that both epithelial and mesenchymal PDAC cells may traverse and
invade down into the collagen matrices (Fig. 4.6).

Fig. 4.6 Fibroblast led PDAC invasion though 3D organotypic matrices. PDAC cells being guided into both (A) wild-type
and (B) SerpinB2-/- MEF collagen I matrices. Inset: Black arrows denote fibroblasts; white arrows denote PDAC cells; black and white
striped arrows denote fibroblasts leading PDAC cells into the matrix. C. SEM analysis of a fibroblast constructed tunnel within (C)
wild-type and (D) SerpinB2-/-MEF collagen I matrices.

SHG analyses of the matrices at the end of the 14-day invasion assay confirmed the reduced structural integrity
of SerpinB2-/- MEF (36 ± 2.1 % collagen coverage) versus wild-type MEF matrices (64 ± 4.3% collagen
coverage), respectively, corresponding to a 56% decrease in the mean collagen coverage between matrices
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(Fig. 4.4F-H). Hence, the compromised structural integrity of matrix formed in the absence of stromal cell
SerpinB2 markedly influenced PDAC cell migration and invasion.
4.3.3

Exogenous SerpinB2 inhibits PDAC cell invasion

After it was elucidated that SerpinB2 deletion with the stroma significantly increases PDAC invasion, the next
question posed was what effect SerpinB2 directly has upon epithelial PDAC cells. Importantly, the telomeraseimmortalised fibroblasts (TIFs) used for matrix contraction express low if not negligible levels of uPA/uPAR
(Fig 4.7F). This was necessary in order to ascertain individual uPA/uPAR effects of PDAC cells in this model.
Under control conditions (PBS), PDAC cells were highly invasive (invasion index = 71.1 % ± 4.1) with
extensive penetration into the underlying dermal-equivalent matrix (Fig. 4.7A, D) as previously reported
(359,553). In contrast, there was a significant inhibition of PDAC cell invasion observed in the presence of
exogenous SerpinB2 over the 14-day invasion period (invasion index = 42.9 % ± 6.2, P < 0.0001) (Fig. 4.7B,
D). Importantly, invasion of PDAC cells was not affected by SerpinB2R380A, an active-site mutant that is unable
to inhibit uPA (invasion index = 71.1 % ± 4.1, P = 0.2087) (Fig. 4.7C, D). Hence, invasion of PDAC cells
into the underlying stroma in an organotypic culture model was uPA-dependent and regulated by SerpinB2,
one of the key endogenous inhibitors of uPA activity.
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Fig. 4.7. PDAC invasion in TIF/collagen 3D organotypic matrices. A-C: Photomicrographs of pan-cytokeratin stained
sections of 3D organotypic cultures showing invasion of PDACs through the TIF/Collagen I matrix, (A) PBS control, (B) 500 nM
wild-type SerpinB2, C. 500 nM SerpinB2R380A (uPA non-inhibitory mutant); D. Invasion index - calculated as the percentage of
PDACs invading the matrix relative to PDACs present in the layer overlaying the matrix (pan-cytokeratin stain) from 10 fields of
view at areas of highest invasion. Individual values are shown with bars representing mean ± SEM from 3 separate matrices. Statistical
analysis performed using an unpaired t-test. E-F: Flow Cytometry analysis of cell surface uPA and uPAR expression on (E) PDAC and
(F) TIFs. Figures are representative of triplicate determinations.

4.3.4

Exogenous SerpinB2 does not inhibit PDAC invasion in contracted MEF matrices

As SerpinB2 showed successful PDAC cell inhibition of invasion through TIF contracted matrices (with
moderate to high SerpinB2 expression level in these fibroblasts), it was necessary to observe if this would occur
in the context of stromal SerpinB2 absence. Thus, organotypic invasions were undertaken using PDAC cells in
both wild-type and SerpinB2-/- MEF contracted matrices, with exogenous addition of either wild-type
SerpinB2, R380ASerpinB2 or PBS control (Fig. 4.8). Significant differences were observed in PDAC cell invasion
between wild-type or SerpinB2-/- matrices (Fig 4.8, P < 0.0001), as previously shown in section 4. (refer to Fig
4.4C). PDAC cell invasion through wild-type MEF matrices was also significantly abrogated with the addition
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of wild-type SerpinB2 versus R380ASerpinB2 (P < 0.0001), and PBS (P < 0.0001), Fig. 4.8A-C, G). However,
no significant PDAC invasion differences were observed between exogenous addition of wild-type SerpinB2,
R380A

SerpinB2 or PBS through SerpinB2-/- MEF contracted matrices (P > 0.05, Fig. 4.8D-F).

Fig. 4.8. PDAC invasion in wild-type or SerpinB2-/- MEF/collagen I 3D organotypic matrices. A-C: Photomicrographs
of pan-cytokeratin stained sections of 3D organotypic cultures showing invasion of PDACs through the wild-type MEF/Collagen I
matrix, (A) PBS control, (B) 500 nM R380ASerpinB2 (uPA non-inhibitory mutant), (C). 500 nM wild-type SerpinB2; D-F:
Photomicrographs of pan-cytokeratin stained sections of 3D organotypic cultures showing invasion of PDACs through the SerpinB2-/MEF/Collagen I matrix, (D) PBS control, (E) 500 nM R380ASerpinB2 (uPA non-inhibitory mutant), (F). 500 nM wild-type SerpinB2;
G. Invasion index - calculated as the percentage of PDACs invading the matrix relative to PDACs present in the layer overlaying the
matrix (pan-cytokeratin stain) from10 fields of view (of triplicate experiments) at areas of highest invasion. Individual values are
shown with bars representing mean ± SEM from 3 separate matrices per experiment. Statistical analysis performed using an unpaired
t-test. Figures are representative of triplicate deeterminations.
.
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4.3.4 PDAC tumour growth and local invasion in vivo
To determine the effects of modulating the expression of SerpinB2 in the stroma in vivo, an allograft experiment
was performed, where PDAC cells and MEFs (wild-type or SerpinB2-/-) were co-injected into Balb/c nude
mice. A MEF:PDAC ratio of 3:1 was used in order to reflect the high fibroblast content and low tumour
cellularity of PDAC tumours (554-556). Seven days post subcutaneous inoculation into the hind flank of the
animal, PDAC tumours formed. Tumours containing SerpinB2-/- MEFs were significantly larger and more
elongated than those formed with wild-type MEFs (mean volume 205 mm3 ± 29, versus 143 mm3 ± 29
respectively, P = 0.0322, Fig. 4.9B). Consistent with the increased size of tumours formed with SerpinB2-/MEFs, IHC showed significantly elevated cell proliferation as evidenced by increased Ki-67 staining in these
tumours compared to those formed with wild-type MEFs (tumour border = 819 ± ± 53.3 vs 506 ± 48.1
positive cells per field of view (FOV), P = 0.0024; tumour centre = 576 ± 65.7 versus 208 ± 48.2 positive
cells per FOV, P = 0.0020; Fig. 4.9C).
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Fig. 4.9. In vivo mixed cell allograft model. A. A mixture of MEFs (wild-type or SerpinB2-/-) and PDACs (at a 3:1 MEF:PDAC
ratio) were inoculated into nude mice and allowed to grow for 7 days prior to the following analyses; B. IVIS imaging of MEF-GFP
fluorescence; tumour volume quantification (mean ± SEM, n = 5); C. Ki-67 staining and quantification at both the border and centre
of tumours; D. Maximum projection of SHG signal intensity of collagen coverage formed within MEF:PDAC tumours (inset: mean
collagen coverage at SHG signal peak); E. Picrosirius staining (with insets showing high magnification view) and quantification of
collagen I/III coverage of tumours. Individual values shown are means from 3 representative images per tumour from 5 animals per
group with mean ± SEM denoted. Statistical analyses were performed using unpaired t-tests.

Consistent with the results from 3D organotypic experiments, significant changes in collagen matrix integrity of
allograft tumours in the absence of SerpinB2 were observed. SHG analysis (Fig. 4.9D) showed a significant
decrease in collagen content at tumour margins in the absence of MEF SerpinB2 (mean collagen coverage 28.7
± 5.8 % versus 11.2 ± 1.9 % in wild-type versus SerpinB2-/- MEF respectively. P = 0.0209). Quantification of
Collagen I and III content in allografts by picrosirius staining (Fig. 4.9E) also revealed significantly decreased
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collagen coverage in tumours formed with SerpinB2-/- MEFs compared to wild-type (48.4 ± 10.1 % versus 3.5
± 0.6 % respectively, P = 0.0021). No significant difference in apoptosis (detected by IHC analysis of cleaved
caspase-3) was detected in the PDAC cell allograft tumours formed with either wild-type or SerpinB2-/- MEFS
(Fig 4.10).

Fig 4.10. Cleaved caspase-3 in mixed cell allograft model. A-B: CC3 staining at centre of (A) wild-type and (B) SerpinB2-/MEF tumours; C: Quantification of CC3 staining at both tumour border and centre of wild-type and SerpinB2-/- MEF:PDAC tumours
(n = 5; Error bars = SD).

This result is quite novel, as most findings in the field report an increase in collagen bundling at the border of
tumours (263,280,557). This result could explain the difference in local invasion, suggesting that PDAC
collective migration is increased when there is less desmoplasia/collagen coverage surrounding the primary
tumour mass (addressed further in the discussion). Loss of E-cadherin (or gain of N-cadherin) was not required
in such a SerpinB2 null ECM (Fig. 4.5), thus traditional EMT migration appeared less advantageous for the
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spread of the tumour. It appears from these results, that for loco-regional progression of PDAC in a SerpinB2
down regulated system, advantages appear to reside in collective tumour migration over disseminating
individual PDAC cells. It is known that large tumour masses produce higher autocrine and paracrine
concentrations of promigratory factors and matrix proteases while also protecting inner cells from
immunological targeting (558,559). Examination of allograft tumour margins by immunofluorescence (Fig.
4.11) revealed that many cells were positive for alpha-smooth muscle actin (α-SMA), marking activated
fibroblasts which are known to lead tumour invasion (344) (see Appendix B for isotype control
immunofluorescence, refer to Fig. A.1). No obvious co-localisation between SerpinB2 and α-SMA was
observed, suggesting that host derived myofibroblasts may have been recruited to the TME over the seven day
experimental time period. This analysis also revealed significantly higher expression of uPA in tumours formed
with SerpinB2-/- MEFs compared to those formed with wild-type MEFs (Fig. 4.11). Expression of uPAR, the
cellular receptor for uPA, was also higher in these tumours (Fig. 4.11). Further, uPA distribution appears to be
localised to discrete regions within tumours formed with wild-type MEFs, with a more homogenous
distribution was observed in tumours formed with SerpinB2-/- MEFs (Fig. 4.11). While many cells showed clear
expression of SerpinB2 in tumours formed with wild-type MEFs, there was only some SerpinB2 detected in
tumours derived using SerpinB2-/- MEF/PDACs, suggesting host derived fibroblast or other stromal cells may
contribute SerpinB2 (Fig. 4.11). In addition, there was only a small amount of observable co-localisation of
uPAR and SerpinB2 within SerpinB2-/- MEF/PDAC tumours versus a moderate amount within wild-type
MEF/PDAC tumours. This result was expected in the SerpinB2-/- MEF/PDAC tumours and suggests that
SerpinB2 expression observed in the wild-type MEF/PDAC tumours may be contributed by intracellular pools
of SerpinB2 that is independent of its extracellular uPA inhibitory role (Fig. 4.11, B).
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Fig 4.11. Immunofluorescence - αSMA, uPA, uPAR, SerpinB2 and SerpinE1 expression in mixed cell allografts.
Immunofluorescence imaging of cryosections from wild-type or SerpinB2-/- MEF:PDAC tumour allografts showing expression of (A)
α-SMA, uPA, uPAR, (B) α-SMA, SerpinB2, uPAR or, (C) (B). α-SMA, SerpinE1, uPAR. Merged images include DAPI nuclear
staining;

Histological analysis of excised tumours showed that those formed with wild-type MEFs were largely
encapsulated (Fig. 4.11A), while tumours formed with SerpinB2-/- MEFS showed significantly enhanced local
169

invasion into both muscle (Fig 4.12A,B) and subcutaneous fat (Fig 4.12C,D). Notably, this result reveals the
differential invasive capacity of tumours with or without stromal SerpinB2 expression.

Fig 4.12. Photomicrographs and quantification of PDAC tumour local invasion. Cell invasion into local muscle tissue (A)
or subcutaneous fat (C), by either wild-type or SerpinB2-/- MEF:PDAC tumours. Black arrows denote single and collective PDAC
local invasion into either muscle or subcutaneous fat tissue; quantification of invasion into local muscle tissue (B) or subcutaneous fat
(D) are shown. E. uPA enzymatic activity (IU/mg) from either wild-type or SerpinB2-/- MEF:PDAC tumour lysates (bars represent
mean ± SEM, n = 3).
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Consistent with increased immunofluorescent detection of uPA protein in allografts formed with SerpinB2-/MEFs (refer to Fig. 4.12), we also observed increased uPA proteolytic activity in these tumours (250.4 ± 51.1
IU/mg versus 654.10 ± 136.0 IU/mg in wild-type and SerpinB2-/- respectively. P = < 0.05, Fig 4.12E).
In summary, the increased proliferation and local invasion observed in mixed cell allograft tumours formed
with SerpinB2-/- MEFs is accompanied by changes in the expression and distribution of uPA and uPAR, and
increased uPA proteolytic activity. These robust changes most likely reflect altered dynamics of uPA/uPAR
turnover on PDAC cells. It seems that SerpinB2 expression within the stroma impinges greatly upon the
migration modality and ability of PDAC cells to locally invade, collectively or singly. Altogether, these novel
findings from two organotypic invasion assays and a mouse model of PDAC provide evidence that the
spatiotemporal expression of SerpinB2 impacts greatly upon stromal remodelling of the ECM as well as the
invasiveness of PDAC cells.
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4.4 DISCUSSION
PDAC represents a worldwide causation of human morbidity and mortality, ranking among the top five causes
of cancer death after gastric, breast, lung and prostate cancer (560). About 55 per cent of pancreatic cancer
cases occur in developed countries (561), where the delayed prognosis for the majority of patients diagnosed
with PDAC means that advanced stages of disease are already in effect. Beyond surgery, current PDAC
treatment options are extremely limited and have not substantially improved the survival of patients with
resectable disease over the past 25 years. Thus, there is an urgent need for new therapeutic strategies to treat
advanced disease, as only 10-20% of patients are eligible for pancreatectomy (562). Tumour-stroma studies are
vital in the understanding PDAC biology and will provide the key to wholly understanding the tumourigenic
process and for the generation of new therapeutic strategies against this insidious disease.
A strong association between increased PLAU mRNA expression and decreased survival in a large cohort of
resectable pancreatic cancer patients (refer to Fig. 4.3) confirmed the power of uPA overexpression as a
marker of disease outcome/survival in PDAC. At the genomic level, there are observed mutually exclusive
alterations of various PAS components in a significant proportion of PDAC cases. PLAU expression is
associated with poor prognosis following pancreatectomy and PAS component genes are frequently altered in
PDAC. The predicted effects of these mutually exclusive alterations are functionally equivalent. That is,
deletion of SERPINB2 is functionally equivalent to amplification of its enzyme target PLAU or enzyme receptor
PLAUR. Mutual exclusivity of genomic alterations within a particular pathway is strongly predictive of a role
for that pathway in driving tumourigenesis (550). In this respect, the pattern of genomic alterations in PAS
components is consistent with a role in driving PDAC tumourigenesis and highlights its potential as a
therapeutic target.
An important consideration in interpreting genome and transcriptome data on whole tumour extracts is the
relatively low tumour cellularity, high stromal content, and related desmoplasia that it characteristic of PDAC
(511). Therefore, to understand the role of uPA in PDAC biology it is critical to consider functional effects in a
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cell-specific context. Only a few clinical studies have looked closely at cell-specific expression in human PDAC
(234,238,549), with varying results that may be confounded by limited sample sizes. Given these limitations, a
functional approach was applied to understand the role of the PAS in PDAC biology. 3D organotypic culture
systems and in vivo models of PDAC were utilised to interrogate the role of the PAS pathway in PDAC
development. These models were successfully used to modulate SerpinB2, and in turn, PAS activity in a
context-dependent manner and demonstrated that uPA activity is necessary for PDAC invasion in vitro and in
vivo. Further, these models proved that SerpinB2 regulates stromal remodeling of collagen and in turn
influences tumour growth and invasion. Organotypic culture models provide an excellent platform for
understanding functional effects of cell-specific interactions in a complex 3D environment. More than 80% of
cancers in the human body originate from the epithelium (23). This means that TME components during
tumourigenesis, invasion and metastatic processes are potentially common between ostensibly distinct tumour
types. The 3D oranotypic model has shown the fidelity and advanced insight into stromal mechanics, made
possible through the creation of a histologically similar tissue bed equivalent to the stroma of tumour systems,
using fibroblasts and collagen I for matrix construction. Such a powerful model is quite time consuming to
prepare, but once the technique has been learnt, can be undertaken with astonishing ease. In order to study cell
migration and remodeling within a 3D context, limiting animal work, yet acquiring a much more realistic
model of the human situation, organotypic models are revolutionising cancer biology research
(354,358,425,563). This approach has provided our laboratory with valuable information in the form of
stromal SerpinB2 effects versus epithelial effects, and is continuing to be found effective in a wide range of
different uses. Future studies will build on these basic principles by increasing the complexity of cell types
included in the cultures, for instance, using lymphocytes, keratinocytes in dermal matrices, and endothelial
cells. The inclusion of endothelial cells, together with fibroblasts in the matrix or separately beneath the
matrix, could allow modelling of angiogenesis concomitantly with the study of tumour-stroma interaction. The
addition of immune cells to this model is another area for development within our laboratory, since it is widely
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reported that tumour-associated macrophages (TAMs) have a large impact on tumourigenesis and metastasis in
vivo (564). Previous studies by Chioni et al. (2008) have reported that co-cultured macrophages with cancer
cells on collagen gels increases autocrine and paracrine signalling loops enhancing cell movement, and similar
experiments are definitely possible with this organotypic culture (565).
Inhibition of PDAC invasion within TIF matrices by recombinant SerpinB2 (but not an inactive mutant)
demonstrated that uPA activity is necessary for PDAC invasion in organotypic culture (refer to Fig. 4.7,B-C).
The underlying mechanisms for this effect likely involve altered dynamics of ECM degradation and remodelling
via attenuated protease activation (including Plg, MMPs etc). Further, SerpinB2 mediates the specific, rapid
inhibition and clearance of cell surface-bound uPA (19,176) and altered dynamics of uPAR recycling and
associated signalling pathways are also likely involved in the dramatic inhibition of PDAC cell invasion by
SerpinB2. The lack of significant inhibition to PDAC cell invasion through SerpinB2-/- matrices with the
addition of wild-type SerpinB2, R380ASerpinB2, or PBS (Fig. 4.9G) suggests that once the collagen I matrix has
been formed without proper collagen fibrils and bundles, uPA may not have as great importance on tumour cell
migration. Once the tissue structure is comprised with such poor integrity and porous structure, once the
tissues structure is already composed and is porous and compromised, lacking a robust matrix system, that the
tumour cells can mobilise more effectively and addition of exogenous SerpinB2 has negligible effect, as
uPA/uPAR axis is not needs to navigate such large routes (utilising Rho/Rock pathways instead).
The major histopathological hallmark of PDAC is the severe fibrosis and desmoplastic reaction that generates a
high stromal-to-epithelial ratio (566). This aberrant inflamed microenvironment surrounding the tumour site is
implicated in the reduced chemoresponse of PDAC patients (536,567,568). PDAC fibrosis is composed of
abundant ECM proteins, of which, several paracrine and autocrine factors between stromal and tumour cells
induce their deposition (566). Fibroblasts/myofibroblasts secrete the precursors of many components of the
extracellular matrix, including collagens, fibronectin, hyaluronic acid, collagenases and many growth factors
(IGF, EGF, TGF-β etc.). Within the TME, tumour (and stromal) cells use the surrounding interstitial matrix as
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a passive substrate while actively promoting increased type-I collagen deposition within the peritumoural space,
in order to enhance invasive activity, local growth, and cancer stem cell formation (569). Myofibroblast
depletion led to extensive remodeling of tumour ECM with a significant decrease in tumour stiffness and total
collagen content, resulting in worse prognoses (570). Myofibroblasts contribute to the production of collagen I.
Other groups have reported this in vivo, where cancer cells migrating away from the primary tumour site move
into a nascent ECM deposited by infiltrating stromal cells, which potentially contain defects in collagen crosslinking (261,571-573). Sabeh et al. (2009) reported that protease-independent mechanisms of cell migration
are only possible when the collagen network is bereft of adequate covalent cross-linking that characterise
homeostatic tissues (451), as likely occurred in this study, and also in vivo in desmoplastic pancreatic carcinoma
tissue. In this study, the ex vivo platform concurred such findings and demonstrated that protease-independent
invasion programs, such as amoeboidal and collective cell clustering, can thus be accommodated by an
immature, wound-like environment at sites surrounding the primary neoplasm (refer to fig. 4.4 and 4.5). In
general PDAC tumourigenicity, advancement of malignancy has classically been reported to proceed through
collagen-rich areas where penetration occurs through EMT style progression, in a slower advancement through
the ECM by proteolytically active neoplastic PDAC populations (536,574-576). The increased synthesis of
collagen by the stroma appears to serve as a pathway for such tumour invasion.
Even though both wild-type and SerpinB2-/- MEF ECM matrices allowed efficient PDAC invasion, the
disordered networks of the SerpinB2-/- MEF matrices increased PDAC permissiveness (Fig. 4.4). Excess
collagen I bundling, enhances PDAC cell proliferation and capacity for escaping the epithelial cell
compartment. Thus, in the context of an in vivo tumour, the ability of CAFs to deregulate the ECM structurally
may be made easier in the absence of SerpinB2. On the basis of differences observed in the morphology and
activity between wild-type and SerpinB2 MEF migration movies in the Collagen I matrices (refer to Fig. 3.6),
the increase in local invasion observed in SerpinB2-/- tumours (Fig. 4.12) and the increased positive staining of
α-SMA on SerpinB2-/- tumours (Fig. 4.11), we can say that fibroblasts displayed an active, cancer associated
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phenotype. There are many previous reports of activated fibroblasts having pro-cancerous effects
(263,450,540,544,577), as found in this study.
Mode and efficiency of PDAC cell migration likely affected by interplay of proteolysis/remodelling and physical
hindrance of the tissue/surrounding stroma. It has been shown that ECM stiffness effects morphogenesis of
tumour cells (558). Altered structural integrity has significant effects on PDAC migration and invasion. The
increase in PDAC invasion in the SerpinB2-/- matrices could explain the differences observed in vivo in local
invasion, suggesting that PDAC migration (and thus, metastasis) is increased when there is less
desmoplasia/collagen coverage surrounding the primary tumour mass. The invading cells from tumours with
SerpinB2-/- MEFS appear to have increased paracrine, autocrine or cell type-specific signalling, as their
migration into muscle and fat was significantly higher than local invasion by cells from tumours formed with
wild-type MEFs. This phenomena has also been reported by other researchers in the PDAC field (352,570).
Ozdemir et al. (2014) found that α-SMA myofibroblast depletion in their PDAC mouse models significantly
reduced ECM stiffness, without increasing gemcitabine efficacy, leading to more undifferentiated tumours,
increased EMT, tumour cell proliferation and EMT invasion, altered immune cell infiltrate profiles and faster
death (570). In addition they showed that tumour angiogenesis was diminished in α-SMA myofibroblast-/- mice,
without altering glycolysis or hypoxia. Rhim et al. (2014) deleted Sonic Hh from mice and reported earlier
onset of undifferentiated PDAC, stroma formation attenuation, increased angiogenesis, more aggressive PDAC
tumours that metastasised and led to faster succumbing of death versus control mice (352). Both Rhim (2014)
and Ozdemir et al. (2014) concluded that desmoplasia protects the host from metastasis and when stroma is
reduced in PDAC, there is an increase in EMT, proliferation, invasion and reduction in overall survival (352)
(570). Both authors also suggest that stroma depletion leads to greater dependence on VEGF, which
intriguingly, should mean enhanced uPA/uPAR activity in such tumour systems, as uPAS activators are are
required on the surface of activated, migrating endothelial cells through VEGF stimulation (29). Ozdemir et al.
(2014) also reported that LOX levels were unchanged in α-SMA myofibroblast-/- mice, despite dramatic
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reductions in ECM stiffness (570). This result further supports the potential role of SerpinB2-TG2 in mediation
of type-I collagen crosslinking, as explained in Chapter 3 (refer to section 3.4).

A major result in this chapter was the loss of E-cadherin by PDACs through the wild-type matrices
recapitulated classical EMT migration (Fig 4.5). This result suggested that PDAC cells might recognise
differentiated features in new tissue sites and up or down-regulate E-cadherin expression. This result has been
observed by others, who report that those cancer cells can transition between EMT and MET, forming cell-cell
adhesions again and returning to an epithelial state (578). E-cadherin is crucial for cell-cell adhesion, holding
epithelial cells tight together upon the basement membrane. When epithelial cells lose E-cadherin expression,
they release β-catenin into their cytoplasm (578). These β-catenin molecules have been shown to migrate into
the nucleus and trigger EMT-inducing transcription factors, which can activate RTK and cause tumour cells to
undergo transformation to a mesenchymal state, initiating metastasis (578). While EMT is a fairly rigid process
completed through widespread alterations in gene transcription, mesenchymal–amoeboid transition (MAT) or
amoeboid–mesenchymal transition (AMT), involve rapid modifications in migratory mode, arising from the
specifics of the tissue microenvironment (579). These transitions are known to play a significant role in several
stages of the metastatic process, when a certain microenvironment requires phenotypical adaptation of the
tumour cells. Metastatic cells are able to undergo significant epigenetic alterations in order to regulate
molecular mechanisms to induce MAT/AMT. Cells using amoeboid-like or cell clustering invasive strategies
are afforded enhanced contractility, promoted by the Rho/ROCK signaling pathway (580), allowing them to
pass through apertures in the passive collagen networks and adapt their cell bodies to the pre-existing spaces, or
by exerting a sufficient actomyosin force, which can be generated to deform their surrounding ECM
(536,571,581). This study observed such a phenomenon, where amoeboidally migrating PDAC cells moved at
significantly higher rates through the SerpinB2-/- versus wild-type matrices, without adhesion attachment to
collagen I substrate. The sustained expression of E-cadherin suggests that the pore sizes of the SerpinB2-/177

matrices were of sufficient size and that collective cell migration was available. This type of migration is also
seen in vivo within tumourigenic systems. Cancer cell migration through lymph nodes can occur through
stromal cell–lined conduits that support rapid movement through matrix-free zones, orchestrated by fibroblasts
(582). Further, tissues without interstitial collagen networks, e.g., the brain (583), are infiltrated by tumour
cells without necessitating proteolytic remodeling, merely requiring ROCK-regulated pathways to squeeze a
migrating cell through matrix openings smaller than the short axis of its nucleus (584). As aformentioned in
chapter 1 and 3, Valiente et al. (2015) reported that increased SerpinB2 (and SerpinI1) expression was required
for lung and breast metastatic invasion through brain tissue (213). It has been shown that type-I collagen
organisation into fibrils has a significant role in limiting the diffusion of large molecules into the tumour area
(262,583). Pluen et al. (2001) reported that molecules with diameters similar to the interfibrillar space had
much slower diffusion, associated with a higher density of host stromal cells that synthesise and organize type-I
collagen (583). Obviously, type-1 collagen influences PDAC tissue resistance to macromolecule transport,
believed to be caused by proteoglycan/glycosaminoglycan binding and stabilizing of the ECM (262). This,
coupled with hypovascularity, has major implications in chemo-resistance to macromolecule-based therapy. It
therefore necessary to develop site-specific drug carriers to improve the delivery of molecular medicine to solid
tumours, like PDAC (583). The findings presented of PDAC invasion and migratory modality through
SerpinB2-/- matrices, as well as those through dermal fibroblast matrices, support a model wherein the type-I
collagen architecture of the normal interstitium presents itself as a structural barrier to cancer cell traffic (585).
However, when rigid structural barriers occur and pore size is not permissive for collective cell movement,
such as occurs in PDAC desmoplasia, cancer cells appear to be reliant on the PA system and MT1-MMP
activity, and conceivably the associated membrane-anchored collagenase (585,586).
3D Organotypic results were reproduced in vivo, as SerpinB2-/- MEFs in the mixed allograft model formed
larger and more invasive tumours, with altered collagen deposition (refer to Fig.4.9). Also significant
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differences in uPA/uPAR expression on PDACs in SerpinB2-/- allograft tumours, was concomitantly reflected
in increased uPA activity in SerpinB2-/- tumours (refer to Fig. 4.11C).
Future therapeutic treatments for pancreatic cancer should consider targeting critical pathways in the growth,
advancement, and prolongation of the tumour stroma. In the pursuit of more effective therapeutic
intervention, researchers must attain deeper understanding of the tumour stroma in the specific context of
PDAC. The unfortunate failure of systemically administered chemotherapy in PDAC can attest to this
perspective; clearly extensive tumour–stromal interactions affect PDAC malignancy, such as SerpinB2
alteration. Through acquiring a better understanding of the signaling mechanisms most vital in the development
and perpetuation of PDAC stroma, drug design and development can be enhanced with clearer rationale,
leading to an increased stromal-targeting efficacy, offering better outcomes for PDAC patients.
Given that PaSCs regulate ECM turnover, one such approach could include co-administration of an anti-fibrotic
reagent such as pirfenidone, to target the desmoplastic regions around PDAC tumours, initiating fibrolysis and
potentially reducing chemoresistance in PDAC patients. This chapter clearly establishes a definitive role for
uPA in pancreatic cancer and reveals novel evidence for both tumour and stromal cell specific effects of
SerpinB2 on PDAC invasion. The availability of this well characterised mutant K-Ras/p53 PDAC model
histologically recapitulates PDAC in human pathology and has revolutionised the field of PDAC research. This
model mimics both the central epithelial component of human PDAC but also the incredibly complex TME, a
feature for which much of treatment failure is accredited. Due to the failure of therapies targeting the TME,
work in our lab is aimed at stromal targets, which are being evaluated in mouse models of PDAC.
The advent of this model with uPAS enquiry has generated much knowledge about how PDAC migration can
be initiated around the TME and potentially how the disease progresses. Both uPA and SerpinB2 clearly affect
PDAC TME development and stromal maintenance. SerpinB2 deletion within stroma impinges on ECM
formation/structural integrity and influences invasive capacity and migratory mode of stromal and tumour
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cells. The results presented in this chapter suggest that a better understanding of stromal biology and
desmoplasia in the mechanism of PDAC will likely provide significant opportunities for better treatments for
this devastating cancer. Fibroblasts clearly play a major role in PDAC, and it is well reported that interactions
between PaSCs and cancer cells of PDAC are disease limiting. Hwang et al. (2008) reported that PaSC
conditioned media increased PDAC cell proliferation, migration, invasion, while also decreasing the
effectiveness of radiation and chemotherapy (gemcitabine) (577). These data strongly point out important roles
for the desmoplasia of PDAC in the mechanism of stromal remodeling and local invasion, implicating SerpinB2
heavily within these processes. The next challenge for our laboratory is to understand when is an ideal
timeframe to exploit the PAS pathway for therapeutic success. Crucial to this effort will be determining the
molecular basis of how SerpinB2 is activated and exactly which other pathways it is sigThus, it is vital to
understand how these interactions in the tumour epithelium and the microenvironment impact upon other
pathways, such as Rho/Rock. As these important milestones are achieved, new paths of opportunity will be
uncovered to offer new routes of therapeutics for PDAC malignancy.
Finally, the findings in this chapter identified the uPA/SerpinB2 axis as a driver of PDAC invasion and a marker
of disease outcome/survival, strongly supporting the further development of uPA-targeted therapeutics for the
treatment of PDAC. Development of new anticancer therapies represents a crucial challenge for the biomedical
community and these data present significant insight into mechanisms of PDAC invasion and impact upon the
potential use of SerpinB2 in a drug delivery system to target PDAC stroma. Heavily expressed on PDAC
tumours, uPA inhibition by SerpinB2 warrants further preclinical investigation as a potential therapeutic target.
Increased uPA activity in SerpinB2-/- allograft tumours, could represent a paracrine-like inhibition of PDAC uPA
by SerpinB2 from the wild-type MEFs tumours.
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CHAPTER 5
TOWARDS AN UNDERSTANDING OF THE ROLE OF SERPINB2
IN BREAST TUMOURIGENESIS AND METASTASIS
5.1 INTRODUCTION
The mammary gland is a complex secretory organ composed of epithelial cells, endothelial cells, adipocytes,
fibroblasts and immune cells. It is one of the human body’s most physiologically and structurally dynamic
organs, continually developing through several distinct stages (587). From prenatal life, early development and
puberty, to reproduction and menopause, there are extensive processes, which are critical for normal gland
development and breast tissue homeostasis (587). Processes such as proliferation, angiogenesis, migration,
invasion, and resistance to apoptosis are vital for normative mammary function, yet these aforementioned
processes also facilitate the origination and advancement of breast cancer (587). Endocrine hormones and many
different growth factors must act synergistically in order to develop a healthy mammary gland and normative
breast tissue bed. Initially, prenatal mammary gland development occurs via epithelial cell proliferation and
invasion into the mammary fat pad (Fig. 5.1). These cells then differentiate into small networks of branched
ducts. Mammary gland development pauses here until puberty, when oestrogen release from the ovaries
(combined with IGF-1 and growth hormone) causes these epithelial duct cells to proliferate, swelling the ducts
and forming bulbous structures, known as terminal end buds (TEBs) (refer to Fig 5.1) (587). TEBs are the most
proliferative cell type of the developing mammary gland and they will continue to proliferate, migrate and
branch out into the mammary fat pad (Fig. 5.1). The next phase of mammary gland development occurs during
pregnancy and is the most active phase of growth for the organ. High concentrations of oestrogen and
progesterone (in preparation for lactation) cause rapid proliferation of the mammary gland epithelium (587).
The epithelial cells of TEBs are highly proliferative and homeostatically invasive (during puberty and pregnancy)
during this time, while anti-apoptotic signalling pathways (PI3K/AKT, and RAS/MEK/ERK) prevent
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premature involution of mammary gland tissue (588). These functions are essential for post-natal care,
however extremely detrimental when redeployed within a tumourigenic environment. Once lactation has
concluded, apoptotic signalling is vastly up-regulated (PTEN protein turns off PI3K/AKT pathway) (588),
causing gland involution.

Fig 5.1. Mammary gland development. The mammary gland epithelial cells proliferate and invade into the mammary fat pad.
Cell differentiation results in the formation of epithelial ducts, which swell to form terminal end bud (TEBs). During pregnancy,
TEBs proliferate and undergo branching into the fat pads. Gland involution occurs following lactation whereby the mammary gland
epithelial cells die by apoptosis. There are two branching mechanisms within the mammary gland: Side branching and bifurcation of
TEBs. Neonatally, the mammary epithelium consists of only a few small ducts that grow allometrically until puberty. After 4 weeks
post birth, short tertiary branches form under the influence of progesterone. At the onset of puberty, expansive ductal morphogenesis
and growth is initiated, and the epithelial tissue branches out to fill the fat pad with ducts (stimulated by GH, oestrogen and IGF-1),
achieved by cooperation between plasminogen/plasmin and MMPs. Upon pregnancy, prolactin and progesterone induce
alveologenesis - the growth of alveolar cells. Prolactin stimulates milk production that continues until cessation of weaning, when
signals induce involution – the mammary gland is remodeled back to its original adult state. Modified from (351).

The mammary epithelium consists of two main cell types, basal and luminal. The basal epithelium contains
myoepithelial cells (and a small population of stem cells), which are attached to the basement membrane and
generate the outer layer of the mammary gland (589). The luminal epithelium directly forms the ducts and milk
secreting alveoli, while the myoepithelial cells squeeze milk from the alveolar luminal cells. These two cell
types are most active during puberty and reproduction, when significant hormone presence activates signaling
networks, influencing epithelial-mesenchymal cell interactions (590). These networks involve MAPK and
STAT proteins for cell branching, lactation and gland involution, as well as FGFs and MMPs in mesenchymal
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remodeling of branching ducts and involution (591). Plasminogen has previously been shown essential for
normal mammary development, as plasminogen-/- mice show delays in early ductal expansion and maybe unable
to lactate due to secretory epithelial deficits (592). Conversely, uPA-/- mice display normal mammary
development and gland involution (592). Because of this, evidence by Selvarajan et al. (2001) suggests that
plasma kallikrein is the protein responsible for activating plasminogen within the mammary gland (593).
Previously, Simian et al. (2001) reported that MMPs work in collaboration with PAS during mammary
epithelial morphogenesis and branching in 3D collagen I matrices (594). These studies imply that even if uPA is
not directly responsible for the induction of mammary duct branching, plasmin is still activated and plays a
major role, in an MMP-dependent manner (591). Other studies suggest that MMP-2 promotes ductal
elongation, while MMP-3 stimulates lateral side branching (595).

Normal signaling between developing mammary cell populations is tightly controlled by TGF-β, Wnt, FGF,
hedgehog (also present in PDAC biology, refer to 4.1), EGF, neuregulin3 (an EGF receptor), oestrogen and
notch signaling pathways (1). Furthermore, in the last decade it has come to light that normal mammary gland
functioning is dependent on stem cell processes, involving these key signaling pathways (589). Stem cells in the
mammary gland are thus of key importance for physiological tissue renewal and regeneration following postnatal care. It has previously been shown that deregulation of these specific pathways in the mammary gland can
facilitate breast cancer progression and are hijacked in cancer cells fueling unregulated tumour growth, invasion
and instigating metastatic processes (589).
5.1.1

Breast cancer

Breast cancer is the most common cancer in the world for women, and in 2015 there was an estimated 15,740
new cases of the breast cancer diagnosed in Australia (145 males and 15,600 females) (596). Breast cancer is a
multifaceted and heterogeneous disease (of which there are ten molecular subtypes) involving distinct
histological and genetic aberrations (597). These cancers most commonly originate from basal cells lining the
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inner milk ducts (i.e. basal cells -80% of cases) or the luminal cells of lobules that supply milk to the ducts (15
% of aetiology) (Fig. 5.2). In the majority of cases, breast cancer takes many years to arise and become
diagnosable. Breast tissue is particularly sensitive to tumourigenesis, for several reasons. Oestrogen, the
primary female sex hormone, stimulates breast cell division and is activated strongly and at many occasions
during a woman’s life. Not only does enhanced cell division increase the risk of DNA damage, but breast cells
do not fully mature in women until their first full-term pregnancy (598). Immature breast cells bind
carcinogens much stronger than mature breast cells and are also less efficient at the DNA damage response
(599). When coupled with oestrogen-stimulated mitosis, it unfortunately dramatically increases the risk of
developing breast cancer for many women, especially nulliparous women.

Fig 5.2. Mammary gland tumourigenesis. A. Illustration of the gross anatomy of the mammary gland (showing both an invasive
lobular carcinoma and a ductal carcinoma in situ - DCIS). B. The two layers of a mammary duct composed of luminal and basal
myoepithelial cells (and their tumourgenic counterparts) as well as stem and progenitor cells. Adapted from (600).

Breast cancers are divided into 5 intrinsic sub-divisions known as luminal A, luminal B, human epidermal
growth factor receptor 2 (HER-2)-enriched, basal-like and normal-like, and are further placed into 3 specific
sub-groups by their receptor expression type (601). These sub-groups are hormone receptor [oestrogen (ER+)
or progesterone (PR+) receptor] positive, HER-2+, and triple negative (lacking ER, PR and not over185

expressing HER-2) breast cancer (TNBC). ~ 75% of all breast cancers are ER+, where patients tumours grow
in response to oestrogen stimulation (602). ~65% of ER+ tumours are also PR+ (603). HER-2+ breast
cancers account for ~20-25% of all breast tumours, and tend to be rapid growing and aggressive in their
phenotype (604). Lastly, TNBCs account for between 10-17% of all breast cancers, tend to be highly aggressive
(605), and are commonly associated with the breast cancer gene, BRCA1 (606).
5.1.2

TNBC

TNBC is commonly taken for a basal-like sub-type of breast cancer as approximately 75% of TNBCs express
basal cell markers (601,607,608). TNBC tumours carry a poorer prognosis than luminal tumours (609,610),
with African-American, African and menopausal women having a threefold higher risk of developing TNBC
versus all other women (611). TNBC also has been associated with deprivation status, younger age at diagnosis,
with more advanced stage tumours, hereditary and BRCA1 mutations (611). As TNBCs lack the traditional
targetable receptors, common treatments like hormone therapy and cyto-toxic or –static drugs targeting
estrogen, progesterone, and HER-2 are ineffective, often requiring combinatorial therapeutic regimen (606).
In addition, women with TNBC are more likely to experience a peak risk of recurrence within 3 years from
diagnosis, and mortality rates are increased for 5 years after diagnosis (611). Standard treatment for TNBC is
chemotherapy, allowing for a higher rate of breast-conserving surgeries, followed by adjuvant chemotherapy
and radiotherapy (if required). Evaluation of the response to chemotherapy gives important individual clues to
particular chemo-sensitivity or –resistance. TNBCs are usually sensitive to chemotherapy however, some cases
do not elicit any or a complete response, and the response does not correlate with overall survival (612). This
makes TNBC particularly complicated to curatively treat. However, chemotherapy is still an effective option,
as many women do respond well initially. Five years post-diagnosis, TNBC patients have the same rate of
relapse as women with ER+, PR+ or HER-2+ breast cancers (613). Further, after 10 years from diagnosis,
recurrence is even less likely in TNBC patients versus recurrence in patients with other breast cancer types
(613). Pooled data of all TNBC subtypes versus other breast cancer types indicate that with adequate treatment
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plans, 20-year survival rates are not significantly different between TNBC patients and patients with hormone
positive breast cancers (614). Paradoxically, some types of TNBCs are extremely aggressive, exhibiting poor
prognosis and an unpredictable relapse pattern (615). These TNBC subtype cases are often fatal within the first
1-2 years from diagnosis and have a much higher risk of relapse in the first 3–5 years and also absolute relapse
and survival rate differences across subtypes (614,615). One explanation for this is that TNBCs comprise a
vastly heterogeneous cancer group (616). Within these tumour systems the TME is a major constituent in
determining the behaviour of each tumour, thus depending on the composition of stromal cells and ECM
factors present, these can influence a tumours aggressiveness and potentiate an invasive system that is extremely
difficult to treat. By taking into account the role of the neoplastic epithelium and the local microenvironment,
medical science is elucidating the powerful interplay that tumour systems participate in. Upregulation of MMPs
which digest fibrillar and membranous collagens can result in a tissue microenvironment of altered fibrillar
composition, where degraded basement membrane is a key feature in the instigation of cancer cell migration
and intravasation into the vasculature (18). Furthermore, altered ECM impairs molecular diffusion in tissue
beds, which impacts upon drug delivery to breast tumours (364). At present, ECM alteration is recognised as a
hallmark in the progression of breast cancer, with many observable changes in tissue signaling during tumour
invasion and metastasis (617). In order to begin to understand the complex tumour-stromal interactions in
breast cancer that are hindering the effectiveness of current therapies, there is an essential need to enhance the
field’s knowledge of these processes. In that regard, this chapter focused on the role of uPAS in tumour
growth, migration and local invasion in breast cancer.
5.1.3 The role of uPAS in breast cancer
The proteolytic activity of uPA is negatively regulated by SerpinB2, and in many human malignancies, levels of
uPA are significantly higher than in the corresponding normal tissues, directly related to patient prognosis
(refer to Table 1, section 1.5). Current literature strongly supports that individual uPAS factors are involved in
the process of rendering malignant breast tumours invasive, and high levels of tumoural uPA are associated with
187

metastasis and shorter survival than those with lower uPA tumour expression, therefore signifying uPAS as an
attractive target for cancer therapy (16,18,71,84,98,101,124,618,619). Genetic expression of PAS inhibitor,
SerpinB2, in recurrent free survival in breast cancer subtypes Luminal (A and B), Basal, HER-2+, or all subtypes combined can be observed in Fig. 5.3. High SerpinB2 expression levels are advantageous for patient
survival without relapse in both Luminal A and B sub-types (but not basal and HER-2+ individually) or when all
BC sub-types are combined (Fig. 5.3, E). This interesting finding indicates that SerpinB2’s control over the
feed-forward plasmin and uPA/uPAR loop is advantageous and may, in part, inhibit disease progression in
these tumour types.
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Fig. 5.3. SerpinB2 gene expression and recurrent free survival in breast cancer. Kaplan-meyer plots showing overall
survival in relation to SerpinB2 expression for cohorts of patients with (A) Luminal A, (B) Luminal B, (C) Basal, (D) HER-2+, and
(E) All sub-types (grouped together) of breast cancer. Red lines indicate high SerpinB2 expression and black lines indicate low
SerpinB2 expression. Data from KM Plotter. Accessed June 2015.
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Like all solid tumour systems, in order for invasion and metastasis to occur, the ECM must be remodeled.
ECM-directed mammary morphogenesis is currently not well understood, however, involves epithelial
'invasion' into adipose tissue, a process that also occurs by normative epithelial cells within ductal branching,
during puberty and pregnancy, as discussed above (Section 5.1). Exactly how this mammary morphogenesis is
dysregulated and subverted in the progression of BC in the specific context of PAS is of paramount importance.
Thus, this chapter sought to address various aspects of ECM alteration in the context of breast tumour invasion
and metastatic progression in the metastatic derived (pleural effusion) invasive triple-negative human mammary
epithelial carcinoma cell line, MDA-MB-231, and it’s even higher metastatic daughter cell line, MDA-MB231HM. These cells are aneuploid female (range = 52 to 68), with chromosome counts in the near-triploid
range (620). They both express epidermal growth factor (EGF), transforming growth factor alpha (TGF-α), as
well as the WNT7B oncogene (621). In addition, our laboratory has previously shown that MDA-MB-231 cells
over express uPA and uPAR (622).
In a study by Finak et al. (2008), stromal SerpinB2 gene expression was reported to be significantly reduced
(>16-fold) in isolated invasive tumour stroma compared with matched normal stroma in breast cancer patients
(623). This dramatic reduction in SerpinB2 expression is also a robust predictor of clinical outcome in breast
cancer, with greater recurrence free survival in patients with higher levels of SerpinB2, see (19). As previously
mentioned (see Chapter 1, refer to section 1.5.3), SerpinB2 efficiently, specifically and irreversibly binds and
clears uPA from uPA over-expressed cell surfaces, without activating pro-invasive pathways in tumour cells
(19,25). Furthermore, SerpinB2 lacks individual binding sites for LRP, VLDLR and vitronectin and thus does
not stimulate the pro-invasive phenotype that is associated with SerpinE1 (24,25,177,624). SerpinB2 is also
non-toxic and even at highest known in vivo concentration during third trimester pregnancy, where it can
consistently reach levels above 250 ng/mL in plasma (134,625), there are no reported associated health risks
(626). Additionally, SerpinB2 cannot inhibit pro-tPA or fibrin bound tPA (627), meaning there are no
overactive fibrinolysis side effects when administering high doses of SerpinB2. High tumour SerpinB2 levels are
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associated with improved patient outcome in breast cancer (see Fig. 5.3), and in node negative breast cancer
high tumour SerpinB2 is only statistically relevant if uPA levels are concurrently high (6,19). Moreover, high
levels of SerpinB2 expression in breast carcinomas has been correlated with increased, relapse-free survival (fig.
5.3) (17,18,221,628-631), while low expression has exhibited the opposite effect. Furthermore, treatment of
uPA over-expressing tumour xenografts in animal models with SerpinB2 demonstrated inhibition or complete
prevention of metastasis (215,244).
The aforementioned studies indicate that SerpinB2 is a valid therapeutic option in breast and other cancer
states, and can be directly delivered to cell surface uPA and internalised into tumour cells via receptormediated endocytosis (RME). This system avoids any damage to normal, healthy cells, and this approach could
potentially be used combinatorially with chemotherapy treatments to enhance efficacy or provide cytostatic
effects for uPA expressing cancers.
Previous studies have reported conjugation of SerpinB2 to
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bismuth (an α-emitting radioisotope)

preferentially targeted breast, prostate and melanoma cancer xenografts in animal models and micrometastases
in vivo (227,373,632,633). In addition, our laboratory has shown that 2’-deoxy-5-fluorouridine (a pro-drug
form of the common chemotherapeutic 5-fluorouracil) or an anti-mitotic dibrominated-N-alkylisatin (a potent
cytotoxin), conjugated to SerpinB2 was able to preferentially kill uPA/uPAR over-expressing cell lines
(130,619).

Overall, further understanding of the spatiotemporal expression of SerpinB2 in breast tumourigenesis and
metastasis is required in order to investigate this powerful PAS inhibitors potential as a novel chemotherapeutic
and provide further rationale for the development of SerpinB2 based targeted therapies in the treatment of
breast and various cancer types.
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The specific aims of this chapter were to:
1.

Characterise the effects of SerpinB2 knockdown upon MDA-MB-231 cell invasiveness in the 3D
organotypic model.

2.

Investigate the invasiveness of highly metastatic MDA-MD-231HM cells through SerpinB2 null
organotypic matrices.

3.

Elucidate the effects of SerpinB2 upon tumour growth in a mixed cell xenograft mouse model of
TNBC.

5.2 METHODS
5.2.1

Cell lines and culture conditions

The invasive triple-negative human mammary epithelial carcinoma cell line MDA-MB-231 originally purchased
from American Type Culture Collection (ATCC, VA, USA) was maintained in Roswell Park Memorial
Institute medium (RPMI-1640) (Invitrogen, USA), supplemented with 10% fetal bovine serum (FBS), 10 mM
HEPES buffer and 125 IU insulin, at 37 °C in a HERAcell incubator (Kendro Laboratory Products, Germany)
in 95% humidified atmosphere, containing 5% CO2. The highly metastatic breast adenocarcinoma (MDA-MB231HM) cell line [passaged six times through lung metastases (634)], was a gift from Professor Zhi Ming Shao
and Professor Zhou Luo Ou (Breast Cancer Research Institute, Fudan University Shanghai Cancer Center,
China). Three of these MDA-MB-231HM cell lines were stably transfected with fluorescent markers by Dr
Cameron Jonstone (Peter MacCallum Cancer Centre, Victoria, Australia) and donated as a gift to our
laboratory. The three cell lines initially tested were MDA-MB-231HM luciferase expressing (MDA-MB231HM Luc), MDA-MB-231HM tomato expressing (MDA-MB-231HM Tom) and MDA-MB-231HM
luciferase and tomato expressing (MDA-MB-231HM Luc and Tom). All MDA-MB-231 parent and daughter
cell lines were routinely cultured as mentioned above. Fibroblast cell lines, normal Fre-85 (NAFs) (635), and
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Breast CAF (CAFs) line, were a gift from Dr Lily Huschtscha (Children’s Medical Research Institute, New
South Wales, Australia). Both NAFs and CAFs were routinely cultured in DMEM:F12 medium containing
100IU insulin, 1 ng/mL FGF-2 and 10% (v/v) heat-inactivated FBS. For subculturing, cells were detached at
subconfluency (80-90% confluency) using sterile 1 × PBS containing 5 mM EDTA (pH 7.4) followed by 0.05%
(w/v) trypsin-EDTA (1×), centrifugation at 1,200 rpm for 5 min at RT using a Heraeus Megafuge 1.0R
(ThermoFisher Scientific, USA) and resuspension in fresh culture medium, prior to each experiment. All cell
experiments were conducted using cells in exponential growth, passaged 48 h prior. Cell viability and cell
number were assessed prior to experimentation using the Trypan blue (Sigma-Aldrich) exclusion method, with
viable cells counted using a haemocytometer. Cell lines were also routinely tested for Mycoplasma
contamination (in-house testing conducted by IHMRI technical staff) and found to be negative.
5.2.2 Cell migration wound healing assays
Individual wells of an Imagelock 96-well plate (Essen Bioscience, USA) were coated with 50 µL of collagen I
(300 µg/mL) in 17.4 mM acetic acid, on ice. All assays were performed in a humidified 5.0% CO2 atmosphere
at 37 ºC using the IncuCyte ZOOM imaging system (Essen BioScience). Individual wells were seeded with
either MDA-MB-231 (shGFP ±Dox, sh1C1 ±Dox, or sh2A2 ±Dox) cells at even density (25,000/well) in
octet of the pre-coated ImageLock 96-well plates and allowed to attach and spread over 8 h with aforementioned
media, in the presence or absence of 2 µg/ml Dox. After two subsequent wash steps with PBS, the wells were
refreshed with media in the presence or absence of 2 µg/ml Dox. Scratch wounds were generated with the
Woundmaker tool and images taken every 2 h. Images were processed using IncuCyte ZOOM system (10 ×
objective) and wound regions were measured using automated analysis. Relative Wound Density (%, value of 0 =
no migration, value of 100 = completed migration, when the cell density inside the wound is the same as the cell
density outside the initial wound) was analysed as a percentage (± SEM).
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5.2.3 Western blotting
To ascertain the relative expression of translated SerpinB2 within different breast cancer cell lines, western blot
analysis was undertaken, as previously explained (refer to 2.2.10.1). 30 µg protein from whole cell lysates of
either non-malignant human mammary epithelial cell lines (184B5, MCF10A, MCF12A), human mammary
luminal carcinoma cell lines (T-47D, MCF7, MDA-MB-134, MDA-MB-175, MDA-MB-330, MDA-MB-361,
BT483, BT474) or human mammary basal carcinoma cell lines (HCC1569, HCC1954, HCC38, HCC70,
HCC1187, HCC1500, HCC1532, BT20, BT549, MDA-MB-157, MDA-MB-231, MDA-MB-436, MDA-MB468) were used for separation under non-reducing conditions by 10% SDS-PAGE and transferred to PVDF
membranes. The membranes were immunoprobed overnight at 4°C with antibodies against SerpinB2, or Actin
as per standard protocol (refer to Supplementary Antibodies Table of Appendix – Table A1). The membranes
were incubated with the appropriate HRP-conjugated secondary antibody and then developed according to
enhanced chemilluminescence protocol (32106, ThermoScientific).

In order to elucidate the relative expression of translated SerpinE1 and SerpinB2 within both the epithelium and
stroma of the breast TME, western blot analysis was undertaken (refer to 2.2.10.1). 20-30 µg protein from
whole cell lysates of either human mammary basal carcinoma cell lines (MDA-MB-231, MDA-MB-231HM),
primary human mammary normal- and carcinoma-associated fibroblasts (NAFs, CAFs), or telomerase
immortalised human fibroblasts (TIFs) were used for separation under non-reducing conditions by 10% SDSPAGE and transferred to PVDF membranes. The membranes were immunoprobed overnight at 4°C with
antibodies against SerpinB1, SerpinB2 or GAPDH as per standard protocol (refer to Supplementary Antibodies
Table of Appendix – Table A1). The membranes were incubated with the appropriate HRP-conjugated
secondary antibody and then developed according to enhanced chemilluminescence protocol.
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5.2.4

3D organotypic culture
5.2.4.1 SerpinB2 knockdown in MDA-MB-231 effects on 3D invasion

Invasion of MDA-MB-231 cells with SerpinB2 knockdown through TIF contracted collagen I matrices was
performed using 3D organotypic assays as aforementioned (refer to 3.2.2). After fibroblast-mediated collagen I
matrix contraction, 2.0 × 105 MDA-MB-231 (either shGFP ±Dox, sh1C1 ±Dox, or sh2A2 ±Dox) cells were
seeded on top of each matrix in 24-well plates and grown for three days – after this time a wholly confluent
monolayer was formed. The matrices were then transferred to a liquid-air grid interface for invasion (359), in
which the liquid phase was supplemented with or without 2 µg/mL Dox. After 14 days, the matrices were
fixed in 10% NBF for 2 days and kept in 70% ethanol at room temperature. Samples were embedded in
paraffin wax and sections were then acquired for histological and microscopic analyses.
5.2.4.2 MDA-MB-231HM invasion into 3D collagen matrices
Invasion of the highly metastatic MDA-MB-231HM cell line through collagen I matrices contracted by either
TIFs, wild-type or SerpinB2-/- MEFs was performed as aforementioned (refer to 3.2.2). After fibroblastmediated Collagen I matrix contraction, 2.0 × 105 MDA-MB-231HM cells were seeded on top of each matrix
in 24-well plates and grown for three days – after this time a wholly confluent monolayer was formed. The
matrices were then transferred to a liquid-air grid interface for invasion (359). Initially, pilot assays were
conducted through both TIF and MEF contracted collagen I matrices in order to determine the optimal length
of invasion for this cell line. After 7 or 14 days, the matrices were fixed in 10% NBF for 2 days and kept in 70%
ethanol at room temperature. Samples were embedded in paraffin wax and sections were then acquired for
histological and microscopic analyses.
5.2.4.3 Pilot 3D Organotypic breast tumour spheroid invasion assay
A pilot experimient was undertaken to investigate the effects of tumour spheorids in this 3D organotypic model.
This system would recapitulate the in vivo situation with greater biomimicry and potentially allow for increased
therapeutic insight when testing novel drugs. The 3D spheroid culture differed from the models above in that
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contraction of collagen I matrices was undertaken by TIFs and MCF-7s, or TIFS and MCF-7s, MDA-MB-231s
and SK-BR-3s. Initially, breast cancer cells were seeded (5.0 × 103 of MCF-7 or 1.66 × 103 each of MCF-7,
MDA-MB-231 and SK-BR-3, per well) in 60 wells of a round bottom 96-well ultra-low adherent cell plate
(Corning, USA - distributed by Sigma). After 3 days, fully formed spheroids were collected and 60 spheroids
(either MCF-7 or MCF-7/MDA-MB-231/SK-BR-3) were co-cultured with quiescent TIFs (8.0 × 104 per
matrix) in Collagen I solution per matrix (V2: 2.5 mL) in a 35 mm petri dish. Matrices were then allowed to
contract for two days in complete media (DMEM, supplemented with 10% FBS and penicillin-streptomycin).
After this time, MCF-7/TIF/Collagen I or MCF-7/MDA-MB-231/SK-BR-3/TIF/Collagen I matrices were
moved to a 24 well plate and incubated for a further 2 days in the presence of either 500 nM SerpinB2 or PBS
control. After this time, the matrices were fixed in 10% neutral buffered formalin for 2 days and kept in 70%
ethanol at RT. Samples were embedded in paraffin and sections were then acquired for histological analyses
[H&E, PanCK, Picrosirius red and Ki-67; refer to Supplementary Antibodies Table of Appendix (Table A1. for
further details)].
5.2.5

Mixed cell xenograft model

In order to better understand the intrplay between stromal and tumour cells in vivo, MDA-MB-231HM cells
and MEFs were trypsinised and resuspended in cold PBS. 7.5 x 105 MEFS (wild-type or SerpinB2-/-) were
mixed with 2.5 × 105 MDA-MB-231HM cells (1 × 106 cells in total at a 3:1 MEF:MDA-MB-231HM ratio) and
injected into the intramammary fat pad (IMFP) of the 1st mammary gland of of 4 week old female BALB/cFox1nuAusb mice (5 per group). Tumour volume was quantified using a digital vernier caliper while mice were
conscious and calculated using the equation, xy2/2 (548). Mice were weighed and monitored daily in
compliance with the University of Wollongong’s Animal Experimentation and Ethics Committee guidelines
(approval #AE13/18). Mice were anaesthetised 15 days post injection and tumour weight and volume
compared between treatments.
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5.2.6 Statistical analyses
Unless stated otherwise, data is presented as the mean (± SEM) of at least three independent experiments
performed in either triplicate or sextuplet. Differences in the mean of two groups were analysed by an unpaired
t-test. Comparisons of more than two groups were made by a one-way (or two-way) ANOVA with post hoc
Holm-Sidak (or other post hoc) analysis for pairwise comparisons and comparisons versus control. P values <
0.05 were considered statistically significant. Unless stated otherwise, data and statistical analyses were
performed using GraphPad Prism (version 6.0, USA).

5.3 RESULTS
5.3.1

SerpinB2 expression in breast cancer cell lines

Western blot analysis was undertaken to compare SerpinB2 protein levels in normal (transformed) breast cell
lines as well as luminal, basal and HER-2+ BC epithelial cell lines (Fig. 5.4). Compared to the control (1 µg)
recombinant SerpinB2 used in the western blot, the normal (transformed) breast epithelial cell lines, 184B5 and
MCF10A, expressed moderate to high levels of SerpinB2, while the MCF12A line expressed low to negligible
levels of full-length SerpinB2 (Fig. 5.4). The lower (~37 kDa) sized SerpinB2 observed on western blots [of
which MCF12A cells expressed moderate and similar levels to that of 184B5 (labeled as 184 in Fig. 5.4) and
MCF10A cells] is potentially a cleaved form of SerpinB2. All of the human mammary luminal carcinoma cell
lines (T-47D, MCF7, MDA-MB-134, MDA-MB-175, MDA-MB-330, MDA-MB-361, BT483, BT474)
expressed low to negligible levels of both full-length and cleaved SerpinB2 (Fig. 5.4). Lastly, the human
mammary basal carcinoma cell lines, HCC1954, HCC1500, HCC1532 and MDA-MB-436, all expressed
moderate to high levels of full-length SerpinB2, while HCC1500, HCC1532, BT549, MDA-MB-157, MDAMB-231, MDA-MB-436 and MDA-MB-468 cells expressed moderate to high levels of cleaved SerpinB2 (Fig.
5.4).
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Fig 5.4. SerpinB2 expression in malignant and non-malignant mammary cell lines. Western blots showing expression of
SerpinB2 in non-malignant human mammary epithelial cell lines (184B5, MCF10A, MCF12A), human mammary luminal carcinoma
cell lines (T-47D, MCF7, MDA-MB-134, MDA-MB-175, MDA-MB-330, MDA-MB-361, BT483, BT474) or human mammary basal
carcinoma cell lines (HCC1569, HCC1954, HCC38, HCC70, HCC1187, HCC1500, HCC1532, BT20, BT549, MDA-MB-157,
MDA-MB-231, MDA-MB-436, MDA-MB-468). Blots were reprobed for Actin as equiloading controls.

5.3.2 SerpinB2 and SerpinE1 characterisation in breast epithelial and stromal cells
Further, it was necessary to understand the expression levels of both PAS inhibitors, SerpinE1 and SerpinB2,
within both epithelial and stromal cells for use in proceeding in vitro and in vivo experiments. Analysis of
stromal cell expression of both PAS serpins revealed that NAFs express little to negligible levels of SerpinB2,
while CAFs and TIFs express moderate to high levels of SerpinB2 (Fig. 5.5). SerpinE1 levels were comparable
to SerpinB2 within CAFs, however not so for NAFs and TIFs. NAFs expressed moderate to high levels of
SerpinE1, while TIFs expressed lower levels to that of SerpinB2. Within epithelial BC lines tested, the parent
MDA-MB-231 cell line expressed relatively high levels of SerpinB2, while it’s daughter metastatic cell line,
MDA-MB-231HM, expressed no SerpinB2 (Fig. 5.5). SerpinE1 levels were comparable to SerpinB2 within
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MDA-MB-231HM cells, while MDA-MB-231 cells expressed lower SerpinE1 levels to that of SerpinB2 (Fig.
5.5).

Fig 5.5. SerpinB2 and SerpinE1 expression in breast epithelial and fibroblast cell lines. Western blots showing
expression of SerpinB2 and SerpinE1 in NAFs, CAFs, TIFs, MDA-MB-231 and MDA-MB-231HM (Tom and Luc) cells. Blots were
reprobed for GAPDH as equiloading controls.

5.3.3 Cell surface detection of uPA
An immunofluorescence assay was performed to determine MDA-MB-231HM cell surface uPA expression.
Three MDA-MB-231HM cell lines, differing only in fluorescent reporters, were used in order to determine
which was the best line to utilise for continuing experiments. All lines appeared to express high levels of cell
surface uPA when analysed by flow cytometry in comparison to the fluorescence peak obtained using a noninduced rabbit IgG2A antibody control (Fig. 5.6). MDA-MB-231HM Tom cells expressed high levels of uPA
(geometric mean = 40 ± 3.08 fluorescence units, versus IgG2A control geometric mean = 9.67 ± 2.23
fluorescence units) (Fig. 5.6, A,D; P > 0.001). Similarly, MDA-MB-231HM Luc cells also expressed high
levels of uPA (geometric mean = 43.4 ± 2.14 fluorescence units, versus IgG2A control geometric mean = 11.7
± 1.16 fluorescence units) (Fig. 5.6, B,E; P > 0.001). Lastly, MDA-MB-231HM Luc and Tom cells expressed
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the highest levels of uPA (geometrical mean = 57 ± 2.49 fluorescence units, versus IgG2A control geometrical
mean = 11.7 ± 3.36 fluorescence units) (Fig. 5.6, C,F; P > 0.001), of all the MDA-MB-231HM cell lines.
These data suggest, that as a transformed TNBC model for understanding PAS expression spatiotemporally,
these cell lines were ideal given the high uPA expression levels. As MDA-MB-231HM Luc and Tom cells
expressed the highest cell surface levels of uPA, this cell line was used for 3D organotypic and in vivo
experiments.

Fig. 5.6. Cell surface detection of uPA MDA-MB-231HM cell lines. A,D. MDA-MB-231HM Tom, 84% of cell population
(gated) analysed; B,E. MDA-MB-231HM Luc, 84.6% of cell population (gated) analysed; C,F. MDA-MB-231HM Tom and Luc,
89.7% of cell population (gated) analysed. Charcoal shaded histograms represent cells probed with negative control (non-induced
rabbit IgG antibody). White histograms represent cells probed with rabbit anti-mouse uPA polyclonal antibody. Bound primary
antibody was detected with goat anti-rabbit, FITC-conjugated antibody. Inset boxes of D, E and F display mean intensity of
fluorescence at 515 nm.
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5.3.4

SerpinB2 knockdown effects on migration in MDA-MB-231 cells

Before 3D experimentation was undertaken, investigations into the effects of SerpinB2 knockdown on MDAMB-231 cell migration on collagen I was employed. MDA-MB-231 cells were used as these express SerpinB2
(see Fig. 5.2). Wound healing assays showed that through separate Dox induced GFP- (Fig 5.7, A) and
SerpinB2-hairpin (sh1C1 Fig 5.7, B; sh2A2 Fig 5.7, C) production in MDA-MB-231 cells, there were no
significant differences recorded on cell migration between either ±Dox induction of individual hairpins or
between cohorts (Fig. 5.7). Trends towards decreased wound healing rates in Dox induced MDA-MB-231 cells
across all cohorts were observed, however this slower migration rate was not dramatic or significant. Thus,
SerpinB2 knockdown in MDA-MB-231 cells had no effect on cell migration in a 2D collagen I wound healing
system. This is unlike the effects observed in fibroblast 2D migration experiments (see Chapter 3, refer to
secion 3.3.3)
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Fig 5.7. Effect of SerpinB2 knockdown on the migration of MDA-MB-231 cells. Comparative time-course of migration of
stably transduced MDA-MB-231 cells measured using IncuCyte ZOOM (Essen Biosciences). Constructs tested were A. MDA-MB-231
shGFP ±Dox, B. MDA-MB-231 SerpinB2 sh1C1, and C. MDA-MB-231 SerpinB2 sh2A2. Images were processed using IncuCyte
ZOOM system and wound regions were measured using automated analysis. Relative Wound Density (%, value of 0 = no migration, value
of 100 = completed migration, when the cell density inside the wound is the same as the cell density outside the initial wound). Each point
represents the mean of 8 or 16 wells with the vertical bars showing the ±SD.
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5.3.5

SerpinB2 knockdown effects on MDA-MB-231 3D organotypic invasion

Next the effects of SerpinB2 knockdown in MDA-MB-231 cells was tested in the 3D organotypic invasion
assay. Over a 14-day invasion period MDA-MB-231 cell invasion into matrices formed by TIFs was not
significantly different between +Dox or no Dox induction of individual hairpins, and not significantly different
between any of the cohorts (Fig. 5.8). shGFP MDA-MB-231 cells [(+ Dox = 320.6 µm ± 20.64 invasion
distance, versus no Dox = 314.3 µm ± 16.49 invasion distance) (Fig. 5.8 A,D; P = 0.8123)] were not
significant to either SerpinB2 sh1C1 MDA-MB-231 cells [(+ Dox = 329.8 µm ± 12.31 invasion distance,
versus no Dox = 302.3 µm ± 13.78 invasion distance) (Fig. 5.8 B,D; P = 0.1473), or SerpinB2 sh2A2 MDAMB-231 cells [(+ Dox = 337.1 ± 12.32 invasion distance, versus no Dox = 330.3 ± 10.84 invasion distance)
(Fig. 5.8 C,D; P = 0.6788)] within TIF constructed collagen I matrices (Fig. 5.8). The similar invasion distance
detected between cohorts potentially indicates that intracellular SerpinB2 does not affect epithelial invasion into
TIF contracted collagen I matrices. Further, no significant difference was observed in invading MDA-MB-231
cell morphology and migration mode between any of the SerpinB2 or GFP control hairpins (data not shown).
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Fig 5.8. SerpinB2 KD MDA-MB-231 cell invasion through TIF/collagen I matrices. Photomicrographs of H&E stained
sections of organotypic cultures showing invasion of A. shGFP MDA-MB-231 cells (± Dox), B. sh1C1 MDA-MB-231 cells (± Dox),
and C. sh2A2 MDA-MB-231 cells (± Dox) through collagen I matrices formed in the presence of TIFs. D. Invasion distance analysis
was performed on images taken at sites of maximal invasion after 14 days, using 15 fields of view. Individual values are shown with
bars representing mean ± SEM from 4 separate matrices. Statistical analyses were performed using unpaired t-tests.

5.3.6

Pilot 3D invasion assays with highly metastatic MDA-MB-231HM cells

To determine the invasive potential of MDA-MB-231HM cells through TIF or wild-type MEF constructed
collagen I matrices, the 3D organtoypic method was employed. Both 7- and 14-day invasions were undertaken
in order to identify the optimal time length for invasion experiments. After both 7- and 14-days, MDA-MB231HM cells invaded into matrices (Fig. 5.9), however 14-day invasion periods resulted in obvious and
maximal differences for this cell type. Interestingly, MDA-MB-231HM cells invaded further into TIF matrices
than wild-type MEF matrices over a 14-day invasion period, potentially due to species specificity. Also of note,
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the parent MDA-MB-231 cell line did not invade into TIF or wild-type MEF matrices after 7 day invasion
period (data not shown).

Fig. 5.9. MDA-MB-231HM invasion through TIF and wild-type MEF constructed collagen I 3D organotypic
matrices. Photomicrographs of H&E stained sections of 3D organotypic cultures showing invasion of MDA-MB-231HM cells
through either (A-B) TIF or (C-D) wild-type MEF constructed collagen I matrices over a 7 or 14-day time period. Each image
represents a separate matrix.
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5.3.7

High metastatic MDA-MB-231HM cells in wild-type and SerpinB2-/- MEF

constructed collagen I organotypic matrices
As it was earlier confirmed that MDA-MB-231HM cells express negligible levels of SerpinB2, the stromal
contribution of SerpinB2 to the invasion process of these cells within the TNBC microenvironment could be
determined without potential confounding effects of epithelial cell SerpinB2 expression. Invasions using the 3D
organotypic system were undertaken over both 7- and 14-day time periods. After 7-days invasion, MDA-MB231HM cell invasion through matrices formed by SerpinB2-/- MEF matrices was 4.37-fold greater than invasion
of wild-type MEF matrices (36.02 % ± 1.67 versus 8.24 % ± 3.37; P < 0.0001) (Fig. 5.10, A-C). After a 14day invasion period, MDA-MB-231HM cell invasion through matrices formed by SerpinB2-/- MEF matrices was
2.87-fold greater than epithelial invasion through wild-type MEF matrices (45.39 % ± 3.51 versus 15.79 % ±
1.6; P < 0.0001) (Fig. 5.10, D-F).
There was no significant difference observed in invading MDA-MB-231HM cell morphology or migration
modality in matrices formed by SerpinB2-/- MEFs versus wild-type MEFs. MDA-MB-231HM cells invading
through either matrix exhibited a predominantly amoeboidal phenotype (refer to photomicrographs in Fig.
5.10).
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Fig. 5.10. MDA-MB-231HM cell invasion through wild-type and SerpinB2-/- MEF/collagen I matrices. A-B:
Photomicrographs of pan-cytokeratin stained sections of organotypic cultures showing invasion of MDA-MB-231HM cells over a (AB) 7-day or (D-E) 14-day time period through collagen I matrices formed in the presence of either (A,D) wild-type or (B,E)
SerpinB2-/- MEFs; C,F. Invasion index - calculated as the percentage of MDA-MB-231HM cells invading the matrix relative to MDAMB-231HM cells present in the layer overlaying the matrix. Analysis was performed on images taken at sites of maximal invasion after
7- or 14-days, using 10 fields of view. Individual values are shown with bars representing mean ± SEM from 3 separate matrices.
Statistical analyses were performed using unpaired t-tests.
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5.3.8

Mammary tumour growth and local invasion in vivo

After recording such significant invasion differences in our 3D model, these cells were then utilised in an animal
model. To determine whether SerpinB2 absence in MEFs would affect TNBC tumour growth and local invasion
in vivo, a xenograft mixed cell experiment was performed, where MDA-MB-231HM cells and MEFs (wild-type
or SerpinB2-/-) were co-injected into the 1st mammary gland (IMFP) of four week old old female Balb/c nude
mice. A 3:1 MEF:MDA-MB-231HM ratio was utilised as this is clinically representative and allows for the
formation of a pathophysiologically relevant TNBC TME (636,637). Fifteen days post inoculation, TNBC
tumours formed with SerpinB2-/- MEFs were significantly larger (and increasingly oblate spheroid) than those
formed with wild-type MEFs (mean volume 114.5 mm3 ± 7.812, versus 60.98 mm3 ± 5.230 respectively, P =
0.0005; Fig. 5.13).

Fig. 5.11. In vivo mixed cell mammary xenograft model. A. A mixture of MEFs (wild-type or SerpinB2-/-) and MDA-MB231HMs (at a 3:1 MEF:MDA-MB-231HM ratio) were inoculated into the IMFP of the 1st mammary gland of nude mice and allowed
to grow for 15 days. B. Analysis of tumour volume (mean ± SEM, n = 5) was undertaken daily starting from day 2, when tumours
were palpable. C. Quantification of tumour volume after 15 days. Individual values shown are tumour volume measurements taken
from 5 animals per group with mean ± SEM denoted. Statistical analyses were performed using unpaired t-tests.
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These data suggest that SerpinB2 deletion in stromal cells is more influential upon breast tumour invasion. The
decreased tumour-associated SerpinB2 levels in this system reflected a decreased host response to a rapidly
growing and potentially invasive TNBC tumour (Fig. 5.11). Ethical endpoint at day 15 was only an issue for the
SerpinB2-/- MEF cohorts, concurring the protective effect of SerpinB2 overexpression in cancer seen by many
in the field (6,19,98).
5.3.9 Pilot 3D Organotypic breast tumour spheroid invasion assay
In order to make the 3D organotypic model more recapitulative of the human situation, a pilot experiment was
undertaken. The initial aim was to understand primarily if it was feasible for tumour spheroids to both survive
and invade within collagen I beds. Initially, after talks with PhD colleague, James Conway (The Kinghorn
Cancer Centre, Sydney, NSW), MCF-7 breast cancer cells were employed to determine whether they would
survive, and potentially migrate through the collagen matrices. After matrix contraction and a subsequent
liquid-air interface invasion period, the matrices were sectioned and it was observed that the spheroids were
both viable and migratory (Fig. 5.12).

Fig. 5.12. MCF-7 breast tumour spheroid invasion through TIF/collagen I matrices. A-B: Photomicrographs of H&E,
Picrosirius red and Ki-67 stained sections of organotypic cultures showing MCF-7 breast tumour spheroids within collagen I matrices
formed in the presence of TIFs. Photomicrographs were obtained at 20 x magnification.

This experimental idea was then applied using MDA-MB-231HM, MCF-7 and SK-BR-3 breast tumour
spheroids in TIF/collagen I matrices, with the addition of ± 500 nM SerpinB2 (Fig. 5.13). Examination of
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H&E, pan-cytokeratin, Picrosirius red and Ki-67 stained sections did not show any significant differences
between invasions with or without 500 nM SerpinB2. This experiment revealed that the breast cancer cells
invaded out from the spheroid and that this experimental model is viable and requires further testing.

Fig. 5.13. MDA-MB-231HM, MCF-7 and SK-BR-3 breast tumour spheroid invasion through TIF/collagen I
matrices. A-B: Photomicrographs of H&E, pan-cytokeratin, Picrosirius red and Ki-67 stained sections of organotypic cultures
showing invasion of MDA-MB-231HM MDA-MB-231HM, MCF-7 and SK-BR-3 breast tumour spheroid cells over a 2-day time
period through collagen I matrices formed in the presence of TIFs. Photomicrographs were obtained at 20 x magnification.

5.4 DISCUSSION
Breast Cancer (BC) is the most common type of cancer in women world-wide and the incidence is only
increasing (611). Approximately 10-12% of BCs are TNBCs, which are usually more invasive and have a poorer
prognosis than the majority of other BC sub-types (601), thus it is essential to understand the aetiology of these
tumours. The advancement of TNBC marks a critical phase in breast cancer evolution, wherein dynamic
tumour-stroma interactions are in constant interplay and affecting host response and treatment efficacy. Direct
genetic mutations, deletions, amplifications have all been demonstrated to play an important role in the
progression and metastasis of TNBC (616). Thus, tumour-stroma studies are essential for understanding TNBC
biology in order to attain a deeper knowledge off all the key players and further develop therapeutic strategies
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for TNBC patients. This chapter outlines the development of a TNBC model to investigate the effects of
SerpinB2 modification on TNBC (MDA-MB-231 and MDA-MB-231HM cell) invasion. Initially, analysis of
SerpinB2 expression within both mammary epithelial and fibroblast cells was undertaken. It was shown that all
normal (yet transformed) human mammary epithelial cell lines expressed SerpinB2 and human mammary basal
carcinoma cell epithelial lines expressed moderate to high levels of cleaved SerpinB2 (refer to Fig. 5.4).
Conversely, the entire collection of human mammary luminal carcinoma cell lines tested (T-47D, MCF7,
MDA-MB-134, MDA-MB-175, MDA-MB-330, MDA-MB-361, BT483, BT474) expressed low to negligible
levels of SerpinB2 (refer to Fig. 5.4). This is interesting because high SerpinB2 expression levels are associated
with recurrent free patient survival in both Luminal A and B sub-types (Fig. 5.3, E), which infers that luminal
BCs benefit without intratumoural SerpinB2 expression. Potentially, luminal BCs require control over PAS
activation in order for tumour progression (to activate endothelial cells and/or migrate further etc.), as they
have the basal myoepithelial layer as an additional barrier before the basement membrane and mammary ECM.
Alternatively, it has been reported that luminal epithelial cells display reduced polarity due to the loss of
myoepithelial cells within luminal tumour systems, which leads to progression and invasion via collective cell
migration (638). These results also suggest that perhaps it is not so much a function of the epithelial cellular
expression of SerpinB2 that drives invasiveness, but a stromal component. Indeed, this remodeled TME would
definitely benefit the tumour without uPA inhibition. Thus, the 3D organotypic culture system was used to
interrogate the role of SerpinB2 in BC development and invasion. These models were efficaciously used to
elucidate SerpinB2 effects in a context-dependent manner and demonstrated that endogenous SerpinB2 activity
is not required for MDA-MB-231 invasion in vitro or ex vivo (refer to Fig. 5.7). Potentially, the endogenous
SerpinE1 that is still expressed within SerpinB2 shRNA MDA-MB-231’s may be compensatory. However, these
unexpected results infer that epithelial cell invasion does not require SerpinB2 for invasion through collagen I
matrices in both an ex vivo or in vitro system. This result was made even more interesting when using the higher
metastatic daughter line, MDA-MB-231HM, for proceeding experimentation. The rationale being that this cell
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line expresses no apparent SerpinB2 or SerpinE1 (refer to Fig. 5.5). After initial pilot experiments (14 days was
optimal; refer to Fig. 5.9) through TIF and wild-type MEF matrices, MDA-MB-231HM cells were found to be
1.6-fold more invasive than the parent MDA-MB-231 line, and thus ideal for this 3D invasion model. These
cells were employed in order to understand the role of SerpinB2 in TNBC biology. As it is critical to consider
functional effects in each cellular compartment of tumour tissue, MDA-MB-231HM cells were used in
experiments with wild-type and SerpinB2-/- MEF matrices. This was ideal as there was little to no SerpinB2 in
the system for these assays (MDA-MB-231HM/SerpinB2-/- MEF matrices) and this approach yielded valuable
information, highlighting the stromal SerpinB2 effects influencing upon tumour cell invasion. Even though both
wild-type and SerpinB2-/- MEF ECMs allowed efficient MDA-MB-231HM invasion, the disordered collagen
networks of matrices generated by SerpinB2-/- MEFs (refer to Chapter 3, section 3.3.4) increased MDA-MB231HM penetration by nearly 3-fold (after 14 days; refer to Fig. 5.10). Thus, without fibroblastic SerpinB2
expression, it appears that MDA-MB-231HM cells can invade collectively (ameboidal-based migration) and
further within collagen I matrices, which was similarly reported in the PDAC cell invasion experiments (refer
to Chapter 4, section 4.3.2).

On the basis of the insignificant invasion distances between the parent line MDA-MB-231 SerpinB2 knockdown
cohorts (refer to Fig. 5.8), coupled with an increase of invasion using the MDA-MB-231HM cells (lacking
SerpinB2 expression; refer to Fig. 5.10), in vivo testing was undertaken. A significant increase in tumour
volume (1.88-fold) was recorded in mice with SerpinB2-/- MEF tumours versus mice with wild-type MEF
tumours (Fig. 5.11), potentially demonstrating an active CAF phenotype related to SerpinB2 absence within the
TME. Unfortunately time constraints did not allow for further post-hoc analyses of tumours, and only tumour
volume was quantified in this experiment. Nonetheless, the tumour volume differences recorded were
extremely significant and may be due, at least in part, to the serpin function of wild-type MEFs. This is
supported by data showing that epithelial SerpinB2 knockdown in MDA-MB-231 cells does not alter invasion
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into collagen I matrices (Fig. 5.8), while MDA-MB-231HM invasion into MEF constructed collagen I matrices
is higher without fibroblastic SerpinB2 expression (Fig. 5.10). Thus, these data infer that stromal cell SerpinB2
activity potentially reduces the invasive and metastatic capacity of breast tumours. The efficiency of tumour
growth in this in vivo model was potentially affected by interplay of both proteolysis and local ECM
remodelling, reducing physical hindrance of the surrounding stroma by MEFs lacking SerpinB2 (Fig. 5.11).
Similarly, as was observed in Chapter 4 (refer to section 4.3.4), within the in vivo PDAC allograft model, the
increase in MDA-MB-231HM tumour growth in the SerpinB2-/- MEF cohorts suggest that MDA-MB-231HM
progression and local invasion is increased when there is less desmoplasia/collagen coverage surrounding the
primary tumour mass. Although not tested here, the invading cells from tumours with SerpinB2-/- MEFs seem
to increase cell type-specific signalling within the TME, affording increased tumour growth rates. Future
tumour studies utilising both MDA-MB-231 and/or MDA-MB-231HM cells with SerpinB2-/- MEF in to look at
metastases in this model would be ideal to ascertain whether SerpinB2-/- MEF tumours have increased
metastatic capactiy.
3D Organotypic results in this chapter show that collective, amoeboidal cell migration was predominant in both
wild-type and SerpinB2-/- MEF collagen I matrices. This has also been reported by Wolf et al. (2003) where
MMP inhibition did not impede MDA-MB-231 cell migration through collagen I matrices, with cells invading in
an ameboidal migration modality (639). Whether this is a compensatory mechanism by MDA-MB-231 cells or
perhaps a transition from proteolytic mesenchymal migratory phenotype towards a non-proteolytic amoeboidal
movement mode is unclear, however it highlights the supramolecular plasticity of breast tumour cells to
facilitate a migratory mechanism even after abrogation of pericellular proteolytic pathways.
Furthermore, the pilot 3D breast spheroid model was successful in showing that breast tumour spheroids can be
utilised in this organotypic format. The invasion period was only 2 days, which is potentially why the addition
of 500 nM SerpinB2 had no significant observable effect on the invasion of breast cancer cells. Nonetheless, this
experimental model is feasible and should be repeated. Moreover, the addition of tumour-associated
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macrophages (with modified expression levels of SerpinB2) would act as a biomimic for TME even more so and
has been done by others. Dwyer et al. (2016) recently showed invasion in their co-culture spheroid model
utilising PyVmT mouse mammary tumour-derived cells and mouse bone marrow-derived macrophages (640).
Embedding of these “mammospheres” within Matrigel beds lead to invasion of both breast tumour cells and
macrophages into the surrounding matrix (640). Utilising 3D live imaging on both breast and pancreatic
spheroid organotypic invasions is now a viable experimental apparatus for our laboratory and one that should be
definitely utilised.
In addition, not only do spheroid organotypic invasions recapitulate the human situation, the individual tumour
cells of a spheroid will have a greater ability to infiltrate interstitial collagen networks without necessitating
proteolytic remodeling and classical EMT pathways [(584) and refer to section 4.4 for more references]. It has
been reported that dissemination of a primary tumour mass of ~1 cm size (corresponding to ~1 × 109 cancer
cells) can supply the circulatory system with one million tumour cells each day (641). However, subsequent
extravasation and secondary site colonisation is limited because of incompatible distal tissue beds. Perhaps
SerpinB2 expression within these metastatic populations can assist in cytoprotection in these new environments
(164,305), but more often than not, SerpinB2 expression is downregulated in metastatic cells of secondary
tumour sites.
As aforementioned, experimentation by Finak et al. (2008) reported that SerpinB2 expression within isolated
human breast tumours was ~16-fold decreased within invasive carcinoma compared with matched normal
breast stroma (P < 0.0001, n = 1440) (623). This reduction in SerpinB2 expression in invasive tumour stroma
compared with normal breast stromal tissue over such a large cohort provides strong evidence that SerpinB2
deletion within stroma promotes breast cancer progression. Possibly, without SerpinB2, stromal remodelling
around breast tumour tissue sites promotes tumour growth and invasion through a loose extracellular matrix
phenotype, and may define disease progression and metastatic lesion development. Indeed, from the data
presented in this chapter, and that within Chapter 4 (PDAC chapter), it is hypothesised that the apparent lack
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of mechanical forces between the cells and the ECM allows for collective amoeboidal tumour invasion and
demonstrates the cell plasticity to adapt to a defunct tensional landscape, allowing for dramatic increases in
breast tumour size and invasion. Therefore, the transition to an invasive phenotype appears to be in part a
mechanical one, aided by the surrounding tissue compliance of breast tumour systems. The deregulated ECM in
breast tissue around these tumourigenic sites is a complex process requiring elucidation, which the SerpinB2
models appear to be useful for isolating specific elements of the mammary TME, allowing for the dissection of
PAS componency in tumour versus stromal tissue. The changes in the stroma surrounding tumours is largely
due to the actions of activated myofibroblasts/CAFs in the stroma (23,642-644). It is still unclear in the field
whether or not CAFs are resident fibroblasts, activated by paracrine cytokines and growth factors, or whether
they are of mesenchymal stem cell origination that are genetic precursors to fibroblasts and are reverted to
fibroblast-like cells within the breast TME (645). Certainly, isolating individual cell types from tumour extracts
is a difficult task. The unique and variable proportion of stromal and epithelial cells in patient extracted tumour
tissue can sometimes not provide information on the actual levels or proportion of each protein produced by
specific cellular compartments. Additionally, the relative contribution of specific cellular secretions (whether
from tumour cell, stromal or immune cell) affecting tumour progression is assumed. It is not possible to know
what particular gene expression change has occurred in a specific cell of origin and it must not be assumed that
all cell types of a tumour extract are expressing this same genetic alteration. Additionally, only approximately
50% of BC tumour masses are composed of epithelial cells (646), thus there is a dire need for better
classification of expression signatures. This pitfall needs to be addressed either through state-of-the-art cellsorting technology, or through categorisation of the specific genetic signatures of cell types (647), or in patients
and their treatment responsiveness to adjuvant or neo-adjuvant therapy, which is currently underway (648).
SerpinB2 expression and quantification within stroma of clinical samples is warranted, and it would be ideal to
see if there is a relationship between tumour stage and stromal SerpinB2 expression, as well as metastasic site
SerpinB2 expression level vesus primary tumour SerpinB2 expression level.
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The results of this chapter demonstrate that there is immense potential for the development and future
utilisation of SerpinB2 re-introduction into specific BC TMEs. SerpinB2’s relatively small size,
immunoneutrality and proven in vitro and in vivo targeting ability, provide it with rapid internalisation through
RME, beneficial for therapeutic regimen (19,130). With a better understanding of the signaling mechanisms
most vital in the development and perpetuation of TNBC, particularly within the stroma, drug design and
development can be enhanced with clearer rationale, affording increased ECM targeting, drug synergism and
overall better outcomes for TNBC patients. Future treatments for TNBC cancer must reflect the critical
pathways in an individual patients tumour tissue, to inhibit growth, progression, and perpetuation of the
tumour stroma. The results of this chapter and many research groups, support a role for PAS in TNBC
malignancy (649,650), thus in the pursuit of greater clinical efficacy and personalised treatment regimen, our
laboratory has been attaining deeper understanding of the tumour stroma in a TNBC specific context, and
optimising drugs to target PAS in these systems. In this regard, a uPA targeted combinatorial therapeutic could
offer increased efficacy upon invasive BC tumour cells. As it has been shown that high levels of SerpinB2 do not
produce any apparent associated health risks (626), this may allow for the simultaneous IV-administration of
both free SerpinB2 and SerpinB2 drug formulations, which could improve the outcome for cancer patients at
high yet tolerable concentrations. Moreover, SerpinB2 has been shown by our laboratory to have inhibitory
effects on endothelial cell (EC) tubule formation at high concentrations, which is possibly linked to the
reduction of plasmin generation and MMP knock on effects in activation of key growth factors such as bFGF,
VEGF, PDGF and TGF-β. bFGF, VEGF, HGF and PDGF stimulate EC proliferation, migration and integrin
expression and TGF-β enhances EC differentiation (651-656). Notably, HGF and bFGF can also stimulate ECs
to produce uPA, further inducing ECM degradation and promoting the plasmin positive-feedback loop (651)
Extracellular growth factors, as well as uPA, bind to cell surface receptors, enhancing and inducing the
downstream activation of intracellular signalling cascades by prolonging tyrosine phosphorylation, which leads
to the transcriptional activation of genes that express other growth factors (657). Moreover, activated ECs
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recruited in the establishment of angiogenesis, facilitating tumour metastasis, have been shown to up-regulate
uPA and uPAR (29).

Through a combined understanding of PAS functioning in diseased systems and concurrent drug design and
development, our laboratory is enhancing understanding of TNBC biology and leading the way in uPA/uPAR
targeting drug-loaded nanoparticle systems. Previously, our laboratory has shown that through the utilisation of
a uPA targeting moiety, a highly cytotoxic anti-mitotic drug (N-AI) can be specifically delivered to, and kill,
cancerous BC cells, while unaffecting normal, healthy tissue (129). Current in vitro and in vivo studies have
proved promising, demonstrating specific and enhanced efficacy of SerpinB2 drug conjugates over their unconjugated free drug counterpart (130). It is hypothesised that the selective targeting of different BC cell
subtypes using a SerpinB2 prodrug formulation will provide a means to treat multi-drug resistant tumours in
uPA-positive BC. There are multiple benefits available with this targeted approach: firstly, through an enhanced
efficacy of the drug due to its targeted, receptor specific delivery; and secondly, by the decrease in systemic
toxicity and side-effects due to the targeted drug only being activated at the site of interest (130). The
mechanism of N-AI relies upon the destabilisation of microtubules, causing G2 and M phase arrest, inhibiting
the normal function of mitosis (130,658). As such, the more proliferative a cell line, the more susceptible it is
to N-AI during mitosis and cytokinesis, where tubulin polymerisation and microtubule formation is largely
required, which produces a greater cytotoxic effect, hence ideal for most tumour systems (131).
Additionally, as PAS is also upregulated by activated endothelial cells, as found in angiogenic vessels; a SerpinB2
drug approach may additionally be very useful against angiogenesis. At present, there are many phase I and II
clinical trials underway utilising monoclonal antibodies (WX-671/Mesupron and WX-UK1, respectively)
which target uPA and interfere with the growth, spread and metastasis of solid malignant tumours (21). To
date, there have been promising results in reducing metastatic spread and extending the lifespan of breast or
pancreatic cancer patients (21). However, monoclonal antibodies are expensive to synthesise, meaning dosage
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regimes are not affordable for many cancer patients. Additionally, several drugs targeting uPA have been
reported to lack the specificity required to only interact with tumour-associated uPA, causing significant side
effects (21). The production of the naturally occurring SerpinB2 ligand, conjugated to a potent cytotoxin that
specifically targets uPA, would offer a more cost effective way to target uPA positive cancers and potentially
reduce side effects. Conversely, the biggest problem with uPA targeting drugs is the interaction that can occur
with healthy tissue, since uPA can be expressed and secreted by normal cells, supporting fibrinolysis, tissue
remodeling, vessel growth or wound healing. (81,659). To overcome this, experiments need to be conducted
on different cancer types that are uPA expressive in order to determine when non-preferred uPA interaction is
not a problem and what type of patients will benefit the most from uPA-specific targeted cancer therapy (219).
Albeit costly and time consuming, in vivo tests are warranted from the findings in this work and are essential
because of the complex nature of vascular responses to test reagents, of which no in vitro model has the capacity
to determine. This study provides deeper insight and impetus to further develop and test our laboratory’s
SerpinB2 cancer drugs upon in vivo in order to determine their potential therapeutic targeting in the inhibition
of breast and other cancer types.
Finally, this chapter confirms SerpinB2’s significant role in the progression of breast cancer invasion and
metastasis, providing valuable information of TNBC biology. This work validates our laboratory’s design and
testing of SerpinB2 drug conjugates as potential chemotherapy options for both primary, metastatic and
angiogenic cells, offering great potential therapeutic value in the future.
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CONCLUSIONS AND FUTURE DIRECTIONS
The findings in this thesis confirm SerpinB2 as a powerful modulator of the growth, progression and local
invasion of both breast and pancreatic cancer. Through the utilisation of both in vitro and in vivo 2D and 3D
imaging technology this study examined cancer progression at a sub-cellular and molecular level. We used both
3D organotypic matrices and in vivo models and advanced imaging approaches to decipher the cellular migration
and tumour progression of both epithelial and stromal cell types, in which SerpinB2 expression was also
modified. This approach allows for the real-time in vivo assessment of single-cell migration and invasion events,
enabling the understanding of how tumour and stromal cells interact. Through elucidation of critical
checkpoints (i.e. ECM remodeling, cell migration and local invasion) within these systems, a deeper knowledge
of the effects of PAS regulation on breast and pancreatic cancer progression has been discovered. It is clear that
without SerpinB2 in fibroblasts, the key cell component coordinating the majority of stromal remodeling within
the TME of solid tumours, a diffuse stroma is generated, which can be infiltrated with both greater ease and
collectively by both TNBC and PDAC cancer cells (Fig. 6.1). These findings provide strong evidence for a role
for both SerpinB2 and uPA/uPAR in TNBC and PDAC stroma and certainly require further investigation. As
such, this work opens up the potential for developing uPAS-targeted therapeutics for molecular subtypes of BC
(personalised medicine) with enhanced activity and efficacy. Further understanding into the biochemical
functioning of PAS in these (and other) contexts will help facilitate the design of novel therapies, offering
structural and functional information for more efficient tumour-stroma targeting strategies.
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Fig 6.1. Schematic representation of the proposed effects of SerpinB2 within the TME. The TME with (A) and without
(B) SerpinB2 expression. Tumour epithelial cells (blue) are able to degrade the basement membrane and invade into the underlying
ECM with the help of CAFs (orange). The stromal composition of the SerpinB2 null/reduced ECM is decreased in stiffness and less
occupied by collagen I networks allowing greater migration of tumour cells in (B).

Through the implementation of Gateway lentiviral systems for both overexpression and attenuation of SerpinB2
gene expression, the potential for development of SerpinB2 gene therapies was demonstrated and should be
exploited as a targeted cancer therapy approach in the future. Lentiviral vectors provide a powerful method to
inducibly manipulate SerpinB2 in both epithelial and fibroblast cell types. With the ability to over-express and
knockdown genes of interest in a temporal, spatial, and cell-type specific fashion, this inducible genetic
approach can not only help elucidate differential roles of SerpinB2 in the TME, but also could be used for gene
editing. The use of CRISPR offers greater fidelity over lentiviral systems and could potentially revolutionise
gene therapy, not just within the cancer arena. There are obviously beneficial applications for this within
clinical studies, such as fibroblastic SerpinB2 modulation. The constructs produced herein could either be
utilised directly or as a guide for future CRISPR work in the modification of SerpinB2 in other cell types and
research platforms, including those used to study tumour-stroma interactions within pancreatic and breast
cancer (refer to chapters 4 and 5, respectively).

221

Collectively, the findings in this thesis highlight the possibility that there are broader biological implications in
stromal remodeling of SerpinB2. Potential associations between FAKs and TG2 are possible, and these
explanations require elucidation. In the collagen contraction model, SerpinB2-/- MEFs potentially exhibit
decreased integrin (α2ß1) binding (without TG2-fibronectin/fibrin/integrin bond stabilisation), reducing FAK
(Vinculin, Paxillin and FAK) activation/phosphorylation, attenuating actin re-organisation and eventually ECM
remodelling, causing changes in cellular adhesion, proliferation, migration and cell survival. Future
experiments are required to investigate this further. Interestingly, actin-related protein 2/3 complex subunit
1B (ARPC1B) was present at twice the amount compared to that of wild-type matrices, as assessed by LC/MS.
This increase was potentially to compensate for the decreased LOX pathway activity (refer to Fig. 3.10) as
ARPC1B is a subunit of the Arp2/3 complex, involved in regulation of actin polymerisation and formation of
branched actin networks. Welch et al. (1997) showed that Arp2/3 complex is localised to the lamellipodia of
both stationary and motile fibroblasts and suggested that this complex promotes both actin assembly in
lamellipodia and could facilitate lamellipodial protrusion (469). This 2-fold increase in SerpinB2-/- MEF
ARPC1B level is potentially associated with the 0.7-fold up-regulation of actin within SerpinB2-/- MEF matrices
(refer to Fig. 3.10) and may be a compensatory mechanism to stimulate proper fibroblast lamellipodial
protrusion for adequate ECM remodelling. Thus, SerpinB2-FAK association studies are warranted.
Cell-cell and cell ECM signaling in the stroma and subcellular locations within both breast and pancreatic
cancer (and probably other cancer types) may involve SerpinB2, with strong biological implications. The
aspects of stromal biology that appear to aid both PDAC and TNBC tumour progression and invasion within
our models involve collagen cross-linking and alignment, matrix stiffness and the influx and potential crosstalk
of various tumour and stromal cells. Moreover, the observation that pancreatic and breast stromal density
affects local invasion is clinically relevant and loose and stiff stromal ECM will become increasingly appreciated
as influencing the initiation of metastases in both breast and pancreatic carcinomas. The challenge going forward
is to determine a reliable diagnostic assay for both the presence of specific PAS biomarkers as early as possible,
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and also in particular, for the assessment of collagen density and alignment within a patient’s TME. This has the
potential to assist surgeons and oncologists, for application during both biopsy and surgical resection, as SHG
microscopy utilised for such imaging does not require any labeling and can be performed rapidly on fresh,
unstained tissue. Already, collagen deposition and fibril alignment as a biomarker is paired with the
determination of specific biomarkers (660). Further understanding of the contextual role of collagen deposition
with the ECM of both breast and pancreatic cancer in facilitating tumour cell invasion is required and will
present new opportunities to diagnose, predict and treat many different cancer types.

The biological implications of these thesis findings also have the power to deliver substantial improvements in
patient prognostic outcome and predicting therapeutic response. There is potential that these stromal processes
around tumour sites during specific ECM events could be manipulated via PAS regulation to increase clinical
efficacy, particularly in identified patients with high uPA/uPAR. However, prior to such testing, the prognostic
significance of cellular SerpinB2 expression within cellular and ECM events identified in this study must be
elucidated clinically. The decreased survival of 1.6 years in patients with high uPA expressing PDAC tumours is
testament to the significant effect of PAS in tumour aggression and metastatic potential, and this increases the
likelihood that these data presented will be corroborated in clinical data. Considering the potent activity of
SerpinB2 to inhibit the aggressive PDAC line in 3D organotypic matrices, subsequent experiments were
undertaken in an effort to further ascertain the stromal versus epithelial cell effects of SerpinB2. Dramatic
differences were seen in SerpinB2-/- matrices, offering clues to SerpinB2’s role in stromal remodeling within the
TME. In order to further understand the effects of SerpinB2 on collagen cross-linking and the stromal
remodeling process, future SerpinB2-/- 3D models future experiments are required to essentially prove or
disprove this. Future work should include state-of-the-art imaging systems such as FRAP and FLIM–FRET, to
analyse SerpinB2-FAK co-localisation in fibroblast migration during both matrix contraction and PDAC/TNBC
invasion experiments. In addition, these imaging techniques have the power to examine anti-uPA drugs
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targeting the ECM, thereby offering early validation before more time-consuming, expensive and complex in
vivo assessment. Additionally, there is a dire necessity for increased examination and imaging of the stroma
around primary, peri-tumoural, micrometastatic and metastatic sites, as these zones still remain poorly
understood. This would be ideal for testing in SerpinB2-/- tissues and SerpinB2-/- mice, as these are
recapitulative of most highly invasive tumour systems and metastatic lesions, making it especially beneficial for
the development of new combinatorial treatments targeting uPA/uPAR and/or the stroma of inoperable
tumours.
Moreover, it would be extremely interesting to compare and contrast SerpinB2 expression (mRNA and
protein) in the tumour vs. stroma of the APGI PDAC tumours. To elucidate whether stromal SerpinB2
expression was associated with increased survival in the APGI cohort would be ideal. From the results obtained
in this project, it would be expected that high SerpinB2 expression specifically in the stroma of APGI PDAC
tumours would signify good prognosis, with less invasive tumours versus a low stromal SerpinB2 expression.
Therefore, future studies should examine SerpinB2 expression in both PDAC and TNBC tumours, where
cohorts are available. The functional effects of SerpinB2 in a cell-specific context could be directly addressed in
the APGI PDAC tumour cohorts. IHC for SerpinB2 in the stroma of this cohort could potentially be correlated
to local invasion and perhaps overall survival. Concurrently, this should also be performed for the TNBC
cohorts as available and stromal vs. cancer evaluation of SerpinB2 expression could be undertaken and
correlated to clinicopathological indicators and survival. This could one day lead to SerpinB2 expression in
stroma being utilised as a marker to personalise treatment for patients who have low or negligible levels of
SerpinB2 in stroma. Recombinant SerpinB2 could be administered as an ECM block on tumour invasion, as an
adjuvant to surgery and/or chemotherapy, as results within this project have illustrated. Furthermore, this
thesis offers insight and impetus for the potential use of SerpinB2 as a drug delivery system to target uPA
positive tumours and warrants further preclinical investigation (129-131). In this context, a SerpinB2
functionalised drug could be expected to exhibit an improved efficacy and in vivo, than corresponding free drug,
224

when administered to a patient with a uPA positive malignancy. In addition, the ex vivo results in this work
demonstrated that the organotypic assay system can provide high in vitro fidelity to support further in vivo drug
discovery. Despite great advances in 3D cell culture methodology, such as the organotypic model, it must also
be considered that matrix specific effects upon the movement of molecules through tissue beds at both a microand macroscopic scale will impact upon the spatial distribution of oxygen, growth factors, metabolites and
other signaling molecules (23). There are specific gradients of biological molecules within tissue beds
modulated by the vasculature, angiogenesis and the ECM (23). As such, not all cells in the TME of a solid
tumour are exposed to the same microenvironment and this diversity is a major factor contributing to the
heterogeneity of tumour and stromal cell populations in vivo (661). This is tremendously difficult to reproduce
in vitro and although it is not yet possible to recapitulate arterial blood flow within these 3D culture systems,
the inclusion of endothelial cells together with fibroblasts, either within the collagen I matrix or beneath it,
could allow for adequate angiogenic modeling, in conjunction with the investigation of tumour-stroma
interactions. Additionally, the supplementation of immune cells to the culture system is another important area
for development, as it is well known that T-cells and tumour-associated macrophages impinge upon cancer cell
biology. Previous studies utilising co-cultures of macrophages and tumour cells on collagen gel beds have shown
strong evidence of intercellular signaling loops that regulate 3D cell movement (565,662), and similar
experiments are achievable and should be investigated within our organotypic culture approach. As
demonstrated in Chapter 5 (refer to Section 5.3.7), a pilot 3D organotypic experiment was undertaken to
investigate the effects of tumour spheroids within the matrices. This model was successful and recapitulates the
human situation with greater biomimicry potentially allowing for increased therapeutic insight during drug
design. Future studies in our laboratory will utilise this 3D organotypic spheroid model and further optimise it
to be even more in vivo similar. Organotypic culture technology is fast becoming one of the most accessible and
physiologically relevant models to study TME dynamics of both tumour and stromal cells in a controlled
environment, and ECM equivalent matrices can be derived from a variety of sources, as exemplified by the
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thesis work presented herein. At present, there is much interest in 3D organotypic culture models and
commercial development of a more standardised, validated culture system would be extremely valuable in
ensuring that the organotypic system becomes more inclusive and accessible to a wider range of academic and
clinical scientists, thereby helping to maximise its potential. Through a more diverse yet defined ECM, specific
for each tumour context, coupled with the appropriate cell culture media, it is foreseeable that a highly
accurate, reproducible 3D organotypic culture model could emerge, potentially making it possible to offer real
time translational experimentation from bench to bedside. Through coupling these types of benchside culture
models with integrated analyses of a patient’s genomic, epigenomic and transcriptomic characteristics, there is
future therapeutic relevance and biological insights to be gained.
Most recently, a paper by Bailey et al. (2016), combining Australian researchers from the International Cancer
Genome Consortium has identified four distinct types of PDAC, arising from 32 recurrently mutated genes
from ten different cellular trigger points (663). These four subtypes identified were squamous, pancreatic
progenitor, immunogenic and aberrantly differentiated endocrine exocrine PDAC, based on the differential
expression of transcription factors and downstream targets in specific lineages during pancreas development and
regeneration (663). This elegant paper not only highlights the extreme complexity of PDAC, but also reveals
the fields increased appreciation of the role of the immune system in malignant progression. Immunotherapy is
now a rapidly growing field in in cancer therapy, both academically and commercially. Many new therapies are
specifically targeting mechanisms through which tumours evade the immune system. A large amount of clinical
trials are underway utilising immunotherapies both individually and combinatorially with current gold-standard
chemotherapies, with varied results of both increased and decreased efficacy. Indeed, patient selection is of, and
will remain to be, consistently important for efficacy of cancer therapeutic regimen. Direct differences in the
molecular evolution of a patient’s unique cancer subtype is required to identify the best pathway for therapeutic
success for every person.
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In conclusion, the results of this thesis offer further insight and understanding into the biochemical properties
and diverse cellular functions of SerpinB2. The relationships between SerpinB2 uPA inhibitory function and
ECM remodeling provide further rationale for the use of SerpinB2 as both a marker of invasive potential and
metastatic progression. These data impact on the potential future use of individual PAS components (i.e. uPA
and uPAR) as biomarkers in pancreatic and breast cancer patients who are potentially at a higher risk of
metastatic progression. Finally, these findings also further validate the importance for the continued
development of SerpinB2 as a targeted cancer therapeutic. Through the combined understanding of PAS
functioning and concurrent drug design and development, improved outcomes for cancer patients are surely on
the horizon.
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APPENDIX A
SOLUTIONS AND MEDIA
Buffers and Solutions
Phosphate Buffered Saline (PBS), pH 7.4
12 mM Na2HPO4
2 mM Na2HPO4
2.7 mM KCl
137 mM NaCl
Phosphate Buffered Saline (PBS), pH 8.5
12 mM Na2HPO4
2 mM Na2HPO4
2.7 mM KCl
137 mM NaCl
Hanks binding buffer, pH 7.4
0.98% (w/v) Hanks balanced salts
20 mM HEPES
1 mM CaCl2
1 mM MgCl2
0.1% (w/v) BSA
Sodium phosphate buffer
20 mM NaH2PO4
pH 6.0
HEPES buffer, pH 7.5
150 mM NaCl
20 mM HEPES

DNA Purification
Cell Resuspension Solution
50 mM Tris-HCl, pH 7.5
10 mM EDTA
100 µg/mL RNase A
Cell Lysis Solution
0.2 M NaOH
1% (w/v) SDS
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Bacterial culture media
Luria-Bertani Broth (LB)
1% (w/v) tryptone
0.5% (w/v) yeast extract
170 mM NaCl
LB Agar
1% (w/v) tryptone
0.5% (w/v) yeast extract
170 mM NaCl
1.5% (w/v) agar
Teriffic Broth (TB)
1.2% (w/v) tryptone
2.4% (w/v) yeast extract
0.4% (v/v) glycerol

Protein Purification
Binding Buffer, pH 7.0
50 mM NaH2PO4
300 mM NaCl
Wash Buffer, pH 7.0
50 mM NaH2PO4
300 mM NaCl
5 mM imidazole
Elution Buffer, pH 7.0
50 mM NaH2PO4
300 mM NaCl
150 mM imidazole

SDS-PAGE
4 X SDS Sample Buffer
20% (v/v) 1 M Tris-HCl, pH 6.8
8% (w/v) SDS
40% (w/v) glycerol
4% (v/v) 14.7 M β-mercaptoethanol
10% (v/v) 0.5 M EDTA
0.08% (w/v) bromophenol blue
10% Resolving Acrylamide Gel
25% (v/v) 37.5:1 bis/acrylamide
25% (v/v) 1.5 M Tris base, pH 8.8
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0.1% (w/v) SDS
0.04% (v/v) TEMED
0.1% (w/v) ammonium persulfate
5% Stacking Acrylamide Gel
12.5% (v/v) 37.5:1 bis/acrylamide
12.5% (v/v) 0.5M Tris base, pH 6.8
0.1% (w/v) SDS
0.1% (v/v) TEMED
0.1% (w/v) ammonium persulfate
SDS Running Buffer, pH 8.3
120 mM Tris base
120 mM glycine
2 mM SDS
Coomassie Staining Solution
0.2% (w/v) Coomassie blue R-250
40% (v/v) methanol
10% (v/v) glacial acetic acid
Coomassie Destaining Solution
40% (v/v) methanol
10% (v/v) glacial acetic acid

Ion-exchange chromatography
Start Buffer
20 mM Tris-HCl
pH 8.0
Elution Buffer
20 mM Tris-HCl
0.5 M NaCl
pH 8.0
Washing Buffer
20 mM Tris-HCl
1 M NaCl
pH 8.0
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Tissue Culture Media
MDA-MB-231 Tissue Culture Media
94% (v/v) RPMI Media
5% (v/v) foetal bovine serum
1% (v/v) glutamine
MDA-MB-231HM Tissue Culture Media
89% (v/v) RPMI 1640 Media
9 % (v/v) foetal bovine serum
1% (v/v) 1M HEPES Buffer
125 IU Insulin
PDAC R172H Tissue Culture Media
90% (v/v) DMEM Media
10% (v/v) foetal bovine serum
MEF Tissue Culture Media
90% (v/v) DMEM Media
10% (v/v) foetal bovine serum
Cell Freeze-Down Media
80% (v/v) RPMI 1640 or DMEM Media
10% (v/v) foetal bovine serum
10% (v/v) dimethyl sulfoxide
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APPENDIX B
IMMUNOFLUORESCENCE ANTIBODY CONTROL

Fig. A1. Immunofluorescence isotope controls. Immunofluorescence imaging of cryosections from wild-type or SerpinB2-/MEF:PDAC tumour allografts probed with Antibody isotype controls (IgG1, IgG2A). Merged images include DAPI nuclear staining.
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APPENDIX C
LIST OF ANTIBODIES
Table A1. Antibodies used for immunohistochemistry, immunofluorescence and western blotting.

Antigen
Actin

Antibody
description
Mouse monoclonal,
recognises multiple
species (IgG1)

Antibody
supplier &
catalog #
Abcam;
ab3280

Antibody
dilutions
used
IF: N/A
IHC: N/A
WB: 1:2500

Secondary antibodies2

Anti-mouse IgG-HRP3

Murine αsmooth muscle
actin

Mouse monoclonal,
cross-reacts with
human (IgG2A)

Abcam;
ab7817

IF: 1:500
IHC: N/A
WB: N/A

Human Ecadherin

Mouse monoclonal,
cross-reacts with
mouse (IgG1)

BD
Biosciences;
610181

IF: N/A
IHC: 1:200
WB: N/A

Murine Ncadherin

Rabbit polyclonal,
cross-reacts with
human (IgG)

Santa Cruz;
SC-7939

IF: N/A
IHC: 1:200
WB: N/A

Chicken IgG

Mouse monoclonal
(IgG1)

Negative control antibody - diluted to the
same concentration as the test antibodies

Human cleaved
caspase-3

Rabbit polyclonal,
cross-reacts with
mouse (IgG)

Merck
Millipore;
MABC002
Cell Signaling;
#9661

Human Ki67

Rabbit monoclonal
(IgG)

Murine MultiCytokeratin

Mouse monoclonal
(IgG1)

Thermo
Scientific;
RM9106-S1
Novocastra;
NCL-C11

Naïve rabbit
sera Rabbit
Murine
SerpinB1

Rabbit polyclonal
(IgG)
Rabbit Polyclonal
(IgG)

IF: N/A
IHC: 1:500
Goat–anti rabbit IgG-HRP
WB: N/A
IF: N/A
IHC: 1:500
Goat–anti mouse IgG-HRP
WB: N/A
Negative control antibody - diluted to the
same concentration as the test antibodies
IF: 1:500
Goat anti-rabbit Alexa-Fluor
488

Various
Abcam;
ab28207

IF: N/A
IHC: 1:300
WB: N/A

Anti-mouse IgG Alexa Fluor
647

IHC: Goat–anti mouse IgGHRP4

Goat–anti rabbit IgG-HRP

Goat–anti rabbit IgG-HRP

2 For flow cytometry, IgG-FITC secondary antibodies were from Sigma-Aldrich. For IF, IgG-Alexa Fluor
secondary antibodies were from Life Technologies. For IHC and western blotting, IgG-HRP secondary
antibodies were from DAKO and Sigma-Aldrich, respectively. Secondary antibodies were used within
concentration ranges recommended by the manufacturers.
3
4

Bound secondary antibodies detected using PicoWest ECL reagent (Pierce) and autoradiography
Bound secondary antibodies detected using Liquid DAB+ Substrate Chromogen System K3468 (DAKO)
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Murine/human
SerpinB2

Rabbit polyclonal
(IgG)

Abcam;
ab137588

Murine
SerpinB2

Rabbit polyclonal
(IgG) (raised against
the CD loop)

(198)

Trinitrophenyl–
KLH

Rat monoclonal
(IgG2A)

BD
Pharmingen;55
3996

Negative control antibody - diluted to the
same concentration as the test antibodies

Human uPA

Mouse monoclonal
(IgG1)

IF: 1:250
IHC: N/A
WB: N/A

Murine uPA

Rabbit polyclonal
(IgG)

Sekisui
Diagnostics
GmbH:
ADG3689
Abcam;
ab20789

Human uPAR

Mouse monoclonal
(IgG1)

R&D Systems;
MAB807

Murine uPAR

Rat monoclonal
(IgG2A)

R&D Systems;
MAB531

Murine IgG

Negative Control
Mouse monoclonal
(IgG1)
Rabbit polyclonal

DAKO;
X0943

IF: 1:500
Goat anti-rabbit Alexa Fluor
IHC: N/A
488
WB: N/A
IF: 1:500
Goat anti-mouse IgG-FITC
IHC: N/A
WB: N/A
IF: 1:500
Goat anti-rat IgG-FITC or
IHC: N/A
IgG-Alexa Fluor 555
WB: N/A
Negative control antibody - diluted to the
same concentration as the test antibodies

DAKO;
X0903

Negative control antibody - diluted to the
same concentration as the test antibodies

Rabbit IgG

IF: 1:500
IHC: N/A
WB: 1:2000
IF: 1:500
IHC: N/A
WB: 1:2000

Goat anti-rabbit Alexa-Fluor
488
Anti-rabbit IgG –HRP
Goat anti-rabbit Alexa Fluor
488
Anti-rabbit IgG –HRP

Goat anti-mouse IgG-FITC
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APPENDIX D
SUPPLEMENTARY MOVIE LEGENDS
Movie 1. Animated z-stack of SHG imaging from wild-type MEF contracted matrices at Day 4 of contraction.
Movie 2. Animated z-stack of SHG imaging from wild-type MEF contracted matrices at Day 12 of contraction.
Movie 3. Animated z-stack of SHG imaging from SerpinB2-/- MEF contracted matrices at Day 4 of contraction.
Movie 4. Animated z-stack of SHG imaging from SerpinB2-/- MEF contracted matrices at Day 12 of contraction.
Movie 5. Animation of rendered z-stacks of SHG imaging from SerpinB2-/- (L) and wild-type (R) MEF contracted matrices at
Day 12 of contraction.
Movie 6 and 7. Animation of migration of wild-type (movie 6) or SerpinB2-/- (movie 7) MEFs through Collagen I matrices
over 10 h at the midpoint of matrix contraction (day 6). Collagen (magenta) was detected using SHG and wild-type or
SerpinB2-/- MEFs were detected through stable GFP expression.
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APPENDIX E
LENTIVIRAL CONSTRUCT SEQUENCES
A
CTTGGTCGTACTAGGCCTAGGCGTCTGATCACTAGTGACTCTAGTCCTAGTCGACTAGGGATAACAGGGTAATTGTTTGAAT
GAGGCTTCAGTACTTTACAGAATCGTTGCCTGCACATCTTGGAAACACTTGCTGGGATTACTTCTTCAGGTTAACCCAACAGA
AGGCTCGAGAAGGTATATTGCTGTTGACAGTGAGCGAGGTAGTTATCCTGATGCGATTTAGTGAAGCCACAGATGTAAATCG
CATCAGGATAACTACCCTGCCTACTGCCTCGGAATTCAAGGGGCTACTTTAGGAGCAATTATCTTGTTTACTAAAACTGAATA
CCTTGCTATCTCTTTGATACATTTTTACAAAGCTGAATTAAAATGGTATAAATTAAATCACTTTTTTCAATTGGAAGACTAATG
CGTTTTCGAGATATCTAGACCCAGCTTTCTTGTACAAAGTTGGCATTATAAGAAAGCTGTGTCTAGCTATCTCGTGAACGCAT
TAGTCCTCTAATTGAAAAAAGTGATTTATTTTTTGCCTTTTAATTGCATTTCTGATGTTTTCAGAGGGAATCTGGGATGTGGC
TTTGTACAAAAGAAAATTATATCATGATGAGCCAGAAATCTGGGGTGGTTACCGGGGTAGTAATACGATGGGTGTTATGAGG
TCATATTCTACAGGATACGTCGATGCCTCGATTAGATTCCAACATGCATGCTCATTTATATGGGTATAAATGTTTCTCGCGAT
GATGTCGCGGAATCAGGTGCGACTATCTATCGCTTGTATGGGAAGCCCGATGCGCCATATTTGTTTCTGAAACATGGTGTAG
GTATCGTTGCCCAATGATGTTACAGATGAGATGGTCAGACTAAACTGGCTGACGGAAATTTATGCCTCTTCCGAACCATCAA
GCATTTTTATCCGCTAGCTCCATGATGATGCATGGTTTACATCGACCCAGCTGCCGAATCCCCCCGAGAACAAACCAGCAAT
TTCGACGTTATTTAGAAAGAAATATCTCTGCAATTCAGGGGATGAAAAATTATTTGGATTGGATGGCAGCATGAGAGCAGGT
GTTCGCTTGACGACTCGGATTTGCAGAATTCCGAAATGTTCTCGCTCTGGGTATCCAG

B

Fig A2. Entry clone analysis of pEN_TmiRc3-SerpinB2 shRNA1 vector sequence. A. Wt SerpinB2 sequence with
SerpinB2 shRNA1, highlighted in green. B. Sequence analysis of entry clone pEN_TmiRc3-SerpinB2 shRNA1 using Finch TV analysis
program. SerpinB2 shRNA1 sequence is highlighted.
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A
CTTCGGCCGTACTAGGCCTAGGCGTCTGATCACTAGTGACTCTAGTCCTAGTCGACTAGGGATAACAGGGTAATTGTTT
GAATGAGGCTTCAGTACTTTACAGAATCGTTGCCTGCACATCTTGGAAACACTTGCTGGGATTACTTCTTCAGGTTAACC
CAACAGAAGGCTCGAGAAGGTATATTGCTGTTGACAGTGAGCGCGCAGGCACAAGCTGCAGATAATAGTGAAGCCACAG
ATGTATTATCTGCAGCTTGTGCCTGCATGCCTACTGCCTCGGAATTCAAGGGGCTACTTTAGGAGCAATTATCTTGTTTA
CTAAAACTGAATACCTTGCTATCTCTTTGATACATTTTTACAAAGCTGAATTAAAATGGTATAAATTAAATCACTTTTTTCA
ATTGGAAGACTAATGCGTTTTCGAGATATCTAGACCCAGCTTTCTTGTACAAAGTTGGCATTATAAGAAAGCAGTGCTTA
TCTATTTGGTGCACGCATTAGGCCTCTATTTGTCAAAAGTGAGTCATTTTTTGCCATCCAGCTGCAGCTCTGGGCCGTGT
CTCAAAATCTCTGATGTGACATTGCACAAAAGAAAATTATATCATGATGAGCCAGTAGTCTGGCTGGTTACAGAAGCAGT
AAGACGAGGGGTGTTATGAGCCATATTCGACGGGAAACGTCGAGGGCGCGATTACATTCCAACATGGATGCTGATTTAT
ATGTGTATAAATGGGCTCGCGATAATGTCGGGCAATCAGGTGCGACAATCTATCGCTTGTATGGGAAGCCCGATGCGCC
AGAGTTGTTTCTGAAACATGGGAAAGGTAGCGTTGCCAATGATGTTACAGATGAGATGGTCAGACGTAAACTGGCTGAC
GGAATTTATGCCTCTTCCGACCATCAAGCATTTTTATCCCGTACTCCTGATGATGCCATGGTTTACTCACCACCTGCGAA
TCCCCCGGAAAAACAGGCATTTCCAGGTATTAGAAGAAATATCCTGATTTCCAGTTGAAAAATATTGCTTGATGCCGCTG
GCAGTGATCCCCTGCCGCCGGTTTGCCAATTCCGAATTCCTGTTATTGTAATTGATCCCCTTTCTTTTCTAAAACCAGGC
CGAGCA

B

Fig. A3. Entry clone analysis of pEN_TmiRc3-SerpinB2 shRNA2 vector sequence. A. Wt SerpinB2 sequence with
SerpinB2 shRNA2, highlighted in green. B. Sequence analysis of entry clone pEN_TmiRc3-SerpinB2 shRNA2 using Finch TV analysis
program. SerpinB2 shRNA2 sequence is highlighted.
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Fig A4. Destination clone analysis of pSLIK-SerpinB2 shRNA1 vector sequence. A. Wt SerpinB2 sequence with SerpinB2
shRNA 1C1, highlighted in green. B. Sequence analysis of destination clone pSLIK-SerpinB2 shRNA1 using Finch TV analysis
program. SerpinB2 shRNA2 sequence is highlighted.

Fig. A5. Destination clone analysis of pSLIK-SerpinB2 shRNA2 vector sequence. A. Wt SerpinB2 sequence with SerpinB2
shRNA 1C1, highlighted in green. B. Sequence analysis of pSLIK-SerpinB2 shRNA2 using Finch TV analysis program. SerpinB2
shRNA2 sequence is highlighted.
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Fig. A6. Entry clone sequence analysis of pDONR221 SerpinB2 ∆CD1 vector sequence. A. Nucelotide sequence analysis
of entry vector, pDONR221 SerpinB2 ∆CD1. B. Translated protein analysis of sequence of pDONR221 SerpinB2 ∆CD1 construct
versus SerpinB2 ∆CD (Homo sapiens) protein sequence. Plasmid sample was extracted from transformed DH5α E. coli and sequenced
as described in section 2.2.2. Sequence analysis performed using Finch TV and 4 Peaks analysis programs, compared to SerpinB2
template using blastx. The red line undermarks the R380A mutation – arginine residue at position 380 with an alanine residue.
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Fig. A7. Entry clone sequence analysis of pDONR221 SerpinB2 ∆CD2 vector sequence. A. Nucelotide sequence analysis
of entry vector, pDONR221 R380ASerpinB2 ∆CD1. B. Translated protein analysis of sequence of pDONR221 SerpinB2 ∆CD2
construct versus SerpinB2 ∆CD (Homo sapiens) protein sequence. Plasmid sample was extracted from transformed DH5α E. coli and
sequenced as described in section 2.2.2. Sequence analysis performed using Finch TV and 4 Peaks analysis programs, compared to
SerpinB2 template using blastx.

290

Fig. A8. Entry clone sequence analysis of pDONR221 R380ASerpinB2 full-length 1 vector sequence. A. Nucelotide
sequence analysis of entry vector, pDONR221 R380ASerpinB2 full-length 1. B. Translated protein analysis of both Forward and
Reverse sequence of pDONR221 R380ASerpinB2 full-length 1 construct versus SerpinB2 (Homo sapiens) protein sequence. Plasmid
sample was extracted from transformed DH5α E. coli and sequenced as described in section 2.2.2. Sequence analysis performed using
Finch TV and 4 Peaks analysis programs, compared to SerpinB2 template using blastx. The red line undermarks the R380A mutation
– arginine residue at position 380 with an alanine residue.
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Fig. A9. Entry clone sequence analysis of pDONR221 R380ASerpinB2 full-length 2 vector sequence. A. Nucelotide
sequence analysis of entry vector, pDONR221 R380ASerpinB2 full-length 2. B. Translated protein analysis of both Forward and
Reverse sequence of pDONR221 R380ASerpinB2 full-length 2 construct versus SerpinB2 (Homo sapiens) protein sequence. Plasmid
sample was extracted from transformed DH5α E. coli and sequenced as described in section 2.2.2. Sequence analysis performed using
Finch TV and 4 Peaks analysis programs, compared to SerpinB2 template using blastx. The red line undermarks the R380A mutation
– arginine residue at position 380 with an alanine residue.
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Fig. A10. Entry clone sequence analysis of pDONR221 R380ASerpinB2 ∆CD1 vector sequence. A. Nucelotide sequence
analysis of entry vector, pDONR221 R380ASerpinB2 ∆CD1. B. Translated protein analysis of sequence of pDONR221 R380ASerpinB2
∆CD1 construct versus SerpinB2 ∆CD (Homo sapiens) protein sequence. Plasmid sample was extracted from transformed DH5α E.
coli and sequenced as described in section 2.2.2. Sequence analysis performed using Finch TV and 4 Peaks analysis programs,
compared to SerpinB2 template using blastx. The red line undermarks the R380A mutation – arginine residue at position 380 with an
alanine residue.
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Fig. A11. Entry clone sequence analysis of pDONR221 R380ASerpinB2 ∆CD2 vector sequence. A. Nucelotide sequence
analysis of entry vector, pDONR221 R380ASerpinB2 ∆CD2. B. Translated protein analysis of sequence of pDONR221 R380ASerpinB2
∆CD2 construct versus SerpinB2 ∆CD (Homo sapiens) protein sequence. Plasmid sample was extracted from transformed DH5α E.
coli and sequenced as described in section 2.2.2. Sequence analysis performed using Finch TV and 4 Peaks analysis programs,
compared to SerpinB2 template using blastx. The red line undermarks the R380A mutation – arginine residue at position 380 with an
alanine residue.
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